{"items": "154", "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish", "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.", "feed": [{"title": "Corcept Submits Application for Another Cushing's Syndrome Drug", "url": "https://www.zacks.com/stock/news/2390198/corcept-submits-application-for-another-cushings-syndrome-drug", "time_published": "20241231T184000", "authors": ["Zacks Equity Research"], "summary": "CORT makes pipeline progress with the submission of a new drug application for relacorilant to treat patients with endogenous hypercortisolism.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.917436"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.270579, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CORT", "relevance_score": "0.306963", "ticker_sentiment_score": "0.16313", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RIGL", "relevance_score": "0.156461", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.156461", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dow Jumps Over 200 Points, Crude Oil Gains 1.5% - Greenfire Resources  ( NYSE:GFR ) , Carbon Revolution  ( NASDAQ:CREV ) ", "url": "https://www.benzinga.com/24/12/42673586/dow-jumps-over-200-points-crude-oil-gains-15", "time_published": "20241224T170215", "authors": ["Avi Kapoor"], "summary": "U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 200 points on Tuesday. The Dow traded up 0.53% to 43,132.84 while the NASDAQ climbed 1.05% to 19,972.38. The S&P 500 also rose, gaining, 0.78% to 6,020.96. Consumer discretionary shares jumped by 1.8% ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/24/oil-prices-5079975.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.364293, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "GOEV", "relevance_score": "0.205807", "ticker_sentiment_score": "0.41388", "ticker_sentiment_label": "Bullish"}, {"ticker": "GFR", "relevance_score": "0.205807", "ticker_sentiment_score": "0.449461", "ticker_sentiment_label": "Bullish"}, {"ticker": "RIGL", "relevance_score": "0.205807", "ticker_sentiment_score": "-0.262668", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "LMNR", "relevance_score": "0.205807", "ticker_sentiment_score": "0.244092", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CREV", "relevance_score": "0.103778", "ticker_sentiment_score": "0.24651", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term", "url": "https://www.zacks.com/stock/news/2386694/buy-5-genomics-synthetic-biology-stocks-likely-to-soar-in-short-term", "time_published": "20241223T124900", "authors": ["Nalak Das"], "summary": "These five geonomics and synthetic biology stocks are likely to soar in the short-term. They Are: CRSP, IMCR, GLUE, RIGL, CSTL.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/284.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.149735, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "IMCR", "relevance_score": "0.246582", "ticker_sentiment_score": "0.169061", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RIGL", "relevance_score": "0.124809", "ticker_sentiment_score": "0.02377", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRSP", "relevance_score": "0.124809", "ticker_sentiment_score": "0.044541", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLUE", "relevance_score": "0.246582", "ticker_sentiment_score": "0.055241", "ticker_sentiment_label": "Neutral"}, {"ticker": "CSTL", "relevance_score": "0.206509", "ticker_sentiment_score": "0.07964", "ticker_sentiment_label": "Neutral"}]}, {"title": "Knight Therapeutics Announces Regulatory Approval of TAVALISSE\u00ae in Mexico", "url": "https://www.globenewswire.com/news-release/2024/12/12/2996099/0/en/Knight-Therapeutics-Announces-Regulatory-Approval-of-TAVALISSE-in-Mexico.html", "time_published": "20241212T123000", "authors": ["Knight Therapeutics"], "summary": "MONTREAL, Dec. 12, 2024 ( GLOBE NEWSWIRE ) -- Knight Therapeutics Inc., ( TSX: GUD ) ( \"Knight\" ) a pan-American ( ex-USA ) specialty pharmaceutical company, announced today that its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V., received regulatory approval from COFEPRIS for ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/e9457092-692d-4bfd-b361-9799ee8d73cd", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.062981, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "KHTRF", "relevance_score": "0.561452", "ticker_sentiment_score": "0.18168", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RIGL", "relevance_score": "0.056143", "ticker_sentiment_score": "0.08208", "ticker_sentiment_label": "Neutral"}]}, {"title": "How Much Upside is Left in Rigel  ( RIGL ) ? Wall Street Analysts Think 28.28%", "url": "https://www.zacks.com/stock/news/2372205/how-much-upside-is-left-in-rigel-rigl-wall-street-analysts-think-2828", "time_published": "20241119T145506", "authors": ["Zacks Equity Research"], "summary": "The average of price targets set by Wall Street analysts indicates a potential upside of 28.3% in Rigel (RIGL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default206.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.795202"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}], "overall_sentiment_score": 0.250231, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RIGL", "relevance_score": "0.286193", "ticker_sentiment_score": "0.386733", "ticker_sentiment_label": "Bullish"}]}, {"title": "5 Relative Price Strength Options Available for Investors", "url": "https://www.zacks.com/stock/news/2371771/5-relative-price-strength-options-available-for-investors", "time_published": "20241118T200000", "authors": ["Nilanjan Choudhury"], "summary": "RIGL, SYF, SKYW, ALNT and RSI are five stocks with explosive relative price strength.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/51/2581.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}, {"topic": "Earnings", "relevance_score": "0.998626"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.244748, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SKYW", "relevance_score": "0.241512", "ticker_sentiment_score": "0.208807", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RSI", "relevance_score": "0.241512", "ticker_sentiment_score": "0.206608", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SYF", "relevance_score": "0.241512", "ticker_sentiment_score": "0.242078", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RIGL", "relevance_score": "0.241512", "ticker_sentiment_score": "0.119673", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALNT", "relevance_score": "0.173832", "ticker_sentiment_score": "0.121827", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNXYF", "relevance_score": "0.035035", "ticker_sentiment_score": "0.11958", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rigel Pharmaceuticals  ( RIGL )  Q3 Earnings and Revenues Top Estimates", "url": "https://www.zacks.com/stock/news/2366804/rigel-pharmaceuticals-rigl-q3-earnings-and-revenues-top-estimates", "time_published": "20241107T221510", "authors": ["Zacks Equity Research"], "summary": "Rigel (RIGL) delivered earnings and revenue surprises of 6,900% and 35.92%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default361.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999892"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.135207, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "XBIO", "relevance_score": "0.211806", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.142144", "ticker_sentiment_score": "0.035454", "ticker_sentiment_label": "Neutral"}]}, {"title": "BPMC Beats on Q3 Earnings and Sales, Raises '24 View, Stock Up", "url": "https://www.zacks.com/stock/news/2361780/bpmc-beats-on-q3-earnings-and-sales-raises-24-view-stock-up", "time_published": "20241031T124500", "authors": ["Zacks Equity Research"], "summary": "Blueprint stock gains from better-than-expected third-quarter results, driven by robust Ayvakit sales growth. The company raises revenue guidance for 2024.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/595.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.928769"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.193413, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALLO", "relevance_score": "0.199037", "ticker_sentiment_score": "0.096503", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.050254", "ticker_sentiment_score": "0.104296", "ticker_sentiment_label": "Neutral"}, {"ticker": "BPMC", "relevance_score": "0.587401", "ticker_sentiment_score": "0.253835", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Neurocrine Biosciences  ( NBIX )  Q3 Earnings Miss Estimates", "url": "https://www.zacks.com/stock/news/2360311/neurocrine-biosciences-nbix-q3-earnings-miss-estimates", "time_published": "20241030T121014", "authors": ["Zacks Equity Research"], "summary": "Neurocrine (NBIX) delivered earnings and revenue surprises of -15.65% and 2.98%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default350.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999997"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.164053, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RIGL", "relevance_score": "0.211806", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NBIX", "relevance_score": "0.142144", "ticker_sentiment_score": "0.119122", "ticker_sentiment_label": "Neutral"}]}, {"title": "Optime Care Expands Partnership with Rigel Pharmaceuticals to Include Commercial Distribution for TAVALISSE\u00ae - Rigel Pharmaceuticals  ( NASDAQ:RIGL ) ", "url": "https://www.benzinga.com/pressreleases/24/10/g41357589/optime-care-expands-partnership-with-rigel-pharmaceuticals-to-include-commercial-distribution-for-", "time_published": "20241016T140000", "authors": ["Globe Newswire"], "summary": "ST. LOUIS, Oct. 16, 2024 ( GLOBE NEWSWIRE ) -- Optime Care, a nationally recognized specialty pharmacy and an AscellaHealth Company, today announces an expanded arrangement with Rigel Pharmaceuticals, Inc, effective October 14, 2024, to include commercial distribution of TAVALISSE\u00ae ( ...", "banner_image": "https://ml.globenewswire.com/media/5b0c7bd2-4a27-41e8-812c-1eca6bbf5a79/small/ah-logo-colornotag-4x-png.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.290255, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RIGL", "relevance_score": "0.210579", "ticker_sentiment_score": "0.344375", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Rigel  ( RIGL )  Surges 19.7%: Is This an Indication of Further Gains?", "url": "https://www.zacks.com/stock/news/2340923/rigel-rigl-surges-197-is-this-an-indication-of-further-gains", "time_published": "20240925T083400", "authors": ["Zacks Equity Research"], "summary": "Rigel (RIGL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default98.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}, {"topic": "Earnings", "relevance_score": "0.976913"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.239156, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "INDV", "relevance_score": "0.436009", "ticker_sentiment_score": "-0.10201", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.334762", "ticker_sentiment_score": "0.313795", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Rigel Pharmaceuticals  ( RIGL )  Reports Q2 Loss, Tops Revenue Estimates", "url": "https://www.zacks.com/stock/news/2317375/rigel-pharmaceuticals-rigl-reports-q2-loss-tops-revenue-estimates", "time_published": "20240806T213005", "authors": ["Zacks Equity Research"], "summary": "Rigel (RIGL) delivered earnings and revenue surprises of 83.78% and 13.79%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default247.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999759"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.112391, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "RIGL", "relevance_score": "0.141726", "ticker_sentiment_score": "-0.064765", "ticker_sentiment_label": "Neutral"}, {"ticker": "VYNE", "relevance_score": "0.211191", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Profound Medical  ( PROF )  Expected to Beat Earnings Estimates: Can the Stock Move Higher?", "url": "https://www.zacks.com/stock/news/2314305/profound-medical-prof-expected-to-beat-earnings-estimates-can-the-stock-move-higher", "time_published": "20240801T140121", "authors": ["Zacks Equity Research"], "summary": "Profound Medical (PROF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default222.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.165826, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PROF", "relevance_score": "0.260189", "ticker_sentiment_score": "0.165214", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RIGL", "relevance_score": "0.088147", "ticker_sentiment_score": "-0.00104", "ticker_sentiment_label": "Neutral"}]}, {"title": "Aurinia Pharmaceuticals  ( AUPH )  Q2 Earnings and Revenues Beat Estimates", "url": "https://www.zacks.com/stock/news/2313796/aurinia-pharmaceuticals-auph-q2-earnings-and-revenues-beat-estimates", "time_published": "20240801T111006", "authors": ["Zacks Equity Research"], "summary": "Aurinia (AUPH) delivered earnings and revenue surprises of 100% and 4.19%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default313.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999892"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.123838, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AUPH", "relevance_score": "0.140076", "ticker_sentiment_score": "0.035146", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.208764", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Collegium Pharmaceutical  ( COLL )  Soars 10.6%: Is Further Upside Left in the Stock?", "url": "https://www.zacks.com/stock/news/2312611/collegium-pharmaceutical-coll-soars-106-is-further-upside-left-in-the-stock", "time_published": "20240731T105300", "authors": ["Zacks Equity Research"], "summary": "Collegium Pharmaceutical (COLL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default20.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.164888, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RIGL", "relevance_score": "0.312158", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "COLL", "relevance_score": "0.496915", "ticker_sentiment_score": "0.245201", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Rigel Pharmaceuticals  ( RIGL )  Expected to Beat Earnings Estimates: Can the Stock Move Higher?", "url": "https://www.zacks.com/stock/news/2311986/rigel-pharmaceuticals-rigl-expected-to-beat-earnings-estimates-can-the-stock-move-higher", "time_published": "20240730T140124", "authors": ["Zacks Equity Research"], "summary": "Rigel (RIGL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default55.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.168139, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "IONS", "relevance_score": "0.175859", "ticker_sentiment_score": "0.022662", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.088472", "ticker_sentiment_score": "0.125117", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rigel Pharmaceuticals  ( NASDAQ:RIGL )  Upgraded to \"Buy\" at StockNews.com", "url": "https://www.defenseworld.net/2024/07/05/rigel-pharmaceuticals-nasdaqrigl-upgraded-to-buy-at-stocknews-com.html", "time_published": "20240705T053648", "authors": ["Defense World Staff"], "summary": "Rigel Pharmaceuticals ( NASDAQ:RIGL - Get Free Report ) was upgraded by investment analysts at StockNews.com from a \"hold\" rating to a \"buy\" rating in a research report issued on Friday. Several other equities analysts also recently weighed in on the stock.", "banner_image": "https://www.marketbeat.com/logos/rigel-pharmaceuticals-inc-logo-1200x675.png?v=20221216130713", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999365"}, {"topic": "Earnings", "relevance_score": "0.967321"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.272906, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RIGL", "relevance_score": "0.739411", "ticker_sentiment_score": "0.429758", "ticker_sentiment_label": "Bullish"}, {"ticker": "C", "relevance_score": "0.059785", "ticker_sentiment_score": "0.058996", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rigel Pharmaceuticals  ( NASDAQ:RIGL )  Downgraded by StockNews.com to \"Hold\"", "url": "https://www.defenseworld.net/2024/06/28/rigel-pharmaceuticals-nasdaqrigl-downgraded-by-stocknews-com-to-hold.html", "time_published": "20240628T102242", "authors": ["Defense World Staff"], "summary": "StockNews.com downgraded shares of Rigel Pharmaceuticals ( NASDAQ:RIGL - Free Report ) from a buy rating to a hold rating in a report released on Thursday.", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/rigel-pharmaceuticals-inc-logo.png?v=20221216130713&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999186"}, {"topic": "Earnings", "relevance_score": "0.961735"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.255053, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RIGL", "relevance_score": "0.76676", "ticker_sentiment_score": "0.409274", "ticker_sentiment_label": "Bullish"}, {"ticker": "C", "relevance_score": "0.052801", "ticker_sentiment_score": "0.079656", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRGS", "relevance_score": "0.052801", "ticker_sentiment_score": "0.04503", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rigel Pharmaceuticals  ( NASDAQ:RIGL )  Lifted to \"Buy\" at StockNews.com", "url": "https://www.defenseworld.net/2024/05/11/rigel-pharmaceuticals-nasdaqrigl-lifted-to-buy-at-stocknews-com.html", "time_published": "20240511T051848", "authors": ["Defense World Staff"], "summary": "Rigel Pharmaceuticals ( NASDAQ:RIGL - Get Free Report ) was upgraded by stock analysts at StockNews.com from a \"hold\" rating to a \"buy\" rating in a note issued to investors on Thursday. A number of other research analysts also recently weighed in on the company.", "banner_image": "https://www.marketbeat.com/logos/rigel-pharmaceuticals-inc-logo-1200x675.png?v=20221216130713", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999922"}, {"topic": "Earnings", "relevance_score": "0.972476"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.215875, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PFG", "relevance_score": "0.105372", "ticker_sentiment_score": "0.176775", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RIGL", "relevance_score": "0.739762", "ticker_sentiment_score": "0.344835", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "C", "relevance_score": "0.052801", "ticker_sentiment_score": "0.044864", "ticker_sentiment_label": "Neutral"}, {"ticker": "FROG", "relevance_score": "0.052801", "ticker_sentiment_score": "0.039074", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rigel  ( RIGL )  Upgraded to Buy: Here's What You Should Know", "url": "https://www.zacks.com/stock/news/2272399/rigel-rigl-upgraded-to-buy-heres-what-you-should-know", "time_published": "20240510T160009", "authors": ["Zacks Equity Research"], "summary": "Rigel (RIGL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default101.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.997845"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.692272"}], "overall_sentiment_score": 0.311732, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RIGL", "relevance_score": "0.128478", "ticker_sentiment_score": "0.159113", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Rigel Pharmaceuticals  ( RIGL )  Reports Q1 Loss, Lags Revenue Estimates", "url": "https://www.zacks.com/stock/news/2270036/rigel-pharmaceuticals-rigl-reports-q1-loss-lags-revenue-estimates", "time_published": "20240507T215007", "authors": ["Zacks Equity Research"], "summary": "Rigel (RIGL) delivered earnings and revenue surprises of -66.67% and 5.58%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default10.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999892"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.114712, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "RIGL", "relevance_score": "0.14131", "ticker_sentiment_score": "-0.064653", "ticker_sentiment_label": "Neutral"}, {"ticker": "MEIP", "relevance_score": "0.210579", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rigel Reports First Quarter 2024 Financial Results and Provides Business Update", "url": "https://www.prnewswire.com/news-releases/rigel-reports-first-quarter-2024-financial-results-and-provides-business-update-302138695.html", "time_published": "20240507T200100", "authors": ["Rigel Pharmaceuticals", "Inc."], "summary": "SOUTH SAN FRANCISCO, Calif., May 7, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ( Nasdaq: RIGL ) today reported financial results for the first quarter ended March 31, 2024, including sales of TAVALISSE\u00ae ( fostamatinib disodium hexahydrate ) tablets for the treatment of adults with chronic ...", "banner_image": "https://mma.prnewswire.com/media/681135/rigel_logo_TM_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.818451"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.012143, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GRFS", "relevance_score": "0.016587", "ticker_sentiment_score": "0.023396", "ticker_sentiment_label": "Neutral"}, {"ticker": "KSPHF", "relevance_score": "0.016587", "ticker_sentiment_score": "0.023396", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.148426", "ticker_sentiment_score": "0.06984", "ticker_sentiment_label": "Neutral"}]}, {"title": "Blueprint  ( BPMC )  Q1 Earnings and Revenues Beat, Stock Rises", "url": "https://www.zacks.com/stock/news/2268056/blueprint-bpmc-q1-earnings-and-revenues-beat-stock-rises", "time_published": "20240503T135100", "authors": ["Zacks Equity Research"], "summary": "Blueprint (BPMC) gains from better-than-expected first-quarter 2024 results, driven by robust Ayvakit sales growth. The company raises its revenue guidance for 2024.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/595.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999986"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.154098, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ANIP", "relevance_score": "0.291842", "ticker_sentiment_score": "0.191665", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LGND", "relevance_score": "0.169378", "ticker_sentiment_score": "0.087617", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.042647", "ticker_sentiment_score": "0.188091", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BPMC", "relevance_score": "0.25168", "ticker_sentiment_score": "0.124926", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANVS", "relevance_score": "0.210823", "ticker_sentiment_score": "-0.025387", "ticker_sentiment_label": "Neutral"}]}, {"title": "ProPhase Labs, Inc.  ( PRPH )  Expected to Beat Earnings Estimates: Can the Stock Move Higher?", "url": "https://www.zacks.com/stock/news/2267109/prophase-labs-inc-prph-expected-to-beat-earnings-estimates-can-the-stock-move-higher", "time_published": "20240502T140107", "authors": ["Zacks Equity Research"], "summary": "ProPhase Labs (PRPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default328.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.140605, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "RIGL", "relevance_score": "0.089462", "ticker_sentiment_score": "0.03923", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRPH", "relevance_score": "0.263942", "ticker_sentiment_score": "0.088236", "ticker_sentiment_label": "Neutral"}]}, {"title": "Lyra Therapeutics, Inc.  ( LYRA )  Reports Q1 Loss, Tops Revenue Estimates", "url": "https://www.zacks.com/stock/news/2265431/lyra-therapeutics-inc-lyra-reports-q1-loss-tops-revenue-estimates", "time_published": "20240430T213011", "authors": ["Zacks Equity Research"], "summary": "Lyra Therapeutics (LYRA) delivered earnings and revenue surprises of -34.62% and 33%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default301.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999759"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.112395, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "RIGL", "relevance_score": "0.209365", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LYRA", "relevance_score": "0.404563", "ticker_sentiment_score": "0.071478", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rigel Pharmaceuticals  ( RIGL )  May Report Negative Earnings: Know the Trend Ahead of Q1 Release", "url": "https://www.zacks.com/stock/news/2265127/rigel-pharmaceuticals-rigl-may-report-negative-earnings-know-the-trend-ahead-of-q1-release", "time_published": "20240430T140101", "authors": ["Zacks Equity Research"], "summary": "Rigel (RIGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default219.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.12662, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "RIGL", "relevance_score": "0.088309", "ticker_sentiment_score": "0.125073", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARDX", "relevance_score": "0.175539", "ticker_sentiment_score": "-0.025738", "ticker_sentiment_label": "Neutral"}]}, {"title": "Silence Therapeutics  ( SLN )  Surges 5.7%: Is This an Indication of Further Gains?", "url": "https://www.zacks.com/stock/news/2254407/silence-therapeutics-sln-surges-57-is-this-an-indication-of-further-gains", "time_published": "20240412T122100", "authors": ["Zacks Equity Research"], "summary": "Silence Therapeutics (SLN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default196.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.961735"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.193829, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SLN", "relevance_score": "0.504646", "ticker_sentiment_score": "0.326599", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RIGL", "relevance_score": "0.317527", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rigel Pharmaceuticals  ( NASDAQ:RIGL )  Lowered to \"Hold\" at StockNews.com", "url": "https://www.defenseworld.net/2024/04/04/rigel-pharmaceuticals-nasdaqrigl-lowered-to-hold-at-stocknews-com.html", "time_published": "20240404T062445", "authors": ["Defense World Staff"], "summary": "Rigel Pharmaceuticals ( NASDAQ:RIGL - Get Free Report ) was downgraded by analysts at StockNews.com from a \"buy\" rating to a \"hold\" rating in a note issued to investors on Thursday. Several other research firms also recently weighed in on RIGL. B.", "banner_image": "https://www.marketbeat.com/logos/rigel-pharmaceuticals-inc-logo-1200x675.png?v=20221216130713", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.99977"}], "overall_sentiment_score": 0.266555, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PFG", "relevance_score": "0.123526", "ticker_sentiment_score": "0.210265", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RIGL", "relevance_score": "0.81358", "ticker_sentiment_score": "0.434672", "ticker_sentiment_label": "Bullish"}, {"ticker": "C", "relevance_score": "0.061949", "ticker_sentiment_score": "0.067039", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rigel Pharmaceuticals  ( NASDAQ:RIGL )  Rating Increased to Buy at StockNews.com", "url": "https://www.defenseworld.net/2024/03/28/rigel-pharmaceuticals-nasdaqrigl-rating-increased-to-buy-at-stocknews-com.html", "time_published": "20240328T075643", "authors": ["Defense World Staff"], "summary": "StockNews.com upgraded shares of Rigel Pharmaceuticals ( NASDAQ:RIGL - Free Report ) from a hold rating to a buy rating in a research report report published on Wednesday.", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/rigel-pharmaceuticals-inc-logo.png?v=20221216130713&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.723405"}], "overall_sentiment_score": 0.264018, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MET", "relevance_score": "0.113062", "ticker_sentiment_score": "0.228715", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RIGL", "relevance_score": "0.773157", "ticker_sentiment_score": "0.423691", "ticker_sentiment_label": "Bullish"}, {"ticker": "C", "relevance_score": "0.056674", "ticker_sentiment_score": "0.028947", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rigel Pharmaceuticals  ( NASDAQ:RIGL )  Downgraded by StockNews.com to \"Hold\"", "url": "https://www.defenseworld.net/2024/03/19/rigel-pharmaceuticals-nasdaqrigl-downgraded-by-stocknews-com-to-hold.html", "time_published": "20240319T062842", "authors": ["Defense World Staff"], "summary": "Rigel Pharmaceuticals ( NASDAQ:RIGL - Get Free Report ) was downgraded by equities research analysts at StockNews.com from a \"buy\" rating to a \"hold\" rating in a report released on Tuesday. Several other brokerages have also recently commented on RIGL. B.", "banner_image": "https://www.marketbeat.com/logos/rigel-pharmaceuticals-inc-logo-1200x675.png?v=20221216130713", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.623304"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.214213, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RIGL", "relevance_score": "0.815863", "ticker_sentiment_score": "0.35571", "ticker_sentiment_label": "Bullish"}, {"ticker": "C", "relevance_score": "0.062271", "ticker_sentiment_score": "0.042023", "ticker_sentiment_label": "Neutral"}, {"ticker": "MET", "relevance_score": "0.124164", "ticker_sentiment_score": "0.167825", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WMT", "relevance_score": "0.062271", "ticker_sentiment_score": "0.046294", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rigel Pharmaceuticals  ( NASDAQ:RIGL )  Upgraded to \"Buy\" at StockNews.com", "url": "https://www.americanbankingnews.com/2024/03/12/rigel-pharmaceuticals-nasdaqrigl-upgraded-to-buy-at-stocknews-com.html", "time_published": "20240312T082728", "authors": ["ABMN Staff"], "summary": "Rigel Pharmaceuticals ( NASDAQ:RIGL ) Upgraded to \"Buy\" at ...", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/rigel-pharmaceuticals-inc-logo.png?v=20221216130713&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.americanbankingnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.723405"}], "overall_sentiment_score": 0.305079, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PFG", "relevance_score": "0.135347", "ticker_sentiment_score": "0.255126", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RIGL", "relevance_score": "0.798895", "ticker_sentiment_score": "0.488332", "ticker_sentiment_label": "Bullish"}, {"ticker": "C", "relevance_score": "0.067919", "ticker_sentiment_score": "0.054118", "ticker_sentiment_label": "Neutral"}, {"ticker": "COIN", "relevance_score": "0.067919", "ticker_sentiment_score": "0.063837", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rigel Pharmaceuticals  ( NASDAQ:RIGL )  Upgraded to Buy by StockNews.com", "url": "https://www.defenseworld.net/2024/03/12/rigel-pharmaceuticals-nasdaqrigl-upgraded-to-buy-by-stocknews-com.html", "time_published": "20240312T082641", "authors": ["Defense World Staff"], "summary": "StockNews.com upgraded shares of Rigel Pharmaceuticals ( NASDAQ:RIGL - Free Report ) from a hold rating to a buy rating in a report published on Monday morning. RIGL has been the topic of several other research reports.", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/rigel-pharmaceuticals-inc-logo.png?v=20221216130713&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}], "overall_sentiment_score": 0.310221, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RIGL", "relevance_score": "0.856646", "ticker_sentiment_score": "0.505736", "ticker_sentiment_label": "Bullish"}, {"ticker": "AWON", "relevance_score": "0.064797", "ticker_sentiment_score": "0.002005", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.064797", "ticker_sentiment_score": "0.054038", "ticker_sentiment_label": "Neutral"}, {"ticker": "COIN", "relevance_score": "0.064797", "ticker_sentiment_score": "0.026381", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rigel Pharmaceuticals  ( RIGL )  Reports Break-Even Earnings for Q4", "url": "https://www.zacks.com/stock/news/2236277/rigel-pharmaceuticals-rigl-reports-break-even-earnings-for-q4", "time_published": "20240305T221005", "authors": ["Zacks Equity Research"], "summary": "Rigel (RIGL) delivered earnings and revenue surprises of 100% and 0.26%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default189.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999981"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.137149, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "RIGL", "relevance_score": "0.140896", "ticker_sentiment_score": "0.060549", "ticker_sentiment_label": "Neutral"}, {"ticker": "AKBA", "relevance_score": "0.20997", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update", "url": "https://www.prnewswire.com/news-releases/rigel-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-business-update-302080342.html", "time_published": "20240305T210100", "authors": ["Inc.", "Rigel Pharmaceuticals"], "summary": "SOUTH SAN FRANCISCO, Calif., March 5, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ( Nasdaq: RIGL ) today reported financial results for the fourth quarter and full year ended December 31, 2023, including sales of TAVALISSE\u00ae ( fostamatinib disodium hexahydrate ) tablets for the treatment of ...", "banner_image": "https://mma.prnewswire.com/media/681135/rigel_logo_TM_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999997"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.014494, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GRFS", "relevance_score": "0.044441", "ticker_sentiment_score": "0.053799", "ticker_sentiment_label": "Neutral"}, {"ticker": "KSPHF", "relevance_score": "0.014821", "ticker_sentiment_score": "0.025558", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.132774", "ticker_sentiment_score": "0.041199", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.014821", "ticker_sentiment_score": "-0.009142", "ticker_sentiment_label": "Neutral"}]}, {"title": "OmniAb, Inc.  ( OABI )  Soars 10.5%: Is Further Upside Left in the Stock?", "url": "https://www.zacks.com/stock/news/2233017/omniab-inc-oabi-soars-105-is-further-upside-left-in-the-stock", "time_published": "20240228T132700", "authors": ["Zacks Equity Research"], "summary": "OmniAb, Inc. (OABI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default134.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}, {"topic": "Earnings", "relevance_score": "0.961735"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.167249, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "OABI", "relevance_score": "0.553595", "ticker_sentiment_score": "0.146344", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.352223", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "BioCryst Pharmaceuticals  ( BCRX )  Reports Q4 Loss, Tops Revenue Estimates", "url": "https://www.zacks.com/stock/news/2231435/biocryst-pharmaceuticals-bcrx-reports-q4-loss-tops-revenue-estimates", "time_published": "20240226T131003", "authors": ["Zacks Equity Research"], "summary": "BioCryst (BCRX) delivered earnings and revenue surprises of -16.67% and 4.72%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default86.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999759"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.112395, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BCRX", "relevance_score": "0.142565", "ticker_sentiment_score": "-0.064992", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.212425", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO\u00ae", "url": "https://www.prnewswire.com/news-releases/rigel-pharmaceuticals-acquires-us-rights-to-gavreto-302068670.html", "time_published": "20240222T125000", "authors": ["Rigel Pharmaceuticals", "Inc."], "summary": "SOUTH SAN FRANCISCO, Calif., Feb. 22, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ( \"Rigel\" ) ( Nasdaq: RIGL ) today announced that it has entered into a definitive agreement to acquire the U.S. rights to GAVRETO\u00ae ( pralsetinib ) from Blueprint Medicines Corporation ( \"Blueprint\" ) .", "banner_image": "https://mma.prnewswire.com/media/681135/rigel_logo_TM_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.614606"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.140026, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "RIGL", "relevance_score": "0.21278", "ticker_sentiment_score": "0.110369", "ticker_sentiment_label": "Neutral"}, {"ticker": "BPMC", "relevance_score": "0.030759", "ticker_sentiment_score": "0.026604", "ticker_sentiment_label": "Neutral"}]}, {"title": "Knight Therapeutics Announces Regulatory Submission of Fostamatinib in Brazil", "url": "https://www.globenewswire.com/news-release/2024/02/21/2833208/0/en/Knight-Therapeutics-Announces-Regulatory-Submission-of-Fostamatinib-in-Brazil.html", "time_published": "20240221T223000", "authors": ["Knight Therapeutics"], "summary": "MONTREAL, Feb. 21, 2024 ( GLOBE NEWSWIRE ) -- Knight Therapeutics Inc., ( TSX: GUD ) ( \"Knight\" ) a pan-American ( ex-USA ) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a marketing authorization application to ANVISA, the ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/e9457092-692d-4bfd-b361-9799ee8d73cd", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.016954, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "KHTRF", "relevance_score": "0.662594", "ticker_sentiment_score": "0.103244", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.069495", "ticker_sentiment_score": "0.090957", "ticker_sentiment_label": "Neutral"}]}, {"title": "Knight Therapeutics Announces Regulatory Submission of Fostamatinib in Brazil", "url": "https://www.benzinga.com/pressreleases/24/02/g37249336/knight-therapeutics-announces-regulatory-submission-of-fostamatinib-in-brazil", "time_published": "20240221T223000", "authors": ["Globe Newswire"], "summary": "MONTREAL, Feb. 21, 2024 ( GLOBE NEWSWIRE ) -- Knight Therapeutics Inc., GUD ( \"Knight\" ) a pan-American ( ex-USA ) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a marketing authorization application to ANVISA, the Brazilian ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.016912, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "KHTRF", "relevance_score": "0.651499", "ticker_sentiment_score": "0.098733", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.067919", "ticker_sentiment_score": "0.087729", "ticker_sentiment_label": "Neutral"}]}, {"title": "Celcuity Appoints Eldon Mayer as Chief Commercial Officer", "url": "https://www.globenewswire.com/news-release/2024/02/20/2831689/0/en/Celcuity-Appoints-Eldon-Mayer-as-Chief-Commercial-Officer.html", "time_published": "20240220T120500", "authors": ["Celcuity Inc."], "summary": "MINNEAPOLIS, Feb. 20, 2024 ( GLOBE NEWSWIRE ) -- Celcuity Inc. ( Nasdaq: CELC ) , a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the appointment of Eldon Mayer as Chief Commercial Officer.", "banner_image": "https://ml.globenewswire.com/Resource/Download/e3cc5e67-fdb7-4440-bc4e-2ab43e8148a5", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.100744, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CELC", "relevance_score": "0.436009", "ticker_sentiment_score": "0.056039", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.051111", "ticker_sentiment_score": "0.002998", "ticker_sentiment_label": "Neutral"}, {"ticker": "EIGR", "relevance_score": "0.051111", "ticker_sentiment_score": "0.002998", "ticker_sentiment_label": "Neutral"}]}, {"title": "Celcuity Appoints Eldon Mayer as Chief Commercial Officer - Celcuity  ( NASDAQ:CELC ) ", "url": "https://www.benzinga.com/pressreleases/24/02/g37208534/celcuity-appoints-eldon-mayer-as-chief-commercial-officer", "time_published": "20240220T120500", "authors": ["Globe Newswire"], "summary": "MINNEAPOLIS, Feb. 20, 2024 ( GLOBE NEWSWIRE ) -- Celcuity Inc. CELC, a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the appointment of Eldon Mayer as Chief Commercial Officer.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.095785, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CELC", "relevance_score": "0.462953", "ticker_sentiment_score": "0.058223", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.049221", "ticker_sentiment_score": "0.002994", "ticker_sentiment_label": "Neutral"}, {"ticker": "EIGR", "relevance_score": "0.049221", "ticker_sentiment_score": "0.002994", "ticker_sentiment_label": "Neutral"}]}, {"title": "Can Rigel Pharmaceuticals  ( RIGL )  Beat Q4 Earnings Estimates?", "url": "https://www.zacks.com/stock/news/2227756/can-rigel-pharmaceuticals-rigl-beat-q4-earnings-estimates", "time_published": "20240219T133400", "authors": ["Zacks Equity Research"], "summary": "Rigel Pharmaceuticals' (RIGL) Tavalisse tablet sales are expected to have risen in the fourth quarter, driven by demand growth.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/52/873.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.99998"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.097242, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "RIGL", "relevance_score": "0.637818", "ticker_sentiment_score": "0.116363", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.274012", "ticker_sentiment_score": "-0.093306", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRPT", "relevance_score": "0.274012", "ticker_sentiment_score": "0.067553", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.325924", "ticker_sentiment_score": "-0.107052", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635 ( c )  ( 4 ) ", "url": "https://www.prnewswire.com/news-releases/rigel-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302027467.html", "time_published": "20240105T213000", "authors": ["Inc.", "Rigel Pharmaceuticals"], "summary": "SOUTH SAN FRANCISCO, Calif., Jan. 5, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ( \"Rigel\" ) ( Nasdaq: RIGL ) today announced that it has granted awards pursuant to Rigel's Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement ...", "banner_image": "https://mma.prnewswire.com/media/681135/rigel_logo_TM_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.232119, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RIGL", "relevance_score": "0.779232", "ticker_sentiment_score": "0.408197", "ticker_sentiment_label": "Bullish"}]}, {"title": "Here's Why You Should Bet on Rigel Pharmaceuticals  ( RIGL )  Now", "url": "https://www.zacks.com/stock/news/2205099/heres-why-you-should-bet-on-rigel-pharmaceuticals-rigl-now", "time_published": "20240103T155100", "authors": ["Zacks Equity Research"], "summary": "Here, we discuss some reasons why buying Rigel Pharmaceuticals (RIGL) stock now may turn out to be a prudent move.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/85/906.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.928139"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.193209, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RIGL", "relevance_score": "0.675413", "ticker_sentiment_score": "0.414776", "ticker_sentiment_label": "Bullish"}, {"ticker": "NVO", "relevance_score": "0.211806", "ticker_sentiment_score": "-0.001638", "ticker_sentiment_label": "Neutral"}, {"ticker": "AQST", "relevance_score": "0.345674", "ticker_sentiment_score": "0.044076", "ticker_sentiment_label": "Neutral"}, {"ticker": "PBYI", "relevance_score": "0.211806", "ticker_sentiment_score": "-0.00328", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why You Should Invest in Aquestive  ( AQST )  Stock Now", "url": "https://www.zacks.com/stock/news/2204853/heres-why-you-should-invest-in-aquestive-aqst-stock-now", "time_published": "20240103T131000", "authors": ["Zacks Equity Research"], "summary": "Here, we discuss some reasons why buying Aquestive Therapeutics (AQST) stock now may turn out to be a prudent move.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/52/873.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.928139"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.072023, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "RIGL", "relevance_score": "0.218325", "ticker_sentiment_score": "0.099002", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.164656", "ticker_sentiment_score": "-0.00136", "ticker_sentiment_label": "Neutral"}, {"ticker": "AQST", "relevance_score": "0.420608", "ticker_sentiment_score": "0.058315", "ticker_sentiment_label": "Neutral"}, {"ticker": "PBYI", "relevance_score": "0.164656", "ticker_sentiment_score": "-0.002724", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rigel to Present at the 42nd Annual J.P. Morgan Healthcare Conference", "url": "https://www.prnewswire.com/news-releases/rigel-to-present-at-the-42nd-annual-jp-morgan-healthcare-conference-302025129.html", "time_published": "20240103T130500", "authors": ["Rigel Pharmaceuticals", "Inc."], "summary": "SOUTH SAN FRANCISCO, Calif., Jan. 3, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ( Nasdaq: RIGL ) today announced that Raul Rodriguez, the company's president and CEO, will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024 at 12:00 ...", "banner_image": "https://mma.prnewswire.com/media/681135/rigel_logo_TM_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.121749, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "RIGL", "relevance_score": "0.803061", "ticker_sentiment_score": "0.135755", "ticker_sentiment_label": "Neutral"}]}, {"title": "Corcept  ( CORT )  Falls on Loss of Korlym Patent Lawsuit to Teva", "url": "https://www.zacks.com/stock/news/2204522/corcept-cort-falls-on-loss-of-korlym-patent-lawsuit-to-teva", "time_published": "20240102T162700", "authors": ["Zacks Equity Research"], "summary": "The United States district court for the district of New Jersey rules against Corcept (CORT) in a patent infringement lawsuit against Teva Pharmaceuticals. Stock declines.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/86/1981.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.904684"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.10295, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CORT", "relevance_score": "0.163909", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.465196", "ticker_sentiment_score": "0.270557", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PBYI", "relevance_score": "0.395012", "ticker_sentiment_score": "0.285731", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Eli Lilly  ( LLY )  Stock Up 57% in 2023: Will the Uptrend Continue?", "url": "https://www.zacks.com/stock/news/2204399/eli-lilly-lly-stock-up-57-in-2023-will-the-uptrend-continue", "time_published": "20240102T134300", "authors": ["Zacks Equity Research"], "summary": "Lilly (LLY) is making rapid pipeline progress in areas like obesity, diabetes and Alzheimer's. Mounjaro and Zepbound are expected to be key top-line drivers for Lilly.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}, {"topic": "Earnings", "relevance_score": "0.838487"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.243868, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.598368", "ticker_sentiment_score": "0.380988", "ticker_sentiment_label": "Bullish"}, {"ticker": "RIGL", "relevance_score": "0.203643", "ticker_sentiment_score": "0.133485", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.15347", "ticker_sentiment_score": "0.044317", "ticker_sentiment_label": "Neutral"}, {"ticker": "AQST", "relevance_score": "0.203643", "ticker_sentiment_score": "0.070763", "ticker_sentiment_label": "Neutral"}, {"ticker": "DICE", "relevance_score": "0.051441", "ticker_sentiment_score": "0.033004", "ticker_sentiment_label": "Neutral"}]}, {"title": "Best Momentum Stock to Buy for December 8th", "url": "https://www.zacks.com/commentary/2195329/best-momentum-stock-to-buy-for-december-8th", "time_published": "20231208T150000", "authors": ["Zacks Equity Research"], "summary": "BRSP and RIGL made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 8, 2023.", "banner_image": "https://staticx-tuner.zacks.com/images/charts/6e/1702038067.png", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Real Estate & Construction", "relevance_score": "0.5"}, {"topic": "Life Sciences", "relevance_score": "0.5"}], "overall_sentiment_score": 0.277047, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BRSP", "relevance_score": "0.19117", "ticker_sentiment_score": "0.238623", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RIGL", "relevance_score": "0.371523", "ticker_sentiment_score": "0.095283", "ticker_sentiment_label": "Neutral"}]}, {"title": "New Strong Buy Stocks for November 28th", "url": "https://www.zacks.com/commentary/2189507/new-strong-buy-stocks-for-november-28th", "time_published": "20231128T111900", "authors": ["Zacks Equity Research"], "summary": "AQST, BROS, NSSC, RIGL and RBT have been added to the Zacks Rank #1 (Strong Buy) List on November 28, 2023.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c2/53795.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.682689"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.055738, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NSSC", "relevance_score": "0.541149", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RBTCW", "relevance_score": "0.421485", "ticker_sentiment_score": "-0.082156", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.541149", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BROS", "relevance_score": "0.541149", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AQST", "relevance_score": "0.541149", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Best Momentum Stocks to Buy for November 22nd", "url": "https://www.zacks.com/commentary/2187615/best-momentum-stocks-to-buy-for-november-22nd", "time_published": "20231122T150000", "authors": ["Zacks Equity Research"], "summary": "BWAY, RIGL and BROS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 22, 2023.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.121123, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BRSYF", "relevance_score": "0.580018", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.741116", "ticker_sentiment_score": "0.104455", "ticker_sentiment_label": "Neutral"}, {"ticker": "BROS", "relevance_score": "0.741116", "ticker_sentiment_score": "0.258948", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "New Strong Buy Stocks for November 22nd", "url": "https://www.zacks.com/commentary/2187032/new-strong-buy-stocks-for-november-22nd", "time_published": "20231122T112300", "authors": ["Zacks Equity Research"], "summary": "RIGL, BWAY, AVDX, IMGN and EAT have been added to the Zacks Rank #1 (Strong Buy) List on November 22, 2023.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c2/53795.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.682689"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.087538, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BRSYF", "relevance_score": "0.433523", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "EAT", "relevance_score": "0.55533", "ticker_sentiment_score": "0.186995", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IMGN", "relevance_score": "0.55533", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.55533", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVDX", "relevance_score": "0.55533", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rigel Pharmaceuticals  ( NASDAQ:RIGL )  Stock Rating Lowered by StockNews.com", "url": "https://www.defenseworld.net/2023/11/17/rigel-pharmaceuticals-nasdaqrigl-stock-rating-lowered-by-stocknews-com-2.html", "time_published": "20231117T083302", "authors": ["Defense World Staff"], "summary": "Rigel Pharmaceuticals ( NASDAQ:RIGL ) Stock Rating Lowered by ... Defense World ...", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/rigel-pharmaceuticals-inc-logo.png?v=20221216130713&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.996023"}, {"topic": "Earnings", "relevance_score": "0.947132"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.268719, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RIGL", "relevance_score": "0.768428", "ticker_sentiment_score": "0.430667", "ticker_sentiment_label": "Bullish"}, {"ticker": "PANW", "relevance_score": "0.073321", "ticker_sentiment_score": "0.091888", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMT", "relevance_score": "0.073321", "ticker_sentiment_score": "0.091888", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rigel Reports Third Quarter 2023 Financial Results and Provides Business Update", "url": "https://www.prnewswire.com/news-releases/rigel-reports-third-quarter-2023-financial-results-and-provides-business-update-301980485.html", "time_published": "20231107T210100", "authors": ["Rigel Pharmaceuticals", "Inc."], "summary": "SOUTH SAN FRANCISCO, Calif., Nov. 7, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ( Nasdaq: RIGL ) today reported financial results for the third quarter ended September 30, 2023, including sales of TAVALISSE\u00ae ( fostamatinib disodium hexahydrate ) tablets for the treatment of adults with ...", "banner_image": "https://mma.prnewswire.com/media/681135/rigel_logo_TM_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.976913"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}], "overall_sentiment_score": -0.002419, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GRFS", "relevance_score": "0.048165", "ticker_sentiment_score": "0.057259", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.032121", "ticker_sentiment_score": "-0.010271", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.143796", "ticker_sentiment_score": "0.027877", "ticker_sentiment_label": "Neutral"}]}, {"title": "Revolution Medicines, Inc.  ( RVMD )  Reports Q3 Loss, Lags Revenue Estimates", "url": "https://www.zacks.com/stock/news/2179617/revolution-medicines-inc-rvmd-reports-q3-loss-lags-revenue-estimates", "time_published": "20231106T225005", "authors": ["Zacks Equity Research"], "summary": "Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of 1.98% and 100%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default329.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999759"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.094131, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "RVMD", "relevance_score": "0.397098", "ticker_sentiment_score": "0.010983", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.205225", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rigel Pharmaceuticals  ( NASDAQ:RIGL )  Stock Rating Lowered by StockNews.com", "url": "https://www.defenseworld.net/2023/11/04/rigel-pharmaceuticals-nasdaqrigl-stock-rating-lowered-by-stocknews-com.html", "time_published": "20231104T072049", "authors": ["Defense World Staff"], "summary": "Rigel Pharmaceuticals ( NASDAQ:RIGL ) Stock Rating Lowered by ... Defense World ...", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/rigel-pharmaceuticals-inc-logo.png?v=20221216130713&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.623304"}, {"topic": "Earnings", "relevance_score": "0.928769"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.259087, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RIGL", "relevance_score": "0.762438", "ticker_sentiment_score": "0.41461", "ticker_sentiment_label": "Bullish"}, {"ticker": "STT", "relevance_score": "0.125134", "ticker_sentiment_score": "0.215947", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Rigel Pharmaceuticals  ( NASDAQ:RIGL )  Upgraded by StockNews.com to Buy", "url": "https://www.defenseworld.net/2023/10/27/rigel-pharmaceuticals-nasdaqrigl-upgraded-by-stocknews-com-to-buy-2.html", "time_published": "20231027T071043", "authors": ["Defense World Staff"], "summary": "Rigel Pharmaceuticals ( NASDAQ:RIGL ) Upgraded by StockNews ... Defense World ...", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/rigel-pharmaceuticals-inc-logo.png?v=20221216130713&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Earnings", "relevance_score": "0.947132"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}], "overall_sentiment_score": 0.310576, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RIGL", "relevance_score": "0.822118", "ticker_sentiment_score": "0.499933", "ticker_sentiment_label": "Bullish"}]}, {"title": "Rigel Pharmaceuticals  ( NASDAQ:RIGL )  Downgraded to Hold at StockNews.com", "url": "https://www.defenseworld.net/2023/10/21/rigel-pharmaceuticals-nasdaqrigl-downgraded-to-hold-at-stocknews-com.html", "time_published": "20231021T060244", "authors": ["Defense World Staff"], "summary": "Rigel Pharmaceuticals ( NASDAQ:RIGL ) Downgraded to Hold at ... Defense World ...", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/rigel-pharmaceuticals-inc-logo.png?v=20221216130713&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.99793"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.980509"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.347586, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "FAST", "relevance_score": "0.0699", "ticker_sentiment_score": "0.091297", "ticker_sentiment_label": "Neutral"}, {"ticker": "SSD", "relevance_score": "0.0699", "ticker_sentiment_score": "0.091297", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.74586", "ticker_sentiment_score": "0.535269", "ticker_sentiment_label": "Bullish"}]}, {"title": "Rigel Pharmaceuticals  ( NASDAQ:RIGL )  Upgraded at StockNews.com", "url": "https://www.defenseworld.net/2023/10/11/rigel-pharmaceuticals-nasdaqrigl-upgraded-at-stocknews-com.html", "time_published": "20231011T071443", "authors": ["Defense World Staff"], "summary": "Rigel Pharmaceuticals ( NASDAQ:RIGL - Get Free Report ) was upgraded by equities research analysts at StockNews.com from a \"hold\" rating to a \"buy\" rating in a note issued to investors on Wednesday.", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/rigel-pharmaceuticals-inc-logo.png?v=20221216130713&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.54554"}], "overall_sentiment_score": 0.368068, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "RIGL", "relevance_score": "0.800175", "ticker_sentiment_score": "0.574667", "ticker_sentiment_label": "Bullish"}, {"ticker": "GILD", "relevance_score": "0.068112", "ticker_sentiment_score": "0.089021", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Evolving Market Dynamics of Factor-based Bleeding Disorders: Hemophilia A, Hemophilia B, and Von Willebrand Disease | Key Analysis by DelveInsight", "url": "https://www.prnewswire.com/news-releases/the-evolving-market-dynamics-of-factor-based-bleeding-disorders-hemophilia-a-hemophilia-b-and-von-willebrand-disease--key-analysis-by-delveinsight-301950491.html", "time_published": "20231009T210100", "authors": ["LLP", "DelveInsight Business Research"], "summary": "The Evolving Market Dynamics of Factor-based Bleeding Disorders: Hemophilia A, Hemophilia B, and Von Willebrand ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.009725, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BGNE", "relevance_score": "0.018173", "ticker_sentiment_score": "0.026267", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.036338", "ticker_sentiment_score": "0.036038", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.036338", "ticker_sentiment_score": "0.033442", "ticker_sentiment_label": "Neutral"}, {"ticker": "RSSS", "relevance_score": "0.018173", "ticker_sentiment_score": "0.124364", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.036338", "ticker_sentiment_score": "0.036038", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONS", "relevance_score": "0.018173", "ticker_sentiment_score": "0.029703", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.036338", "ticker_sentiment_score": "0.029364", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.036338", "ticker_sentiment_score": "0.034129", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.054483", "ticker_sentiment_score": "0.032874", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACLX", "relevance_score": "0.018173", "ticker_sentiment_score": "0.026267", "ticker_sentiment_label": "Neutral"}, {"ticker": "AGIO", "relevance_score": "0.018173", "ticker_sentiment_score": "0.029703", "ticker_sentiment_label": "Neutral"}, {"ticker": "SLN", "relevance_score": "0.018173", "ticker_sentiment_score": "0.029703", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRTHF", "relevance_score": "0.018173", "ticker_sentiment_score": "0.026267", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALPN", "relevance_score": "0.018173", "ticker_sentiment_score": "0.033264", "ticker_sentiment_label": "Neutral"}, {"ticker": "INCY", "relevance_score": "0.018173", "ticker_sentiment_score": "0.033264", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.018173", "ticker_sentiment_score": "0.033264", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.036338", "ticker_sentiment_score": "0.029364", "ticker_sentiment_label": "Neutral"}, {"ticker": "CCCC", "relevance_score": "0.018173", "ticker_sentiment_score": "0.026267", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.036338", "ticker_sentiment_score": "0.047119", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635 ( c )  ( 4 ) ", "url": "https://www.prnewswire.com/news-releases/rigel-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-301949850.html", "time_published": "20231006T203000", "authors": ["Inc.", "Rigel Pharmaceuticals"], "summary": "SOUTH SAN FRANCISCO, Calif., Oct. 6, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ( \"Rigel\" ) ( Nasdaq: RIGL ) today announced that it has granted awards pursuant to Rigel's Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement ...", "banner_image": "https://mma.prnewswire.com/media/681135/rigel_logo_TM_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.232119, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RIGL", "relevance_score": "0.779232", "ticker_sentiment_score": "0.408197", "ticker_sentiment_label": "Bullish"}]}, {"title": "Rigel Pharmaceuticals  ( NASDAQ:RIGL )  Downgraded by StockNews.com to \"Hold\"", "url": "https://www.defenseworld.net/2023/10/04/rigel-pharmaceuticals-nasdaqrigl-downgraded-by-stocknews-com-to-hold-2.html", "time_published": "20231004T082855", "authors": ["Defense World Staff"], "summary": "Rigel Pharmaceuticals ( NASDAQ:RIGL ) Downgraded by StockNews ... Defense World ...", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/rigel-pharmaceuticals-inc-logo.png?v=20221216130713&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.658903"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.891286"}], "overall_sentiment_score": 0.342822, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RIGL", "relevance_score": "0.72134", "ticker_sentiment_score": "0.522173", "ticker_sentiment_label": "Bullish"}, {"ticker": "RL", "relevance_score": "0.066414", "ticker_sentiment_score": "0.061954", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rigel Pharmaceuticals  ( NASDAQ:RIGL )  Upgraded to Buy by StockNews.com", "url": "https://www.defenseworld.net/2023/09/24/rigel-pharmaceuticals-nasdaqrigl-upgraded-to-buy-by-stocknews-com.html", "time_published": "20230924T054244", "authors": ["Defense World Staff"], "summary": "Rigel Pharmaceuticals ( NASDAQ:RIGL ) Upgraded to Buy by ... Defense World ...", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/rigel-pharmaceuticals-inc-logo.png?v=20221216130713&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.996023"}, {"topic": "Earnings", "relevance_score": "0.891286"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.295841, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.1331", "ticker_sentiment_score": "0.222828", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RIGL", "relevance_score": "0.724016", "ticker_sentiment_score": "0.45948", "ticker_sentiment_label": "Bullish"}, {"ticker": "STT", "relevance_score": "0.1331", "ticker_sentiment_score": "0.222828", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Rigel Pharmaceuticals  ( NASDAQ:RIGL )  Downgraded by StockNews.com to Hold", "url": "https://www.defenseworld.net/2023/09/06/rigel-pharmaceuticals-nasdaqrigl-downgraded-by-stocknews-com-to-hold.html", "time_published": "20230906T073642", "authors": ["Defense World Staff"], "summary": "Rigel Pharmaceuticals ( NASDAQ:RIGL ) Downgraded by StockNews ... Defense World ...", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/rigel-pharmaceuticals-inc-logo.png?v=20221216130713&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}, {"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.35238, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "RIGL", "relevance_score": "0.751437", "ticker_sentiment_score": "0.542687", "ticker_sentiment_label": "Bullish"}, {"ticker": "UBS", "relevance_score": "0.070725", "ticker_sentiment_score": "0.242621", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Rigel to Participate in Upcoming September Investor Conferences", "url": "https://www.prnewswire.com/news-releases/rigel-to-participate-in-upcoming-september-investor-conferences-301913181.html", "time_published": "20230830T120500", "authors": ["Rigel Pharmaceuticals", "Inc."], "summary": "SOUTH SAN FRANCISCO, Calif., Aug. 30, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ( Nasdaq: RIGL ) today announced that Raul Rodriguez, the company's president and chief executive officer, and Dean Schorno, the company's chief financial officer, will participate in the following investor ...", "banner_image": "https://mma.prnewswire.com/media/681135/rigel_logo_TM_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.102828, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "WFC", "relevance_score": "0.407844", "ticker_sentiment_score": "0.124274", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.716023", "ticker_sentiment_score": "0.129585", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rigel Pharmaceuticals  ( NASDAQ:RIGL )  Rating Increased to Buy at StockNews.com", "url": "https://www.defenseworld.net/2023/08/24/rigel-pharmaceuticals-nasdaqrigl-rating-increased-to-buy-at-stocknews-com.html", "time_published": "20230824T051848", "authors": ["Defense World Staff"], "summary": "Rigel Pharmaceuticals ( NASDAQ:RIGL ) Rating Increased to Buy at ... Defense World ...", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/rigel-pharmaceuticals-inc-logo.png?v=20221216130713&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Earnings", "relevance_score": "0.905476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999186"}], "overall_sentiment_score": 0.285934, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RIGL", "relevance_score": "0.810464", "ticker_sentiment_score": "0.461648", "ticker_sentiment_label": "Bullish"}]}, {"title": "StockNews.com Upgrades Rigel Pharmaceuticals  ( NASDAQ:RIGL )  to \"Buy\"", "url": "https://www.defenseworld.net/2023/08/05/stocknews-com-upgrades-rigel-pharmaceuticals-nasdaqrigl-to-buy.html", "time_published": "20230805T085459", "authors": ["Defense World Staff"], "summary": "Rigel Pharmaceuticals ( NASDAQ:RIGL - Get Free Report ) was upgraded by stock analysts at StockNews.com from a \"hold\" rating to a \"buy\" rating in a research note issued to investors on Thursday.", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/rigel-pharmaceuticals-inc-logo.png?v=20221216130713&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}], "overall_sentiment_score": 0.23183, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RIGL", "relevance_score": "0.825924", "ticker_sentiment_score": "0.384837", "ticker_sentiment_label": "Bullish"}]}, {"title": "Rigel Pharmaceuticals  ( RIGL )  Reports Q2 Loss, Tops Revenue Estimates", "url": "https://www.zacks.com/stock/news/2130668/rigel-pharmaceuticals-rigl-reports-q2-loss-tops-revenue-estimates", "time_published": "20230801T211505", "authors": ["Zacks Equity Research"], "summary": "Rigel (RIGL) delivered earnings and revenue surprises of 50% and 3.34%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default131.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999892"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.121426, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ASRT", "relevance_score": "0.141726", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.141726", "ticker_sentiment_score": "-0.064765", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rigel Reports Second Quarter 2023 Financial Results and Provides Business Update", "url": "https://www.prnewswire.com/news-releases/rigel-reports-second-quarter-2023-financial-results-and-provides-business-update-301890811.html", "time_published": "20230801T200100", "authors": ["Inc.", "Rigel Pharmaceuticals"], "summary": "SOUTH SAN FRANCISCO, Calif., Aug. 1, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ( Nasdaq: RIGL ) today reported financial results for the second quarter ended June 30, 2023, including sales of TAVALISSE\u00ae ( fostamatinib disodium hexahydrate ) tablets for the treatment of adults with chronic ...", "banner_image": "https://mma.prnewswire.com/media/681135/rigel_logo_TM_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.998947"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}], "overall_sentiment_score": 0.01451, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GRFS", "relevance_score": "0.034307", "ticker_sentiment_score": "0.064253", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.085629", "ticker_sentiment_score": "0.027049", "ticker_sentiment_label": "Neutral"}]}, {"title": "7 Cheap Penny Stocks to Buy According To Analysts, Targets Up To 1,090%", "url": "https://pennystocks.com/featured/2023/07/17/7-cheap-penny-stocks-to-buy-according-to-analysts-targets-up-to-1090/", "time_published": "20230717T154911", "authors": ["J. Samuel"], "summary": "Interested in discovering the top penny stocks to invest in? You're certainly not the only one. Capitalizing on the stock market's opportunities is the key to this process. However, the precise method of execution varies based on each individual's trading style and approach.", "banner_image": "https://pennystocks.com/wp-content/uploads/2023/07/penny-stocks-to-buy-Rigel-Pharmaceuticals-RIGL-stock-chart.jpg", "source": "PennyStocks.com", "category_within_source": "n/a", "source_domain": "pennystocks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999701"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Real Estate & Construction", "relevance_score": "0.5"}], "overall_sentiment_score": 0.238178, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RIGL", "relevance_score": "0.084127", "ticker_sentiment_score": "0.057253", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLDE", "relevance_score": "0.125898", "ticker_sentiment_score": "0.050693", "ticker_sentiment_label": "Neutral"}, {"ticker": "WTII", "relevance_score": "0.042122", "ticker_sentiment_score": "0.026806", "ticker_sentiment_label": "Neutral"}, {"ticker": "RMTI", "relevance_score": "0.125898", "ticker_sentiment_score": "0.121485", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gout Market to Accelerate Positively, Estimates DelveInsight | Key Companies Active in the Market - InventisBio, Allena, Olatec, Shanton, LG Chem, Arthrosi, Jiangsu Hengrui Medicine, AstraZeneca, R-Pharm, Arrowhead, Horizon", "url": "https://www.prnewswire.com/news-releases/gout-market-to-accelerate-positively-estimates-delveinsight--key-companies-active-in-the-market---inventisbio-allena-olatec-shanton-lg-chem-arthrosi-jiangsu-hengrui-medicine-astrazeneca-r-pharm-arrowhead-horizon-301869396.html", "time_published": "20230704T210100", "authors": ["LLP", "DelveInsight Business Research"], "summary": "Gout Market to Accelerate Positively, Estimates DelveInsight | Key Companies Active in the Market - InventisBio, Allena ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.01703, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TINLF", "relevance_score": "0.029327", "ticker_sentiment_score": "0.105816", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARWR", "relevance_score": "0.029327", "ticker_sentiment_score": "0.105816", "ticker_sentiment_label": "Neutral"}, {"ticker": "JWCTF", "relevance_score": "0.058615", "ticker_sentiment_score": "0.096001", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALNAQ", "relevance_score": "0.058615", "ticker_sentiment_score": "0.101", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.029327", "ticker_sentiment_score": "0.105816", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.029327", "ticker_sentiment_score": "0.105816", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALNY", "relevance_score": "0.029327", "ticker_sentiment_score": "0.105816", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.029327", "ticker_sentiment_score": "0.105816", "ticker_sentiment_label": "Neutral"}, {"ticker": "SELB", "relevance_score": "0.058615", "ticker_sentiment_score": "0.096001", "ticker_sentiment_label": "Neutral"}]}, {"title": "Cisco, Boot Barn Holdings And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Applied Digital  ( NASDAQ:APLD ) , Boot Barn Holdings  ( NYSE:BOOT ) ", "url": "https://www.benzinga.com/news/23/05/32461489/cisco-boot-barn-holdings-and-other-big-stocks-moving-lower-in-thursdays-pre-market-session", "time_published": "20230518T103436", "authors": ["Lisa Levin"], "summary": "Boot Barn Holdings, Inc. BOOT shares dropped 15.8% to $62.99 in pre-market after the company issued weak financial guidance for Q1 and FY24. Applied Digital Corporation APLD shares declined 5.3% to $6.68 in pre-market trading.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/05/18/cisco_systems_-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.980922"}, {"topic": "Earnings", "relevance_score": "0.744043"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.104783, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CSCO", "relevance_score": "0.501398", "ticker_sentiment_score": "0.593889", "ticker_sentiment_label": "Bullish"}, {"ticker": "NRGV", "relevance_score": "0.348103", "ticker_sentiment_score": "-0.113189", "ticker_sentiment_label": "Neutral"}, {"ticker": "APLD", "relevance_score": "0.501398", "ticker_sentiment_score": "0.286788", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RIGL", "relevance_score": "0.348103", "ticker_sentiment_score": "-0.105143", "ticker_sentiment_label": "Neutral"}, {"ticker": "CNSL", "relevance_score": "0.348103", "ticker_sentiment_score": "-0.102252", "ticker_sentiment_label": "Neutral"}, {"ticker": "BOOT", "relevance_score": "0.348103", "ticker_sentiment_score": "0.138707", "ticker_sentiment_label": "Neutral"}, {"ticker": "SQM", "relevance_score": "0.348103", "ticker_sentiment_score": "-0.60426", "ticker_sentiment_label": "Bearish"}]}, {"title": "Rigel Pharmaceuticals  ( NASDAQ:RIGL )  Stock Rating Lowered by StockNews.com", "url": "https://www.defenseworld.net/2023/05/07/rigel-pharmaceuticals-nasdaqrigl-stock-rating-lowered-by-stocknews-com.html", "time_published": "20230507T062243", "authors": ["Defense World Staff"], "summary": "Rigel Pharmaceuticals ( NASDAQ:RIGL ) Stock Rating Lowered by ... Defense World ...", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/rigel-pharmaceuticals-inc-logo.png?v=20221216130713&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.287765, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMD", "relevance_score": "0.085022", "ticker_sentiment_score": "0.170255", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RIGL", "relevance_score": "0.912398", "ticker_sentiment_score": "0.483435", "ticker_sentiment_label": "Bullish"}, {"ticker": "C", "relevance_score": "0.085022", "ticker_sentiment_score": "0.047088", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBS", "relevance_score": "0.085022", "ticker_sentiment_score": "0.248282", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Rigel Pharmaceuticals  ( RIGL )  Reports Q1 Loss, Tops Revenue Estimates", "url": "https://www.zacks.com/stock/news/2088505/rigel-pharmaceuticals-rigl-reports-q1-loss-tops-revenue-estimates", "time_published": "20230502T211507", "authors": ["Zacks Investment Research"], "summary": "Rigel (RIGL) delivered earnings and revenue surprises of 11.11% and 7.32%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default126.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999892"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.11911, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AUPH", "relevance_score": "0.209365", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.140485", "ticker_sentiment_score": "-0.064431", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rigel Reports First Quarter 2023 Financial Results and Provides Business Update", "url": "https://www.prnewswire.com/news-releases/rigel-reports-first-quarter-2023-financial-results-and-provides-business-update-301813614.html", "time_published": "20230502T200100", "authors": ["Rigel Pharmaceuticals", "Inc."], "summary": "Rigel Reports First Quarter 2023 Financial Results and Provides ... PR ...", "banner_image": "https://mma.prnewswire.com/media/681135/rigel_logo_TM_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.875462"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": -0.019408, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GRFS", "relevance_score": "0.013424", "ticker_sentiment_score": "0.019486", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.067045", "ticker_sentiment_score": "0.026181", "ticker_sentiment_label": "Neutral"}]}, {"title": "Earnings Preview: Pacira  ( PCRX )  Q1 Earnings Expected to Decline", "url": "https://www.zacks.com/stock/news/2085089/earnings-preview-pacira-pcrx-q1-earnings-expected-to-decline", "time_published": "20230426T140202", "authors": ["Zacks Investment Research"], "summary": "Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default283.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.105186, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "RIGL", "relevance_score": "0.088472", "ticker_sentiment_score": "-0.002081", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rigel Pharmaceuticals  ( RIGL )  May Report Negative Earnings: Know the Trend Ahead of Q1 Release", "url": "https://www.zacks.com/stock/news/2084216/rigel-pharmaceuticals-rigl-may-report-negative-earnings-know-the-trend-ahead-of-q1-release", "time_published": "20230425T140125", "authors": ["Zacks Investment Research"], "summary": "Rigel (RIGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default281.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.143289, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "RIGL", "relevance_score": "0.102888", "ticker_sentiment_score": "0.12981", "ticker_sentiment_label": "Neutral"}]}, {"title": "Knight Therapeutics Reports Fourth Quarter and Year-End 2022 Results", "url": "https://www.globenewswire.com/news-release/2023/03/23/2633023/0/en/Knight-Therapeutics-Reports-Fourth-Quarter-and-Year-End-2022-Results.html", "time_published": "20230323T113000", "authors": ["Knight Therapeutics"], "summary": "Achieves Record Annual Revenues and EBITDA Achieves Record Annual Revenues and ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/02c4072d-9fea-4ff1-bd39-1b5405586ad1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.999998"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Economy - Macro", "relevance_score": "0.769861"}], "overall_sentiment_score": 0.194838, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CURN", "relevance_score": "0.014256", "ticker_sentiment_score": "0.011397", "ticker_sentiment_label": "Neutral"}, {"ticker": "KHTRF", "relevance_score": "0.085375", "ticker_sentiment_score": "0.085562", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITUB", "relevance_score": "0.007128", "ticker_sentiment_score": "0.067854", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.007128", "ticker_sentiment_score": "0.067038", "ticker_sentiment_label": "Neutral"}, {"ticker": "CIB", "relevance_score": "0.007128", "ticker_sentiment_score": "0.067854", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:UYU", "relevance_score": "0.014256", "ticker_sentiment_score": "0.06713", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:ARS", "relevance_score": "0.014256", "ticker_sentiment_score": "0.06713", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:EUR", "relevance_score": "0.007128", "ticker_sentiment_score": "0.032466", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:CAD", "relevance_score": "0.071187", "ticker_sentiment_score": "0.109452", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.028507", "ticker_sentiment_score": "0.114943", "ticker_sentiment_label": "Neutral"}]}, {"title": "Knight Therapeutics Reports Fourth Quarter and Year-End 2022 Results", "url": "https://www.benzinga.com/pressreleases/23/03/g31471797/knight-therapeutics-reports-fourth-quarter-and-year-end-2022-results", "time_published": "20230323T113000", "authors": ["Globe Newswire"], "summary": "MONTREAL, March 23, 2023 ( GLOBE NEWSWIRE ) -- Knight Therapeutics Inc. GUD ( \"Knight\" or \"the Company\" ) , a leading Pan-American ( ex-US ) specialty pharmaceutical company, today reported financial results for its fourth quarter and year ended December 31, 2022.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Economy - Macro", "relevance_score": "0.769861"}], "overall_sentiment_score": 0.233421, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CURN", "relevance_score": "0.015402", "ticker_sentiment_score": "0.010685", "ticker_sentiment_label": "Neutral"}, {"ticker": "KHTRF", "relevance_score": "0.061552", "ticker_sentiment_score": "0.082047", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITUB", "relevance_score": "0.010269", "ticker_sentiment_score": "0.070174", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.005134", "ticker_sentiment_score": "0.159536", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CIB", "relevance_score": "0.010269", "ticker_sentiment_score": "0.070174", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:UYU", "relevance_score": "0.015402", "ticker_sentiment_score": "0.06179", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:ARS", "relevance_score": "0.015402", "ticker_sentiment_score": "0.06179", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:EUR", "relevance_score": "0.010269", "ticker_sentiment_score": "0.073325", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:CAD", "relevance_score": "0.087111", "ticker_sentiment_score": "0.106845", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.046184", "ticker_sentiment_score": "0.120647", "ticker_sentiment_label": "Neutral"}]}, {"title": "Credit Suisse, MongoDB And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Credit Suisse Group  ( NYSE:CS ) , Etsy  ( NASDAQ:ETSY ) ", "url": "https://www.benzinga.com/government/23/03/31272571/credit-suisse-mongodb-and-other-big-stocks-moving-lower-in-thursdays-pre-market-session", "time_published": "20230309T110957", "authors": ["Lisa Levin"], "summary": "U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today's pre-market trading session. SVB Financial Group SIVB shares dipped 30.9% to $185.00 in pre-market trading after the company announced plans to sell assets and disclosed a $1.75 billion share sale.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/03/09/image-credit_suisse.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.999365"}, {"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.092857, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CS", "relevance_score": "0.31482", "ticker_sentiment_score": "0.18193", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MARA", "relevance_score": "0.31482", "ticker_sentiment_score": "-0.030451", "ticker_sentiment_label": "Neutral"}, {"ticker": "PGY", "relevance_score": "0.31482", "ticker_sentiment_score": "-0.555851", "ticker_sentiment_label": "Bearish"}, {"ticker": "SIVB", "relevance_score": "0.31482", "ticker_sentiment_score": "0.374822", "ticker_sentiment_label": "Bullish"}, {"ticker": "ETSY", "relevance_score": "0.456884", "ticker_sentiment_score": "0.308205", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDB", "relevance_score": "0.31482", "ticker_sentiment_score": "-0.179758", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "RIGL", "relevance_score": "0.456884", "ticker_sentiment_score": "0.514943", "ticker_sentiment_label": "Bullish"}, {"ticker": "SBNY", "relevance_score": "0.31482", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Rigel Pharmaceuticals Stock Is Rocketing Higher Today - Rigel Pharmaceuticals  ( NASDAQ:RIGL ) ", "url": "https://www.benzinga.com/news/earnings/23/03/31256674/why-rigel-pharmaceuticals-stock-is-rocketing-higher-today", "time_published": "20230308T135045", "authors": ["Adam Eckert"], "summary": "Rigel Pharmaceuticals Inc RIGL shares are on the move Wednesday after the company reported fourth-quarter results well above analyst expectations. What Happened: Rigel reported fourth-quarter revenues of $51.3 million, which beat consensus estimates of $27.97 million, according to Benzinga Pro.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/03/08/analysis-gaa5b461a9_1920.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.576289"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.246396, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RIGL", "relevance_score": "0.588876", "ticker_sentiment_score": "0.530005", "ticker_sentiment_label": "Bullish"}]}, {"title": "Why Rigel Pharmaceuticals Shares Are Trading Higher By Over 30%; Here Are 20 Stocks Moving Premarket - Audacy  ( NYSE:AUD ) , Adial Pharmaceuticals  ( NASDAQ:ADIL ) ", "url": "https://www.benzinga.com/news/23/03/31255520/why-rigel-pharmaceuticals-shares-are-trading-higher-by-over-30-here-are-20-stocks-moving-premarket", "time_published": "20230308T125728", "authors": ["Lisa Levin"], "summary": "Fresh Tracks Therapeutics, Inc. FRTX rose 51.1% to $2.66 in pre-market trading after the company disclosed topline results from single and multiple ascending dose parts of Phase 1 study of oral DYRK1A inhibitor FRTX-02. Rigel Pharmaceuticals, Inc.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/03/08/image_1.jpg?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.82617"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.053425, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVOS", "relevance_score": "0.153961", "ticker_sentiment_score": "0.215666", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MAXN", "relevance_score": "0.153961", "ticker_sentiment_score": "0.322057", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BNOX", "relevance_score": "0.153961", "ticker_sentiment_score": "-0.35238", "ticker_sentiment_label": "Bearish"}, {"ticker": "MFH", "relevance_score": "0.153961", "ticker_sentiment_score": "0.165207", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WE", "relevance_score": "0.077343", "ticker_sentiment_score": "0.169445", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AUD", "relevance_score": "0.229149", "ticker_sentiment_score": "-0.050613", "ticker_sentiment_label": "Neutral"}, {"ticker": "MESO", "relevance_score": "0.153961", "ticker_sentiment_score": "-0.075424", "ticker_sentiment_label": "Neutral"}, {"ticker": "FRTX", "relevance_score": "0.229149", "ticker_sentiment_score": "-0.07215", "ticker_sentiment_label": "Neutral"}, {"ticker": "OBSV", "relevance_score": "0.153961", "ticker_sentiment_score": "0.175568", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SOUN", "relevance_score": "0.153961", "ticker_sentiment_score": "0.036353", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRKA", "relevance_score": "0.229149", "ticker_sentiment_score": "-0.05833", "ticker_sentiment_label": "Neutral"}, {"ticker": "SYTA", "relevance_score": "0.153961", "ticker_sentiment_score": "-0.227283", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ADIL", "relevance_score": "0.153961", "ticker_sentiment_score": "0.043929", "ticker_sentiment_label": "Neutral"}, {"ticker": "METX", "relevance_score": "0.153961", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.153961", "ticker_sentiment_score": "0.286389", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EFOI", "relevance_score": "0.153961", "ticker_sentiment_score": "-0.01551", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRAX", "relevance_score": "0.229149", "ticker_sentiment_score": "0.085859", "ticker_sentiment_label": "Neutral"}, {"ticker": "SFR", "relevance_score": "0.153961", "ticker_sentiment_score": "-0.351122", "ticker_sentiment_label": "Bearish"}]}, {"title": "Rigel Pharmaceuticals  ( RIGL )  Q4 Earnings and Revenues Surpass Estimates", "url": "https://www.zacks.com/stock/news/2062668/rigel-pharmaceuticals-rigl-q4-earnings-and-revenues-surpass-estimates", "time_published": "20230307T221505", "authors": ["Zacks Investment Research"], "summary": "Rigel (RIGL) delivered earnings and revenue surprises of 114.29% and 36.56%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default5.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999892"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.117095, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "IMPL", "relevance_score": "0.208764", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.140076", "ticker_sentiment_score": "-0.024976", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rigel Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update", "url": "https://www.prnewswire.com/news-releases/rigel-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-business-update-301764931.html", "time_published": "20230307T210100", "authors": ["Inc.", "Rigel Pharmaceuticals"], "summary": "Rigel Reports Fourth Quarter and Full Year 2022 Financial Results ... PR ...", "banner_image": "https://mma.prnewswire.com/media/681135/rigel_logo_TM_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.041093, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GRFS", "relevance_score": "0.033159", "ticker_sentiment_score": "0.103481", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.055236", "ticker_sentiment_score": "0.026001", "ticker_sentiment_label": "Neutral"}]}, {"title": "Revolution Medicines, Inc.  ( RVMD )  Reports Q4 Loss, Tops Revenue Estimates", "url": "https://www.zacks.com/stock/news/2059530/revolution-medicines-inc-rvmd-reports-q4-loss-tops-revenue-estimates", "time_published": "20230227T232506", "authors": ["Zacks Investment Research"], "summary": "Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of 25% and 127.04%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default110.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999759"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.10769, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "RVMD", "relevance_score": "0.399204", "ticker_sentiment_score": "0.100167", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.206392", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "United Therapeutics  ( UTHR )  Q4 Earnings and Revenues Miss Estimates", "url": "https://www.zacks.com/stock/news/2057270/united-therapeutics-uthr-q4-earnings-and-revenues-miss-estimates", "time_published": "20230222T121505", "authors": ["Zacks Investment Research"], "summary": "United Therapeutics (UTHR) delivered earnings and revenue surprises of -35.19% and 0.19%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default324.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999992"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.148641, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "RIGL", "relevance_score": "0.209365", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "UTHR", "relevance_score": "0.404563", "ticker_sentiment_score": "0.13094", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pliant Therapeutics Announces Appointment of Lily Cheung as Chief Human Resources Officer", "url": "https://www.globenewswire.com/news-release/2023/01/25/2595153/0/en/Pliant-Therapeutics-Announces-Appointment-of-Lily-Cheung-as-Chief-Human-Resources-Officer.html", "time_published": "20230125T130100", "authors": ["Pliant Therapeutics", "Inc."], "summary": "SOUTH SAN FRANCISCO, Calif., Jan. 25, 2023 ( GLOBE NEWSWIRE ) -- Pliant Therapeutics, Inc. ( Nasdaq: PLRX ) , a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced Ms. Lily Cheung as its Chief Human ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/07141511-d0cc-4c2f-b6f6-2812f8600f31?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.117956, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.051003", "ticker_sentiment_score": "0.053874", "ticker_sentiment_label": "Neutral"}, {"ticker": "IREHF", "relevance_score": "0.051003", "ticker_sentiment_score": "0.024932", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.051003", "ticker_sentiment_score": "0.053874", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.051003", "ticker_sentiment_score": "0.024932", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.051003", "ticker_sentiment_score": "0.024932", "ticker_sentiment_label": "Neutral"}, {"ticker": "PLRX", "relevance_score": "0.29887", "ticker_sentiment_score": "0.118233", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Penny Stocks That Could Make You Filthy Rich", "url": "https://www.fool.com/investing/2023/01/25/3-penny-stocks-that-could-make-you-filthy-rich/", "time_published": "20230125T123000", "authors": ["George Budwell"], "summary": "These low-priced equities could deliver enormous returns for risk-tolerant shareholders.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F717525%2Fdoctor-money.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.451494"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}, {"topic": "Real Estate & Construction", "relevance_score": "0.5"}], "overall_sentiment_score": 0.2474, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ME", "relevance_score": "0.048621", "ticker_sentiment_score": "0.335833", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PGEN", "relevance_score": "0.239541", "ticker_sentiment_score": "0.292731", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RIGL", "relevance_score": "0.097062", "ticker_sentiment_score": "0.360304", "ticker_sentiment_label": "Bullish"}]}, {"title": "Rigel Pharmaceuticals Provides Business Update", "url": "https://www.prnewswire.com/news-releases/rigel-pharmaceuticals-provides-business-update-301716165.html", "time_published": "20230109T130500", "authors": ["Rigel Pharmaceuticals", "Inc."], "summary": "REZLIDHIA\u2122 U.S. FDA approval and commercial launch for the treatment of adult patients with relapsed or refractory AML with susceptible IDH1 mutation", "banner_image": "https://mma.prnewswire.com/media/681135/rigel_logo_TM_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.997405"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}], "overall_sentiment_score": -0.019356, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GRFS", "relevance_score": "0.025339", "ticker_sentiment_score": "0.053759", "ticker_sentiment_label": "Neutral"}, {"ticker": "KSPHF", "relevance_score": "0.012671", "ticker_sentiment_score": "0.049237", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.063291", "ticker_sentiment_score": "0.04107", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rigel Pharmaceuticals  ( NASDAQ:RIGL )  Lifted to Buy at StockNews.com", "url": "https://reporter.am/2023/01/05/rigel-pharmaceuticals-nasdaqrigl-lifted-to-buy-at-stocknews-com.html", "time_published": "20230105T080842", "authors": ["AM Reporter Staff"], "summary": "Rigel Pharmaceuticals ( NASDAQ:RIGL ) Lifted to Buy at StockNews ... Armenian Reporter ...", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/rigel-pharmaceuticals-inc-logo.png?v=20221216130713&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "reporter.am", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.54554"}], "overall_sentiment_score": 0.263516, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RIGL", "relevance_score": "0.866386", "ticker_sentiment_score": "0.439172", "ticker_sentiment_label": "Bullish"}, {"ticker": "AWON", "relevance_score": "0.074692", "ticker_sentiment_score": "-0.038293", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.074692", "ticker_sentiment_score": "0.059486", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.148731", "ticker_sentiment_score": "0.224984", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "StockNews.com has downgraded Rigel Pharmaceuticals'  ( NASDAQ:RIGL )  stock rating.", "url": "https://beststocks.com/stocknews-com-has-downgraded-rigel-pharmaceuticals/", "time_published": "20221230T012132", "authors": ["Yasmim Mendon\u00e7a"], "summary": "StockNews.com has downgraded Rigel Pharmaceuticals' ( NASDAQ ... Best Stocks ...", "banner_image": "https://beststocks.com/wp-content/uploads/2022/09/Dow-Jones-Today-Stocks-Rise-as-Fed-Speaks.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "beststocks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.692272"}, {"topic": "Earnings", "relevance_score": "0.818451"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.214568, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JPM", "relevance_score": "0.102668", "ticker_sentiment_score": "0.19352", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RIGL", "relevance_score": "0.754476", "ticker_sentiment_score": "0.346151", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "C", "relevance_score": "0.051441", "ticker_sentiment_score": "0.071677", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rigel Pharmaceuticals  ( NASDAQ:RIGL )  Lowered to \"Hold\" at StockNews.com", "url": "https://www.etfdailynews.com/2022/12/29/rigel-pharmaceuticals-nasdaqrigl-lowered-to-hold-at-stocknews-com/", "time_published": "20221229T065844", "authors": ["MarketBeat News"], "summary": "Rigel Pharmaceuticals ( NASDAQ:RIGL ) Lowered to \"Hold\" at ... ETF Daily News ...", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/rigel-pharmaceuticals-inc-logo.png?v=20221216130713&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.etfdailynews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.658903"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.227059, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BK", "relevance_score": "0.146025", "ticker_sentiment_score": "0.205383", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RIGL", "relevance_score": "0.832527", "ticker_sentiment_score": "0.378617", "ticker_sentiment_label": "Bullish"}, {"ticker": "C", "relevance_score": "0.073321", "ticker_sentiment_score": "0.026209", "ticker_sentiment_label": "Neutral"}, {"ticker": "DKS", "relevance_score": "0.073321", "ticker_sentiment_score": "0.115611", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMMP", "relevance_score": "0.073321", "ticker_sentiment_score": "0.115611", "ticker_sentiment_label": "Neutral"}]}, {"title": "McKesson  ( MCK )  Announces Availability of FDA-Accepted Drug", "url": "https://www.zacks.com/stock/news/2032077/mckesson-mck-announces-availability-of-fda-accepted-drug", "time_published": "20221223T181500", "authors": ["Zacks Investment Research"], "summary": "The availability of FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for PEComa.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/49/1007.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}], "overall_sentiment_score": 0.029056, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MMSI", "relevance_score": "0.137278", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCK", "relevance_score": "0.510838", "ticker_sentiment_score": "0.016164", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXAS", "relevance_score": "0.33446", "ticker_sentiment_score": "-0.125462", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.068896", "ticker_sentiment_score": "-0.064189", "ticker_sentiment_label": "Neutral"}, {"ticker": "AADI", "relevance_score": "0.068896", "ticker_sentiment_score": "-0.075458", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.068896", "ticker_sentiment_score": "-0.071218", "ticker_sentiment_label": "Neutral"}, {"ticker": "SWAV", "relevance_score": "0.270523", "ticker_sentiment_score": "0.056419", "ticker_sentiment_label": "Neutral"}]}, {"title": "McKesson  ( MCK )  Announces Availability of FDA-Approved Drug", "url": "https://www.zacks.com/stock/news/2030971/mckesson-mck-announces-availability-of-fda-approved-drug", "time_published": "20221221T140400", "authors": ["Zacks Investment Research"], "summary": "The availability of FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for AML.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/49/1007.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}], "overall_sentiment_score": 0.136272, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MMSI", "relevance_score": "0.116067", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCK", "relevance_score": "0.390613", "ticker_sentiment_score": "0.040554", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXAS", "relevance_score": "0.284861", "ticker_sentiment_score": "-0.110608", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMGN", "relevance_score": "0.058188", "ticker_sentiment_score": "-0.067972", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.058188", "ticker_sentiment_score": "0.015006", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.058188", "ticker_sentiment_score": "-0.042041", "ticker_sentiment_label": "Neutral"}, {"ticker": "SWAV", "relevance_score": "0.229691", "ticker_sentiment_score": "0.04943", "ticker_sentiment_label": "Neutral"}]}, {"title": "RIGL: 1 Pharma Stock to Buy for Under $1 This December", "url": "https://stocknews.com/news/rigl-nvo-pfe-bmy-1-pharma-stock-to-buy-for-under-1-this-december/", "time_published": "20221212T130959", "authors": [], "summary": "Rigel Pharmaceuticals ( RIGL ) surpassed EPS estimates by 18.5% for its 2022 third quarter. Moreover, the U.S. Food and Drug Administration approved its REZLIDHIA ( olutasidenib ) capsules for treating adult patients with relapsed or refractory ( R/R ) acute myeloid leukemia.", "banner_image": "https://stocknews.com/wp-content/uploads/2021/11/shutterstock_517925923-1-scaled.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "0.918141"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.170054, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RIGL", "relevance_score": "0.771193", "ticker_sentiment_score": "0.368537", "ticker_sentiment_label": "Bullish"}, {"ticker": "NVO", "relevance_score": "0.136499", "ticker_sentiment_score": "0.097382", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.136499", "ticker_sentiment_score": "0.097382", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.136499", "ticker_sentiment_score": "0.097382", "ticker_sentiment_label": "Neutral"}]}, {"title": "5 Penny Stocks To Buy According To Analysts, Price Targets Up To 919%", "url": "https://pennystocks.com/featured/2022/12/07/5-penny-stocks-to-buy-according-to-analysts-price-targets-up-to-919/", "time_published": "20221207T151033", "authors": ["J. Phillip"], "summary": "5 Penny Stocks To Watch In December With High Marks From Analysts Trading penny stocks has the potential to be a very profitable technique. However, due to the volatility, these trades are seen as having a more significant risk than other types of investments.", "banner_image": null, "source": "PennyStocks.com", "category_within_source": "n/a", "source_domain": "pennystocks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.998356"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.744043"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.20282, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "C", "relevance_score": "0.029839", "ticker_sentiment_score": "0.127596", "ticker_sentiment_label": "Neutral"}, {"ticker": "EHTH", "relevance_score": "0.089351", "ticker_sentiment_score": "0.058884", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.089351", "ticker_sentiment_score": "-0.029468", "ticker_sentiment_label": "Neutral"}, {"ticker": "FMTX", "relevance_score": "0.029839", "ticker_sentiment_score": "0.113352", "ticker_sentiment_label": "Neutral"}, {"ticker": "CCORF", "relevance_score": "0.029839", "ticker_sentiment_score": "0.062884", "ticker_sentiment_label": "Neutral"}, {"ticker": "EOSE", "relevance_score": "0.029839", "ticker_sentiment_score": "0.300263", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VANI", "relevance_score": "0.089351", "ticker_sentiment_score": "0.105015", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:NANO", "relevance_score": "0.029839", "ticker_sentiment_score": "0.078904", "ticker_sentiment_label": "Neutral"}]}, {"title": "Best Penny Stocks To Buy? 4 Under $1 To Watch Now", "url": "https://pennystocks.com/featured/2022/12/05/best-penny-stocks-to-buy-4-under-1-to-watch-now/", "time_published": "20221205T162927", "authors": ["J. Samuel"], "summary": "The basic definition of penny stocks includes those trading below $5. But if you ask most retail traders, they think of penny stocks as stocks trading for pennies a share. That means the vast majority are hunting for stocks under $1, and 2022 has been a year in which we've seen a sea of stocks ...", "banner_image": "https://pennystocks.com/wp-content/uploads/2021/04/penny-stocks-to-buy-under-1-on-robinhood-right-now.jpg", "source": "PennyStocks.com", "category_within_source": "n/a", "source_domain": "pennystocks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.998356"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.201817, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RIGL", "relevance_score": "0.032602", "ticker_sentiment_score": "0.078044", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.032602", "ticker_sentiment_score": "0.251337", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FMTX", "relevance_score": "0.032602", "ticker_sentiment_score": "0.177002", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "COMS", "relevance_score": "0.161928", "ticker_sentiment_score": "0.039784", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dow Drops 100 Points; Asana Shares Plummet - Asana  ( NYSE:ASAN ) , Anavex Life Sciences  ( NASDAQ:AVXL ) ", "url": "https://www.benzinga.com/news/earnings/22/12/29944454/dow-drops-100-points-asana-shares-plummet", "time_published": "20221202T193043", "authors": ["Lisa Levin"], "summary": "U.S. stocks traded lower toward the end of trading, with the Dow Jones falling around 100 points on Friday. The Dow traded down 0.29% to 34,294.69 while the NASDAQ fell 0.78% to 11,393.43. The S&P 500 also fell, dropping, 0.55% to 4,054.11. Also check this: Ethereum Edges Lower But Remains Above ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/12/02/image38.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.007295, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "RDHL", "relevance_score": "0.131284", "ticker_sentiment_score": "-0.09665", "ticker_sentiment_label": "Neutral"}, {"ticker": "ASAN", "relevance_score": "0.131284", "ticker_sentiment_score": "0.223832", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AVXL", "relevance_score": "0.131284", "ticker_sentiment_score": "0.099239", "ticker_sentiment_label": "Neutral"}, {"ticker": "BKR", "relevance_score": "0.065866", "ticker_sentiment_score": "0.211632", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RIGL", "relevance_score": "0.131284", "ticker_sentiment_score": "0.166403", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IOT", "relevance_score": "0.131284", "ticker_sentiment_score": "0.37023", "ticker_sentiment_label": "Bullish"}, {"ticker": "THTX", "relevance_score": "0.131284", "ticker_sentiment_score": "-0.031892", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:ETH", "relevance_score": "0.065866", "ticker_sentiment_score": "-0.208543", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CRYPTO:DOGE", "relevance_score": "0.065866", "ticker_sentiment_score": "-0.208543", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Rigel  ( RIGL )  Up on FDA Nod to Blood Cancer Drug Rezlidhia", "url": "https://www.zacks.com/stock/news/2025019/rigel-rigl-up-on-fda-nod-to-blood-cancer-drug-rezlidhia", "time_published": "20221202T174300", "authors": ["Zacks Investment Research"], "summary": "The FDA approves Rigel's (RIGL) Rezlidhia (olutasidenib) for treating relapsed/refractory acute myeloid leukemia with a susceptible IDH1 mutation. Stock up.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/62/5473.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.769861"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.19589, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "IMCR", "relevance_score": "0.397517", "ticker_sentiment_score": "0.021889", "ticker_sentiment_label": "Neutral"}, {"ticker": "ASLN", "relevance_score": "0.397517", "ticker_sentiment_score": "0.021884", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.165031", "ticker_sentiment_score": "0.139298", "ticker_sentiment_label": "Neutral"}, {"ticker": "FMTX", "relevance_score": "0.165031", "ticker_sentiment_score": "0.169933", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.323078", "ticker_sentiment_score": "0.281629", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Gold Down 1%; Samsara Shares Spike Higher - Asana  ( NYSE:ASAN ) , Anavex Life Sciences  ( NASDAQ:AVXL ) ", "url": "https://www.benzinga.com/news/earnings/22/12/29942487/gold-down-1-samsara-shares-spike-higher", "time_published": "20221202T170659", "authors": ["Lisa Levin"], "summary": "U.S. stocks traded lower midway through trading, with the Dow Jones falling around 75 points on Friday. The Dow traded down 0.22% to 34,319.84 while the NASDAQ fell 0.71% to 11,401.44. The S&P 500 also fell, dropping, 0.47% to 4,057.57. Also check this: Ethereum Edges Lower But Remains Above This ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/12/02/image-gold.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.0, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "RDHL", "relevance_score": "0.137278", "ticker_sentiment_score": "-0.098888", "ticker_sentiment_label": "Neutral"}, {"ticker": "ASAN", "relevance_score": "0.137278", "ticker_sentiment_score": "0.228905", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BORR", "relevance_score": "0.137278", "ticker_sentiment_score": "0.377239", "ticker_sentiment_label": "Bullish"}, {"ticker": "AVXL", "relevance_score": "0.137278", "ticker_sentiment_score": "0.101673", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.137278", "ticker_sentiment_score": "0.170387", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CEIX", "relevance_score": "0.137278", "ticker_sentiment_score": "0.377239", "ticker_sentiment_label": "Bullish"}, {"ticker": "IOT", "relevance_score": "0.137278", "ticker_sentiment_score": "0.378055", "ticker_sentiment_label": "Bullish"}, {"ticker": "THTX", "relevance_score": "0.137278", "ticker_sentiment_score": "-0.032681", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:ETH", "relevance_score": "0.068896", "ticker_sentiment_score": "-0.209306", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CRYPTO:DOGE", "relevance_score": "0.068896", "ticker_sentiment_score": "-0.209306", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Why UiPath Shares Are Trading Higher By Around 8%; Here Are 24 Stocks Moving Premarket - Asana  ( NYSE:ASAN ) , Achilles Therapeutics  ( NASDAQ:ACHL ) ", "url": "https://www.benzinga.com/news/22/12/29937876/why-uipath-shares-are-trading-higher-by-around-8-here-are-24-stocks-moving-premarket", "time_published": "20221202T124905", "authors": ["Lisa Levin"], "summary": "Rigel Pharmaceuticals, Inc. RIGL shares rose 44.7% to $0.9902 in pre-market trading after the company reported the U.S. FDA approval of REZLIDHIA ( olutasidenib ) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation.", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/12/02/image-uipath.png?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.910869"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.938238"}, {"topic": "Real Estate & Construction", "relevance_score": "0.2"}], "overall_sentiment_score": 0.019462, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PATH", "relevance_score": "0.1331", "ticker_sentiment_score": "0.296946", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ASAN", "relevance_score": "0.1331", "ticker_sentiment_score": "0.239746", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RES", "relevance_score": "0.1331", "ticker_sentiment_score": "0.292188", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GSUN", "relevance_score": "0.1331", "ticker_sentiment_score": "-0.141537", "ticker_sentiment_label": "Neutral"}, {"ticker": "VEEV", "relevance_score": "0.1331", "ticker_sentiment_score": "-0.094518", "ticker_sentiment_label": "Neutral"}, {"ticker": "LOTZ", "relevance_score": "0.1331", "ticker_sentiment_score": "-0.141537", "ticker_sentiment_label": "Neutral"}, {"ticker": "XELA", "relevance_score": "0.198493", "ticker_sentiment_score": "0.176686", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MULN", "relevance_score": "0.198493", "ticker_sentiment_score": "0.310191", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RDHL", "relevance_score": "0.1331", "ticker_sentiment_score": "-0.178652", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BPTS", "relevance_score": "0.1331", "ticker_sentiment_score": "-0.216479", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CEVA", "relevance_score": "0.198493", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "OBSV", "relevance_score": "0.1331", "ticker_sentiment_score": "-0.193381", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CTIB", "relevance_score": "0.1331", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACHL", "relevance_score": "0.1331", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRTS", "relevance_score": "0.198493", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TOPS", "relevance_score": "0.1331", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZS", "relevance_score": "0.1331", "ticker_sentiment_score": "-0.052116", "ticker_sentiment_label": "Neutral"}, {"ticker": "OTIC", "relevance_score": "0.1331", "ticker_sentiment_score": "-0.224149", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "RIGL", "relevance_score": "0.1331", "ticker_sentiment_score": "0.086438", "ticker_sentiment_label": "Neutral"}, {"ticker": "MEIP", "relevance_score": "0.1331", "ticker_sentiment_score": "-0.117357", "ticker_sentiment_label": "Neutral"}, {"ticker": "HLBZ", "relevance_score": "0.262522", "ticker_sentiment_score": "0.354797", "ticker_sentiment_label": "Bullish"}, {"ticker": "SONM", "relevance_score": "0.198493", "ticker_sentiment_score": "-0.045328", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRVL", "relevance_score": "0.1331", "ticker_sentiment_score": "-0.227739", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CRYPTO:SNM", "relevance_score": "0.066784", "ticker_sentiment_score": "-0.028297", "ticker_sentiment_label": "Neutral"}]}, {"title": "U.S. FDA approves Rigel Pharma's treatment for a type of leukemia", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-rigel-pharmas-leukemia-treatment-2022-12-01/", "time_published": "20221201T221900", "authors": ["Reuters"], "summary": "U.S. FDA approves Rigel Pharma's leukemia treatment ...", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/PWHXOLDXM5I3FPIC6TXVITEREI.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.213228, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RIGL", "relevance_score": "0.169676", "ticker_sentiment_score": "0.185466", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FMTX", "relevance_score": "0.169676", "ticker_sentiment_score": "0.129036", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rigel Pharmaceuticals  ( NASDAQ:RIGL )  Upgraded to \"Buy\" by StockNews.com", "url": "https://www.etfdailynews.com/2022/11/12/rigel-pharmaceuticals-nasdaqrigl-upgraded-to-buy-by-stocknews-com/", "time_published": "20221112T082043", "authors": ["MarketBeat News"], "summary": "Rigel Pharmaceuticals ( NASDAQ:RIGL - Get Rating ) was upgraded by equities researchers at StockNews.com from a \"hold\" rating to a \"buy\" rating in a research report issued on Saturday. Other analysts also recently issued research reports about the stock.", "banner_image": "https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&Symbol=RIGL", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.etfdailynews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.54554"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.149853, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PRU", "relevance_score": "0.141726", "ticker_sentiment_score": "0.126942", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.87095", "ticker_sentiment_score": "0.258539", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "C", "relevance_score": "0.071145", "ticker_sentiment_score": "0.058335", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rigel Reports Third Quarter 2022 Financial Results and Provides Business Update", "url": "https://www.prnewswire.com/news-releases/rigel-reports-third-quarter-2022-financial-results-and-provides-business-update-301668180.html", "time_published": "20221103T200100", "authors": ["Inc.", "Rigel Pharmaceuticals"], "summary": "FDA review ongoing for olutasidenib NDA; preparations underway for potential launch Third quarter TAVALISSE\u00ae net product sales of $19.2 million and total revenues of $22.4 million Conference call and webcast scheduled today at 4:30 p.m. Eastern Time", "banner_image": "https://mma.prnewswire.com/media/681135/rigel_logo_TM_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999995"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}], "overall_sentiment_score": 0.024195, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GRFS", "relevance_score": "0.02906", "ticker_sentiment_score": "0.103227", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.072567", "ticker_sentiment_score": "0.030463", "ticker_sentiment_label": "Neutral"}, {"ticker": "FMTX", "relevance_score": "0.014533", "ticker_sentiment_score": "0.07687", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Rogers Shares Are Trading Sharply Lower; Here Are 33 Stocks Moving Premarket - Airbnb  ( NASDAQ:ABNB ) , Arcturus Therapeutics  ( NASDAQ:ARCT ) ", "url": "https://www.benzinga.com/news/22/11/29519517/why-rogers-shares-are-trading-sharply-lower-here-are-33-stocks-moving-premarket", "time_published": "20221102T115858", "authors": ["Lisa Levin"], "summary": "Avinger, Inc. AVGR rose 32% to $1.36 in pre-market trading. Avinger is expected to release its financial results for the third quarter on Wednesday, November 9, 2022. Arcturus Therapeutics Holdings Inc. ARCT shares rose 28.8% to $23.55 in pre-market trading.", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/11/02/image16.jpg?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.982687"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.947132"}, {"topic": "Real Estate & Construction", "relevance_score": "0.2"}], "overall_sentiment_score": 0.016878, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BXRX", "relevance_score": "0.09402", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NXL", "relevance_score": "0.09402", "ticker_sentiment_score": "-0.067395", "ticker_sentiment_label": "Neutral"}, {"ticker": "CCNC", "relevance_score": "0.09402", "ticker_sentiment_score": "-0.288669", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ABNB", "relevance_score": "0.09402", "ticker_sentiment_score": "-0.061873", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENVX", "relevance_score": "0.09402", "ticker_sentiment_score": "-0.17528", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CBAT", "relevance_score": "0.09402", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PHAS", "relevance_score": "0.140621", "ticker_sentiment_score": "0.061949", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHGG", "relevance_score": "0.09402", "ticker_sentiment_score": "0.210194", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TFFP", "relevance_score": "0.09402", "ticker_sentiment_score": "-0.030044", "ticker_sentiment_label": "Neutral"}, {"ticker": "YUMC", "relevance_score": "0.09402", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RLX", "relevance_score": "0.09402", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VYNT", "relevance_score": "0.140621", "ticker_sentiment_score": "-0.172769", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "XCUR", "relevance_score": "0.140621", "ticker_sentiment_score": "-0.042585", "ticker_sentiment_label": "Neutral"}, {"ticker": "LFLY", "relevance_score": "0.09402", "ticker_sentiment_score": "-0.013363", "ticker_sentiment_label": "Neutral"}, {"ticker": "SFET", "relevance_score": "0.140621", "ticker_sentiment_score": "0.129824", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMCI", "relevance_score": "0.09402", "ticker_sentiment_score": "0.191142", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MCLD", "relevance_score": "0.09402", "ticker_sentiment_score": "0.223965", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BAND", "relevance_score": "0.09402", "ticker_sentiment_score": "0.245167", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ROG", "relevance_score": "0.09402", "ticker_sentiment_score": "-0.034524", "ticker_sentiment_label": "Neutral"}, {"ticker": "SELB", "relevance_score": "0.140621", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZI", "relevance_score": "0.09402", "ticker_sentiment_score": "-0.076575", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCK", "relevance_score": "0.09402", "ticker_sentiment_score": "-0.206631", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SCPS", "relevance_score": "0.09402", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLYYY", "relevance_score": "0.047092", "ticker_sentiment_score": "-0.31494", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "HTHT", "relevance_score": "0.09402", "ticker_sentiment_score": "-0.117262", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.09402", "ticker_sentiment_score": "-0.075234", "ticker_sentiment_label": "Neutral"}, {"ticker": "SONN", "relevance_score": "0.140621", "ticker_sentiment_score": "0.121075", "ticker_sentiment_label": "Neutral"}, {"ticker": "EVK", "relevance_score": "0.09402", "ticker_sentiment_score": "-0.333251", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ARCT", "relevance_score": "0.09402", "ticker_sentiment_score": "0.099382", "ticker_sentiment_label": "Neutral"}, {"ticker": "LI", "relevance_score": "0.140621", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVGR", "relevance_score": "0.140621", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MINM", "relevance_score": "0.140621", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Another Clinical Trial Setback For Rigel Pharma's Lead Program, This Time For COVID-19 - Rigel Pharmaceuticals  ( NASDAQ:RIGL ) ", "url": "https://www.benzinga.com/general/biotech/22/11/29516670/another-clinical-trial-setback-for-rigel-pharmas-lead-program-this-time-for-covid-19", "time_published": "20221102T104135", "authors": ["Vandana Singh"], "summary": "Rigel Pharmaceuticals Inc RIGL announced topline efficacy and safety results from the FOCUS Phase 3 trial of fostamatinib in hospitalized COVID-19 patients without respiratory failure who have certain high-risk prognostic factors.", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/11/02/aapharma_2.png?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.180119, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RIGL", "relevance_score": "0.605266", "ticker_sentiment_score": "0.262053", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Biotech Stock Roundup: DICE Up on Study Data, GILD, BIIB's Updates & More", "url": "https://www.zacks.com/stock/news/1991109/biotech-stock-roundup-dice-up-on-study-data-gild-biibs-updates-more", "time_published": "20221012T163400", "authors": ["Zacks Investment Research"], "summary": "Regulatory and pipeline updates from DICE and RIGL are the key highlights from the biotech sector during the past week.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/04/837.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.192181, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.081138", "ticker_sentiment_score": "0.028666", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.081138", "ticker_sentiment_score": "0.105921", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.081138", "ticker_sentiment_score": "0.049742", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.16144", "ticker_sentiment_score": "0.144473", "ticker_sentiment_label": "Neutral"}, {"ticker": "DICE", "relevance_score": "0.121445", "ticker_sentiment_score": "0.20284", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Nasdaq Drops 150 Points; AZZ Shares Plummet - AZZ  ( NYSE:AZZ ) , DICE Therapeutics  ( NASDAQ:DICE ) ", "url": "https://www.benzinga.com/news/earnings/22/10/29225213/nasdaq-drops-150-points-azz-shares-plummet", "time_published": "20221011T191939", "authors": ["Lisa Levin"], "summary": "U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite dropping around 150 points on Tuesday. The Dow traded down 0.08% to 29,178.15 while the NASDAQ fell 1.49% to 10,384.62. The S&P 500 also fell, dropping, 0.94% to 3,578.38.", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/10/11/image42.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.031449, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZZ", "relevance_score": "0.128822", "ticker_sentiment_score": "0.074326", "ticker_sentiment_label": "Neutral"}, {"ticker": "OFIX", "relevance_score": "0.128822", "ticker_sentiment_score": "-0.030273", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPNE", "relevance_score": "0.064623", "ticker_sentiment_score": "-0.02516", "ticker_sentiment_label": "Neutral"}, {"ticker": "LASE", "relevance_score": "0.128822", "ticker_sentiment_score": "0.103136", "ticker_sentiment_label": "Neutral"}, {"ticker": "RAD", "relevance_score": "0.128822", "ticker_sentiment_score": "0.463352", "ticker_sentiment_label": "Bullish"}, {"ticker": "DICE", "relevance_score": "0.128822", "ticker_sentiment_score": "0.053579", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.128822", "ticker_sentiment_score": "0.035387", "ticker_sentiment_label": "Neutral"}, {"ticker": "FORG", "relevance_score": "0.254307", "ticker_sentiment_score": "0.377483", "ticker_sentiment_label": "Bullish"}]}, {"title": "Dow Surges Over 100 Points; Crude Oil Down 2% - DICE Therapeutics  ( NASDAQ:DICE ) , e.l.f. Beauty  ( NYSE:ELF ) ", "url": "https://www.benzinga.com/news/earnings/22/10/29221938/dow-surges-over-100-points-crude-oil-down-2", "time_published": "20221011T160008", "authors": ["Lisa Levin"], "summary": "U.S. stocks pared some losses midway through trading, with the Dow Jones gaining more than 100 points on Tuesday. The Dow traded up 0.51% to 29,350.50 while the NASDAQ fell 0.59% to 10,480.20. The S&P 500 also fell, dropping, 0.26% to 3,603.05.", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/10/11/image39.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.029075, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "OFIX", "relevance_score": "0.126119", "ticker_sentiment_score": "-0.029949", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPNE", "relevance_score": "0.063258", "ticker_sentiment_score": "-0.025127", "ticker_sentiment_label": "Neutral"}, {"ticker": "LASE", "relevance_score": "0.126119", "ticker_sentiment_score": "0.102038", "ticker_sentiment_label": "Neutral"}, {"ticker": "RAD", "relevance_score": "0.126119", "ticker_sentiment_score": "0.45939", "ticker_sentiment_label": "Bullish"}, {"ticker": "DICE", "relevance_score": "0.126119", "ticker_sentiment_score": "0.053048", "ticker_sentiment_label": "Neutral"}, {"ticker": "QNGY", "relevance_score": "0.188193", "ticker_sentiment_score": "0.024181", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.126119", "ticker_sentiment_score": "0.035005", "ticker_sentiment_label": "Neutral"}, {"ticker": "FORG", "relevance_score": "0.249106", "ticker_sentiment_score": "0.371859", "ticker_sentiment_label": "Bullish"}]}, {"title": "Rigel  ( RIGL )  to Not Pursue the WAIHA Program, Cut Jobs", "url": "https://www.zacks.com/stock/news/1990445/rigel-rigl-to-not-pursue-the-waiha-program-cut-jobs", "time_published": "20221011T152700", "authors": ["Zacks Investment Research"], "summary": "Rigel (RIGL) decides to back out from the label expansion of fostamatinib for the treatment of patients with warm autoimmune hemolytic anemia (wAIHA) following the FDA???s review.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ba/1149.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.090748, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.219477", "ticker_sentiment_score": "0.103123", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.147366", "ticker_sentiment_score": "0.200096", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Rigel Pharma Drops FDA Submission Plans For Expanded Use Of Its Lead Product - Rigel Pharmaceuticals  ( NASDAQ:RIGL ) ", "url": "https://www.benzinga.com/general/biotech/22/10/29211869/rigel-pharma-drops-fda-submission-plans-expanded-use-of-its-lead-product", "time_published": "20221011T113629", "authors": ["Vandana Singh"], "summary": "Rigel Pharmaceuticals Inc RIGL received guidance from the FDA's review of its re-analysis of data from the FORWARD Phase 3 trial of fostamatinib for warm autoimmune hemolytic anemia ( wAIHA ) .", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/10/11/aapharma_0.png?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.038787, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "RIGL", "relevance_score": "0.43852", "ticker_sentiment_score": "0.329502", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FMTX", "relevance_score": "0.15347", "ticker_sentiment_score": "-0.257931", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Why Leggett & Platt Shares Are Trading Lower; Here Are 24 Stocks Moving Premarket - Blue Hat Interactive  ( NASDAQ:BHAT ) , Applied DNA Sciences  ( NASDAQ:APDN ) ", "url": "https://www.benzinga.com/news/22/10/29213113/why-leggett-platt-shares-are-trading-lower-here-are-24-stocks-moving-premarket", "time_published": "20221011T113020", "authors": ["Lisa Levin"], "summary": "Vox Royalty Corp. VOXR rose 60.4% to $4.33 in pre-market trading. Vox Royalty's common shares commenced trading on The Nasdaq Stock Market on Monday. Chembio Diagnostics, Inc. CEMI shares rose 18.8% to $0.4293 in pre-market trading after dropping over 9% on Monday.", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/10/11/image_4.jpg?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Real Estate & Construction", "relevance_score": "0.2"}], "overall_sentiment_score": -0.052777, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PEGY", "relevance_score": "0.185781", "ticker_sentiment_score": "-0.156585", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "HYMC", "relevance_score": "0.124486", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISPO", "relevance_score": "0.124486", "ticker_sentiment_score": "-0.315699", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "XELA", "relevance_score": "0.185781", "ticker_sentiment_score": "0.154134", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CRKN", "relevance_score": "0.124486", "ticker_sentiment_score": "-0.05419", "ticker_sentiment_label": "Neutral"}, {"ticker": "MULN", "relevance_score": "0.124486", "ticker_sentiment_score": "-0.203259", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "COSM", "relevance_score": "0.062434", "ticker_sentiment_score": "-0.045304", "ticker_sentiment_label": "Neutral"}, {"ticker": "VOXR", "relevance_score": "0.124486", "ticker_sentiment_score": "0.109285", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRAX", "relevance_score": "0.185781", "ticker_sentiment_score": "-0.069691", "ticker_sentiment_label": "Neutral"}, {"ticker": "PSTV", "relevance_score": "0.124486", "ticker_sentiment_score": "0.101187", "ticker_sentiment_label": "Neutral"}, {"ticker": "CEMI", "relevance_score": "0.124486", "ticker_sentiment_score": "0.147524", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRBP", "relevance_score": "0.185781", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LASE", "relevance_score": "0.124486", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BHAT", "relevance_score": "0.124486", "ticker_sentiment_score": "-0.115072", "ticker_sentiment_label": "Neutral"}, {"ticker": "APDN", "relevance_score": "0.185781", "ticker_sentiment_score": "0.08005", "ticker_sentiment_label": "Neutral"}, {"ticker": "CYRN", "relevance_score": "0.124486", "ticker_sentiment_score": "0.119073", "ticker_sentiment_label": "Neutral"}, {"ticker": "MARK", "relevance_score": "0.124486", "ticker_sentiment_score": "-0.203259", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "LEG", "relevance_score": "0.124486", "ticker_sentiment_score": "-0.212552", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SNTI", "relevance_score": "0.124486", "ticker_sentiment_score": "-0.203259", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MMAT", "relevance_score": "0.185781", "ticker_sentiment_score": "0.165367", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RIGL", "relevance_score": "0.124486", "ticker_sentiment_score": "-0.032957", "ticker_sentiment_label": "Neutral"}, {"ticker": "WHLM", "relevance_score": "0.124486", "ticker_sentiment_score": "-0.203259", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "RUBY", "relevance_score": "0.124486", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NLSP", "relevance_score": "0.185781", "ticker_sentiment_score": "-0.015485", "ticker_sentiment_label": "Neutral"}]}, {"title": "iQIYI, Las Vegas Sands And Some Other Big Stocks Moving Lower In Today's Pre-Market Session - FingerMotion  ( NASDAQ:FNGR ) , iQIYI  ( NASDAQ:IQ ) ", "url": "https://www.benzinga.com/news/22/10/29211045/iqiyi-las-vegas-sands-and-some-other-big-stocks-moving-lower-in-todays-pre-market-session", "time_published": "20221011T094659", "authors": ["Lisa Levin"], "summary": "U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today's pre-market trading session. Leggett & Platt, Incorporated LEG fell 8.3% to $31.79 in pre-market trading as the company lowered its earnings and sales projections for full year 2022. FingerMotion, ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/10/11/image34.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.459462"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": -0.233599, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "IQ", "relevance_score": "0.377142", "ticker_sentiment_score": "-0.25643", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "LVS", "relevance_score": "0.377142", "ticker_sentiment_score": "-0.42807", "ticker_sentiment_label": "Bearish"}, {"ticker": "RBLX", "relevance_score": "0.377142", "ticker_sentiment_score": "-0.615551", "ticker_sentiment_label": "Bearish"}, {"ticker": "RIGL", "relevance_score": "0.377142", "ticker_sentiment_score": "-0.073504", "ticker_sentiment_label": "Neutral"}, {"ticker": "FNGR", "relevance_score": "0.377142", "ticker_sentiment_score": "0.430232", "ticker_sentiment_label": "Bullish"}, {"ticker": "LEG", "relevance_score": "0.377142", "ticker_sentiment_score": "-0.445246", "ticker_sentiment_label": "Bearish"}]}, {"title": "Rigel Pharmaceuticals  ( NASDAQ:RIGL )  Upgraded to Buy by StockNews.com", "url": "https://www.etfdailynews.com/2022/10/11/rigel-pharmaceuticals-nasdaqrigl-upgraded-to-buy-by-stocknews-com/", "time_published": "20221011T065047", "authors": ["MarketBeat News"], "summary": "StockNews.com upgraded shares of Rigel Pharmaceuticals ( NASDAQ:RIGL - Get Rating ) from a hold rating to a buy rating in a report published on Monday. Other equities analysts have also issued reports about the company.", "banner_image": "https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&Symbol=RIGL", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.etfdailynews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.692272"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.256679, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RIGL", "relevance_score": "0.838312", "ticker_sentiment_score": "0.424575", "ticker_sentiment_label": "Bullish"}, {"ticker": "AWON", "relevance_score": "0.069697", "ticker_sentiment_score": "-0.028083", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.069697", "ticker_sentiment_score": "0.039122", "ticker_sentiment_label": "Neutral"}, {"ticker": "HRL", "relevance_score": "0.069697", "ticker_sentiment_score": "0.027693", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLX", "relevance_score": "0.069697", "ticker_sentiment_score": "0.027693", "ticker_sentiment_label": "Neutral"}, {"ticker": "QBBHY", "relevance_score": "0.138863", "ticker_sentiment_score": "0.239737", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Rigel Pharmaceuticals  ( NASDAQ:RIGL )  Upgraded to Buy by StockNews.com", "url": "https://reporter.am/2022/10/11/rigel-pharmaceuticals-nasdaqrigl-upgraded-to-buy-by-stocknews-com.html", "time_published": "20221011T065042", "authors": ["AM Reporter Staff"], "summary": "StockNews.com upgraded shares of Rigel Pharmaceuticals ( NASDAQ:RIGL - Get Rating ) from a hold rating to a buy rating in a report published on Monday. Other equities analysts have also issued reports about the company.", "banner_image": "https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&Symbol=RIGL", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "reporter.am", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.692272"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.256679, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RIGL", "relevance_score": "0.838312", "ticker_sentiment_score": "0.424575", "ticker_sentiment_label": "Bullish"}, {"ticker": "AWON", "relevance_score": "0.069697", "ticker_sentiment_score": "-0.028083", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.069697", "ticker_sentiment_score": "0.039122", "ticker_sentiment_label": "Neutral"}, {"ticker": "HRL", "relevance_score": "0.069697", "ticker_sentiment_score": "0.027693", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLX", "relevance_score": "0.069697", "ticker_sentiment_score": "0.027693", "ticker_sentiment_label": "Neutral"}, {"ticker": "QBBHY", "relevance_score": "0.138863", "ticker_sentiment_score": "0.239737", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Crinetics Pharmaceuticals Appoints Dana Pizzuti, M.D. as Chief Development Officer - Crinetics Pharmaceuticals  ( NASDAQ:CRNX ) ", "url": "https://www.benzinga.com/pressreleases/22/10/g29115877/crinetics-pharmaceuticals-appoints-dana-pizzuti-m-d-as-chief-development-officer", "time_published": "20221003T120000", "authors": ["Globe Newswire"], "summary": "SAN DIEGO, Oct. 03, 2022 ( GLOBE NEWSWIRE ) -- Crinetics Pharmaceuticals, Inc. CRNX today announced the appointment of Dana Pizzuti, M.D., as chief development officer.", "banner_image": "", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999499"}], "overall_sentiment_score": 0.118415, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CRNX", "relevance_score": "0.060236", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.03014", "ticker_sentiment_score": "0.070901", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.03014", "ticker_sentiment_score": "0.070901", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rigel Pharmaceuticals  ( NASDAQ:RIGL )  Rating Increased to Buy at StockNews.com", "url": "https://reporter.am/2022/09/24/rigel-pharmaceuticals-nasdaqrigl-rating-increased-to-buy-at-stocknews-com.html", "time_published": "20220924T051042", "authors": ["AM Reporter Staff"], "summary": "Rigel Pharmaceuticals ( NASDAQ:RIGL - Get Rating ) was upgraded by analysts at StockNews.com from a \"hold\" rating to a \"buy\" rating in a research report issued on Thursday.", "banner_image": "https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&Symbol=RIGL", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "reporter.am", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}, {"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.163942, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RIGL", "relevance_score": "0.924127", "ticker_sentiment_score": "0.287042", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "C", "relevance_score": "0.070725", "ticker_sentiment_score": "-0.010061", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRWD", "relevance_score": "0.070725", "ticker_sentiment_score": "0.113381", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTRS", "relevance_score": "0.140896", "ticker_sentiment_score": "0.185344", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Rigel Pharmaceuticals  ( NASDAQ:RIGL )  Stock Rating Upgraded by StockNews.com", "url": "https://www.etfdailynews.com/2022/09/23/rigel-pharmaceuticals-nasdaqrigl-stock-rating-upgraded-by-stocknews-com/", "time_published": "20220923T085241", "authors": ["MarketBeat News"], "summary": "StockNews.com upgraded shares of Rigel Pharmaceuticals ( NASDAQ:RIGL - Get Rating ) from a hold rating to a buy rating in a report published on Thursday. Several other research analysts have also recently issued reports on the stock.", "banner_image": "https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&Symbol=RIGL", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.etfdailynews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.161647"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.186684, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DRI", "relevance_score": "0.069294", "ticker_sentiment_score": "0.100514", "ticker_sentiment_label": "Neutral"}, {"ticker": "JEF", "relevance_score": "0.069294", "ticker_sentiment_score": "0.034187", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.917988", "ticker_sentiment_score": "0.324457", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "C", "relevance_score": "0.069294", "ticker_sentiment_score": "0.034187", "ticker_sentiment_label": "Neutral"}]}, {"title": "Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer", "url": "https://www.globenewswire.com/news-release/2022/09/12/2513840/29236/en/Cara-Therapeutics-Appoints-Ryan-Maynard-as-Chief-Financial-Officer.html", "time_published": "20220912T110000", "authors": ["Cara Therapeutics", "Inc."], "summary": "STAMFORD, Conn., Sept. 12, 2022 ( GLOBE NEWSWIRE ) -- Cara Therapeutics, Inc. ( Nasdaq: CARA ) , a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Ryan Maynard as Chief ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/48327dc6-4706-40c2-a901-968ca39d50ff?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.230763, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CARA", "relevance_score": "0.33514", "ticker_sentiment_score": "0.145756", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.171485", "ticker_sentiment_score": "0.167361", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IOVA", "relevance_score": "0.171485", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rigel Pharmaceuticals  ( NASDAQ:RIGL )  Raised to Buy at StockNews.com", "url": "https://reporter.am/2022/08/26/rigel-pharmaceuticals-nasdaqrigl-raised-to-buy-at-stocknews-com.html", "time_published": "20220826T063441", "authors": ["AM Reporter Staff"], "summary": "StockNews.com upgraded shares of Rigel Pharmaceuticals ( NASDAQ:RIGL - Get Rating ) from a hold rating to a buy rating in a report issued on Monday morning.", "banner_image": "https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&Symbol=RIGL", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "reporter.am", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.692272"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.179919, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JEF", "relevance_score": "0.061631", "ticker_sentiment_score": "0.002002", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.858187", "ticker_sentiment_score": "0.306688", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "STT", "relevance_score": "0.122894", "ticker_sentiment_score": "0.174682", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABBV", "relevance_score": "0.061631", "ticker_sentiment_score": "0.049335", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rigel Pharmaceuticals  ( NASDAQ:RIGL )  Upgraded at StockNews.com", "url": "https://reporter.am/2022/08/25/rigel-pharmaceuticals-nasdaqrigl-upgraded-at-stocknews-com.html", "time_published": "20220825T073442", "authors": ["AM Reporter Staff"], "summary": "StockNews.com upgraded shares of Rigel Pharmaceuticals ( NASDAQ:RIGL - Get Rating ) from a hold rating to a buy rating in a research report report published on Monday morning. Other research analysts have also issued research reports about the stock.", "banner_image": "https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&Symbol=RIGL", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "reporter.am", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Real Estate & Construction", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.197193, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PENN", "relevance_score": "0.072", "ticker_sentiment_score": "0.131201", "ticker_sentiment_label": "Neutral"}, {"ticker": "JEF", "relevance_score": "0.072", "ticker_sentiment_score": "-0.00508", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.913997", "ticker_sentiment_score": "0.340385", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "C", "relevance_score": "0.072", "ticker_sentiment_score": "-0.00508", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTRS", "relevance_score": "0.143415", "ticker_sentiment_score": "0.238033", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Rigel Pharmaceuticals  ( NASDAQ:RIGL )  Upgraded at StockNews.com", "url": "https://www.defenseworld.net/2022/08/23/rigel-pharmaceuticals-nasdaqrigl-upgraded-at-stocknews-com.html", "time_published": "20220823T063856", "authors": ["admin"], "summary": "StockNews.com upgraded shares of Rigel Pharmaceuticals ( NASDAQ:RIGL - Get Rating ) from a hold rating to a buy rating in a research report released on Monday morning. RIGL has been the subject of a number of other research reports.", "banner_image": "https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&Symbol=RIGL", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.107068, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BBBY", "relevance_score": "0.071145", "ticker_sentiment_score": "-0.096392", "ticker_sentiment_label": "Neutral"}, {"ticker": "BYND", "relevance_score": "0.141726", "ticker_sentiment_score": "-0.123187", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.910195", "ticker_sentiment_score": "0.187919", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AWON", "relevance_score": "0.071145", "ticker_sentiment_score": "-0.028114", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.071145", "ticker_sentiment_score": "-0.008061", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTRS", "relevance_score": "0.141726", "ticker_sentiment_score": "0.235869", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Knight Therapeutics Reports Second Quarter 2022 Results", "url": "https://investingnews.com/knight-therapeutics-reports-second-quarter-2022-results/", "time_published": "20220811T115349", "authors": [], "summary": "Knight Therapeutics Inc. ( TSX: GUD ) ( \"Knight\" or \"the Company\" ) , a leading pan-American ( ex-US ) specialty pharmaceutical company, today reported financial results for its second quarter ended June 30, 2022. All currency amounts are in thousands except for share and per share amounts.", "banner_image": "https://mma.prnewswire.com/media/717028/Bausch_Health_Logo.jpg", "source": "Investing News Network", "category_within_source": "n/a", "source_domain": "investingnews.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.9545"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999986"}, {"topic": "Earnings", "relevance_score": "0.999981"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.133263, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CURN", "relevance_score": "0.015957", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "KHTRF", "relevance_score": "0.174129", "ticker_sentiment_score": "0.069587", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.015957", "ticker_sentiment_score": "0.080485", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:UYU", "relevance_score": "0.015957", "ticker_sentiment_score": "0.010269", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:ARS", "relevance_score": "0.015957", "ticker_sentiment_score": "0.010269", "ticker_sentiment_label": "Neutral"}]}, {"title": "Knight Therapeutics Reports Second Quarter 2022 Results", "url": "https://www.benzinga.com/pressreleases/22/08/g28451022/knight-therapeutics-reports-second-quarter-2022-results", "time_published": "20220811T113000", "authors": ["Globe Newswire"], "summary": "MONTREAL, Aug. 11, 2022 ( GLOBE NEWSWIRE ) -- Knight Therapeutics Inc. GUD ( \"Knight\" or \"the Company\" ) , a leading pan-American ( ex-US ) specialty pharmaceutical company, today reported financial results for its second quarter ended June 30, 2022.", "banner_image": "", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.928139"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999996"}, {"topic": "Earnings", "relevance_score": "0.999999"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.142063, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CURN", "relevance_score": "0.012705", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "KHTRF", "relevance_score": "0.139045", "ticker_sentiment_score": "0.060327", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.025406", "ticker_sentiment_score": "0.095038", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:UYU", "relevance_score": "0.012705", "ticker_sentiment_score": "0.010002", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:ARS", "relevance_score": "0.012705", "ticker_sentiment_score": "0.010002", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial", "url": "https://www.benzinga.com/general/biotech/22/08/28331170/biotech-daily-mercks-two-combo-cancer-trials-miss-main-goal-approval-for-sinovacs-covid-19-shot-f", "time_published": "20220803T141314", "authors": ["Vandana Singh"], "summary": "Here's a roundup of top developments in the biotech space over the last 24 hours: Alnylam Pharmaceuticals Inc's ALNY APOLLO-B Phase 3 study of patisiran for transthyretin-mediated ( ATTR ) amyloidosis with cardiomyopathy met the primary endpoint of change from baseline in the 6-Minute Walk Test ( ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/08/03/biotech10.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.155176, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ARQT", "relevance_score": "0.098659", "ticker_sentiment_score": "-0.044069", "ticker_sentiment_label": "Neutral"}, {"ticker": "FATE", "relevance_score": "0.098659", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.098659", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "UTHR", "relevance_score": "0.098659", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "JAZZ", "relevance_score": "0.098659", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMRN", "relevance_score": "0.098659", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "EYPT", "relevance_score": "0.098659", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RGNX", "relevance_score": "0.098659", "ticker_sentiment_score": "0.04127", "ticker_sentiment_label": "Neutral"}, {"ticker": "VNDA", "relevance_score": "0.098659", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.098659", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCRB", "relevance_score": "0.098659", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PSTX", "relevance_score": "0.147516", "ticker_sentiment_score": "0.239293", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ALNY", "relevance_score": "0.098659", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RCUS", "relevance_score": "0.098659", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "EDIT", "relevance_score": "0.098659", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FMTX", "relevance_score": "0.098659", "ticker_sentiment_score": "0.220278", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMRN", "relevance_score": "0.098659", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.098659", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHRS", "relevance_score": "0.098659", "ticker_sentiment_score": "0.106963", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.098659", "ticker_sentiment_score": "0.220278", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KTRA", "relevance_score": "0.098659", "ticker_sentiment_score": "0.16031", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ICPT", "relevance_score": "0.098659", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.098659", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.195814", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.049424", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SVA", "relevance_score": "0.098659", "ticker_sentiment_score": "0.154965", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why Rigel Pharmaceuticals  ( RIGL )  Shares Are Trading Higher Premarket Today", "url": "https://www.benzinga.com/general/biotech/22/08/28327848/rigel-pharma-expands-blood-cancer-portfolio-with-forma-therapeutics-licensing-pact", "time_published": "20220803T121450", "authors": ["Vandana Singh"], "summary": "Rigel Pharmaceuticals Inc RIGL and Forma Therapeutics Inc FMTX entered into an exclusive, worldwide license agreement to develop, manufacture and commercialize olutasidenib. Olutasidenib is an oral, small molecule inhibitor of mIDH1 being investigated for relapsed/refractory acute myeloid ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/08/03/aapharma.png?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.253764, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RIGL", "relevance_score": "0.546745", "ticker_sentiment_score": "0.540412", "ticker_sentiment_label": "Bullish"}, {"ticker": "FMTX", "relevance_score": "0.682689", "ticker_sentiment_score": "0.575889", "ticker_sentiment_label": "Bullish"}]}, {"title": "Rigel Pharmaceuticals  ( RIGL )  Reports Q2 Loss, Tops Revenue Estimates", "url": "https://www.zacks.com/stock/news/1962511/rigel-pharmaceuticals-rigl-reports-q2-loss-tops-revenue-estimates", "time_published": "20220802T220516", "authors": ["Zacks Investment Research"], "summary": "Rigel (RIGL) delivered earnings and revenue surprises of 33.33% and 26.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default269.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999759"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.131329, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CNCE", "relevance_score": "0.208764", "ticker_sentiment_score": "0.098988", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.140076", "ticker_sentiment_score": "0.019739", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rigel Reports Second Quarter 2022 Financial Results and Provides Business Update", "url": "https://www.prnewswire.com/news-releases/rigel-reports-second-quarter-2022-financial-results-and-provides-business-update-301598393.html", "time_published": "20220802T200200", "authors": ["Rigel Pharmaceuticals", "Inc."], "summary": "Second quarter TAVALISSE\u00ae net product sales of $18.6 million and total revenues of $29.8 million Expanded Rigel's hematology-oncology portfolio by entering into an exclusive license agreement with Forma Therapeutics, Inc. for olutasidenib with an expected launch in 2023", "banner_image": "https://mma.prnewswire.com/media/681135/rigel_logo_TM_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999819"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}], "overall_sentiment_score": 0.038608, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "KSPHF", "relevance_score": "0.011117", "ticker_sentiment_score": "-0.0337", "ticker_sentiment_label": "Neutral"}, {"ticker": "GIFLF", "relevance_score": "0.022233", "ticker_sentiment_score": "0.090222", "ticker_sentiment_label": "Neutral"}, {"ticker": "KHTRF", "relevance_score": "0.011117", "ticker_sentiment_score": "0.032881", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKXJF", "relevance_score": "0.011117", "ticker_sentiment_score": "-0.044414", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.033344", "ticker_sentiment_score": "-0.023742", "ticker_sentiment_label": "Neutral"}, {"ticker": "FMTX", "relevance_score": "0.022233", "ticker_sentiment_score": "0.135781", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKYF", "relevance_score": "0.011117", "ticker_sentiment_score": "-0.044414", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study", "url": "https://www.benzinga.com/general/biotech/22/08/28308082/biotech-daily-trial-setback-for-eliem-therapeutics-allarity-drops-work-on-cancer-monotherapies-ax", "time_published": "20220802T122759", "authors": ["Vandana Singh"], "summary": "Here's a roundup of top developments in the biotech space over the last 24 hours: Allarity Therapeutics Inc ALLR said it would refocus its oncology pipeline strategy away from the development of monotherapies toward combination therapies.", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/08/02/biotech4.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Real Estate & Construction", "relevance_score": "0.333333"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.093866, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "KRYS", "relevance_score": "0.105372", "ticker_sentiment_score": "0.112291", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRPT", "relevance_score": "0.105372", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VALN", "relevance_score": "0.105372", "ticker_sentiment_score": "0.12207", "ticker_sentiment_label": "Neutral"}, {"ticker": "RYTM", "relevance_score": "0.105372", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SAGE", "relevance_score": "0.105372", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.157483", "ticker_sentiment_score": "0.079368", "ticker_sentiment_label": "Neutral"}, {"ticker": "XNCR", "relevance_score": "0.157483", "ticker_sentiment_score": "0.009685", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALLR", "relevance_score": "0.105372", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLLS", "relevance_score": "0.157483", "ticker_sentiment_score": "0.03904", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACIU", "relevance_score": "0.105372", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESPR", "relevance_score": "0.105372", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LXRX", "relevance_score": "0.105372", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXLA", "relevance_score": "0.105372", "ticker_sentiment_score": "0.029933", "ticker_sentiment_label": "Neutral"}, {"ticker": "SOLTF", "relevance_score": "0.105372", "ticker_sentiment_score": "0.084091", "ticker_sentiment_label": "Neutral"}, {"ticker": "NAUT", "relevance_score": "0.105372", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RGEN", "relevance_score": "0.105372", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "INCY", "relevance_score": "0.105372", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.105372", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BPMC", "relevance_score": "0.105372", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HALO", "relevance_score": "0.105372", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Best Penny Stocks to Watch as the Market Crashes Again", "url": "https://pennystocks.com/featured/2022/06/16/best-penny-stocks-watch-market-crashes-again/", "time_published": "20220616T193724", "authors": [], "summary": "3 Top Penny Stocks to Add to Your Watchlist Right Now On Thursday, penny stocks and blue chips saw another bearish day of trading. This comes as the S&P 500 dropped by over 3.6% with the NASDAQ down by over 4.5% at midday.", "banner_image": "https://pennystocks.com/wp-content/uploads/2022/06/best-penny-stocks-to-buy-9.jpg", "source": "PennyStocks.com", "category_within_source": "n/a", "source_domain": "pennystocks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Energy & Transportation", "relevance_score": "0.5"}], "overall_sentiment_score": -0.05664, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "KGC", "relevance_score": "0.197534", "ticker_sentiment_score": "-0.136619", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.197534", "ticker_sentiment_score": "0.085346", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech Stock Roundup: BLUE Up on Regulatory Updates, RIGL's Pipeline News & More", "url": "https://www.zacks.com/stock/news/1939474/biotech-stock-roundup-blue-up-on-regulatory-updates-rigls-pipeline-news-more", "time_published": "20220615T172600", "authors": ["Zacks Investment Research"], "summary": "Regulatory and other updates from bluebird (BLUE) and Rigel (RIGL) are a few key highlights from the biotech sector during the past week.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/85/388.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": -0.020211, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "RIGL", "relevance_score": "0.095574", "ticker_sentiment_score": "-0.586963", "ticker_sentiment_label": "Bearish"}, {"ticker": "MRNA", "relevance_score": "0.095574", "ticker_sentiment_score": "-0.146145", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.142932", "ticker_sentiment_score": "0.531804", "ticker_sentiment_label": "Bullish"}, {"ticker": "VALN", "relevance_score": "0.23596", "ticker_sentiment_score": "-0.050831", "ticker_sentiment_label": "Neutral"}, {"ticker": "COGT", "relevance_score": "0.095574", "ticker_sentiment_score": "0.027847", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Stocks Under $1 Insiders Are Buying", "url": "https://www.benzinga.com/trading-ideas/long-ideas/22/06/27694155/3-stocks-under-1-insiders-are-buying", "time_published": "20220614T122254", "authors": ["Lisa Levin"], "summary": "The Nasdaq Composite dropped by more than 500 points on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects.", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/06/14/image_4.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.161647"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": -0.056419, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CRTD", "relevance_score": "0.703273", "ticker_sentiment_score": "0.014749", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.485711", "ticker_sentiment_score": "-0.110133", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.103778", "ticker_sentiment_score": "0.010794", "ticker_sentiment_label": "Neutral"}, {"ticker": "RCRT", "relevance_score": "0.485711", "ticker_sentiment_score": "-0.033842", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks That Hit 52-Week Lows On Thursday", "url": "https://www.benzinga.com/markets/options/22/06/27629097/52-weeks-high-and-low-article", "time_published": "20220609T172611", "authors": ["Benzinga Insights"], "summary": "On Thursday, 126 companies set new 52-week lows. Amazon.com AMZN was the largest firm on a market cap basis to set a new 52-week low. ThermoGenesis Holdings THMO is the smallest company on a market cap basis to set a new 52-week low.", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/movers_image_10154.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Blockchain", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": -0.030108, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SONX", "relevance_score": "0.041567", "ticker_sentiment_score": "0.018053", "ticker_sentiment_label": "Neutral"}, {"ticker": "AHI", "relevance_score": "0.041567", "ticker_sentiment_score": "-0.004376", "ticker_sentiment_label": "Neutral"}, {"ticker": "DRMA", "relevance_score": "0.041567", "ticker_sentiment_score": "0.007584", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZEN", "relevance_score": "0.041567", "ticker_sentiment_score": "-0.021181", "ticker_sentiment_label": "Neutral"}, {"ticker": "GIFI", "relevance_score": "0.062315", "ticker_sentiment_score": "-0.262727", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "QNRX", "relevance_score": "0.041567", "ticker_sentiment_score": "-0.00194", "ticker_sentiment_label": "Neutral"}, {"ticker": "FRGE", "relevance_score": "0.041567", "ticker_sentiment_score": "-0.007094", "ticker_sentiment_label": "Neutral"}, {"ticker": "XELA", "relevance_score": "0.041567", "ticker_sentiment_score": "0.009129", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZUL", "relevance_score": "0.041567", "ticker_sentiment_score": "-0.007013", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVTA", "relevance_score": "0.041567", "ticker_sentiment_score": "-0.003871", "ticker_sentiment_label": "Neutral"}, {"ticker": "VCSA", "relevance_score": "0.041567", "ticker_sentiment_score": "-0.330308", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SLN", "relevance_score": "0.041567", "ticker_sentiment_score": "-0.02409", "ticker_sentiment_label": "Neutral"}, {"ticker": "MPW", "relevance_score": "0.041567", "ticker_sentiment_score": "-0.005739", "ticker_sentiment_label": "Neutral"}, {"ticker": "TOPS", "relevance_score": "0.041567", "ticker_sentiment_score": "-0.03496", "ticker_sentiment_label": "Neutral"}, {"ticker": "BGXX", "relevance_score": "0.041567", "ticker_sentiment_score": "0.002202", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZENV", "relevance_score": "0.041567", "ticker_sentiment_score": "0.009764", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.041567", "ticker_sentiment_score": "0.002187", "ticker_sentiment_label": "Neutral"}, {"ticker": "NBTX", "relevance_score": "0.041567", "ticker_sentiment_score": "-0.006759", "ticker_sentiment_label": "Neutral"}, {"ticker": "NMRK", "relevance_score": "0.041567", "ticker_sentiment_score": "-0.002396", "ticker_sentiment_label": "Neutral"}, {"ticker": "AUR", "relevance_score": "0.041567", "ticker_sentiment_score": "0.002458", "ticker_sentiment_label": "Neutral"}, {"ticker": "OSUR", "relevance_score": "0.041567", "ticker_sentiment_score": "9.6e-05", "ticker_sentiment_label": "Neutral"}, {"ticker": "SYK", "relevance_score": "0.041567", "ticker_sentiment_score": "0.004824", "ticker_sentiment_label": "Neutral"}, {"ticker": "PGNY", "relevance_score": "0.041567", "ticker_sentiment_score": "-0.020471", "ticker_sentiment_label": "Neutral"}, {"ticker": "MAC", "relevance_score": "0.041567", "ticker_sentiment_score": "-0.028077", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDNA", "relevance_score": "0.041567", "ticker_sentiment_score": "0.000679", "ticker_sentiment_label": "Neutral"}, {"ticker": "OMER", "relevance_score": "0.041567", "ticker_sentiment_score": "-0.010003", "ticker_sentiment_label": "Neutral"}, {"ticker": "ORGO", "relevance_score": "0.041567", "ticker_sentiment_score": "-0.019486", "ticker_sentiment_label": "Neutral"}, {"ticker": "HRTX", "relevance_score": "0.041567", "ticker_sentiment_score": "0.010392", "ticker_sentiment_label": "Neutral"}, {"ticker": "CURO", "relevance_score": "0.041567", "ticker_sentiment_score": "-0.000871", "ticker_sentiment_label": "Neutral"}, {"ticker": "THMO", "relevance_score": "0.08302", "ticker_sentiment_score": "0.026705", "ticker_sentiment_label": "Neutral"}, {"ticker": "APRN", "relevance_score": "0.041567", "ticker_sentiment_score": "-0.011865", "ticker_sentiment_label": "Neutral"}, {"ticker": "TLYS", "relevance_score": "0.041567", "ticker_sentiment_score": "0.007504", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNCY", "relevance_score": "0.041567", "ticker_sentiment_score": "-0.028016", "ticker_sentiment_label": "Neutral"}, {"ticker": "KNTK", "relevance_score": "0.041567", "ticker_sentiment_score": "-0.342184", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "HYFM", "relevance_score": "0.041567", "ticker_sentiment_score": "-0.013982", "ticker_sentiment_label": "Neutral"}, {"ticker": "BXP", "relevance_score": "0.041567", "ticker_sentiment_score": "0.001249", "ticker_sentiment_label": "Neutral"}, {"ticker": "EJH", "relevance_score": "0.041567", "ticker_sentiment_score": "-0.281777", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "VAXX", "relevance_score": "0.041567", "ticker_sentiment_score": "-0.000685", "ticker_sentiment_label": "Neutral"}, {"ticker": "VITL", "relevance_score": "0.041567", "ticker_sentiment_score": "0.018023", "ticker_sentiment_label": "Neutral"}, {"ticker": "AIRC", "relevance_score": "0.041567", "ticker_sentiment_score": "0.001641", "ticker_sentiment_label": "Neutral"}, {"ticker": "EVTL", "relevance_score": "0.041567", "ticker_sentiment_score": "-0.00101", "ticker_sentiment_label": "Neutral"}, {"ticker": "FUSN", "relevance_score": "0.041567", "ticker_sentiment_score": "-0.001309", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILT", "relevance_score": "0.041567", "ticker_sentiment_score": "-0.329402", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CBRE", "relevance_score": "0.041567", "ticker_sentiment_score": "-0.072991", "ticker_sentiment_label": "Neutral"}, {"ticker": "LTCH", "relevance_score": "0.041567", "ticker_sentiment_score": "-0.023483", "ticker_sentiment_label": "Neutral"}, {"ticker": "OAC-U", "relevance_score": "0.02079", "ticker_sentiment_score": "0.000482", "ticker_sentiment_label": "Neutral"}, {"ticker": "GRNQ", "relevance_score": "0.041567", "ticker_sentiment_score": "0.001659", "ticker_sentiment_label": "Neutral"}, {"ticker": "MESO", "relevance_score": "0.041567", "ticker_sentiment_score": "-0.000963", "ticker_sentiment_label": "Neutral"}, {"ticker": "SG", "relevance_score": "0.041567", "ticker_sentiment_score": "0.015301", "ticker_sentiment_label": "Neutral"}, {"ticker": "GCMG", "relevance_score": "0.041567", "ticker_sentiment_score": "0.005945", "ticker_sentiment_label": "Neutral"}, {"ticker": "GWH", "relevance_score": "0.041567", "ticker_sentiment_score": "-0.015944", "ticker_sentiment_label": "Neutral"}, {"ticker": "CION", "relevance_score": "0.041567", "ticker_sentiment_score": "0.003262", "ticker_sentiment_label": "Neutral"}, {"ticker": "TCBP", "relevance_score": "0.041567", "ticker_sentiment_score": "0.000189", "ticker_sentiment_label": "Neutral"}, {"ticker": "JHX", "relevance_score": "0.041567", "ticker_sentiment_score": "0.038232", "ticker_sentiment_label": "Neutral"}, {"ticker": "HURC", "relevance_score": "0.041567", "ticker_sentiment_score": "0.001129", "ticker_sentiment_label": "Neutral"}, {"ticker": "CNMD", "relevance_score": "0.041567", "ticker_sentiment_score": "-0.386161", "ticker_sentiment_label": "Bearish"}, {"ticker": "SMED", "relevance_score": "0.041567", "ticker_sentiment_score": "-0.008922", "ticker_sentiment_label": "Neutral"}, {"ticker": "MARA", "relevance_score": "0.041567", "ticker_sentiment_score": "0.003845", "ticker_sentiment_label": "Neutral"}, {"ticker": "SFT", "relevance_score": "0.041567", "ticker_sentiment_score": "0.003409", "ticker_sentiment_label": "Neutral"}, {"ticker": "GGE", "relevance_score": "0.041567", "ticker_sentiment_score": "-0.006482", "ticker_sentiment_label": "Neutral"}, {"ticker": "BOXD", "relevance_score": "0.041567", "ticker_sentiment_score": "-0.055619", "ticker_sentiment_label": "Neutral"}, {"ticker": "HUT", "relevance_score": "0.041567", "ticker_sentiment_score": "0.000939", "ticker_sentiment_label": "Neutral"}, {"ticker": "AKU", "relevance_score": "0.041567", "ticker_sentiment_score": "-0.015542", "ticker_sentiment_label": "Neutral"}, {"ticker": "CCO", "relevance_score": "0.041567", "ticker_sentiment_score": "-0.032536", "ticker_sentiment_label": "Neutral"}, {"ticker": "GREEL", "relevance_score": "0.02079", "ticker_sentiment_score": "-0.01148", "ticker_sentiment_label": "Neutral"}, {"ticker": "WULF", "relevance_score": "0.041567", "ticker_sentiment_score": "-0.01377", "ticker_sentiment_label": "Neutral"}, {"ticker": "CNVY", "relevance_score": "0.041567", "ticker_sentiment_score": "0.002365", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPNE", "relevance_score": "0.041567", "ticker_sentiment_score": "-0.006905", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMPR", "relevance_score": "0.041567", "ticker_sentiment_score": "-0.004114", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSNUF", "relevance_score": "0.02079", "ticker_sentiment_score": "0.006113", "ticker_sentiment_label": "Neutral"}, {"ticker": "MIND", "relevance_score": "0.041567", "ticker_sentiment_score": "0.008649", "ticker_sentiment_label": "Neutral"}, {"ticker": "CGTX", "relevance_score": "0.041567", "ticker_sentiment_score": "0.058827", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVNA", "relevance_score": "0.041567", "ticker_sentiment_score": "-0.002217", "ticker_sentiment_label": "Neutral"}, {"ticker": "PEAK", "relevance_score": "0.041567", "ticker_sentiment_score": "0.004459", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.041567", "ticker_sentiment_score": "0.003419", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIOT", "relevance_score": "0.041567", "ticker_sentiment_score": "-0.357971", "ticker_sentiment_label": "Bearish"}, {"ticker": "HLBZ", "relevance_score": "0.041567", "ticker_sentiment_score": "0.001443", "ticker_sentiment_label": "Neutral"}, {"ticker": "ONVO", "relevance_score": "0.041567", "ticker_sentiment_score": "-0.00285", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.041567", "ticker_sentiment_score": "0.068225", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:AUR", "relevance_score": "0.02079", "ticker_sentiment_score": "0.002458", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rigel  ( RIGL )  wAIHA Study Fails to Meet Goals, Stock Tanks", "url": "https://www.zacks.com/stock/news/1937005/rigel-rigl-waiha-study-fails-to-meet-goals-stock-tanks", "time_published": "20220609T164800", "authors": ["Zacks Investment Research"], "summary": "Rigel (RIGL) phase III study evaluating fostamatinib in patients with warm autoimmune hemolytic anemia did not demonstrate statistical significance in the primary efficacy endpoint.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.197167, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "ALKS", "relevance_score": "0.314921", "ticker_sentiment_score": "-0.032043", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.160686", "ticker_sentiment_score": "-0.634211", "ticker_sentiment_label": "Bearish"}, {"ticker": "GERN", "relevance_score": "0.238992", "ticker_sentiment_score": "-0.081827", "ticker_sentiment_label": "Neutral"}]}, {"title": "18 Stocks Moving in Thursday's Pre-Market Session", "url": "https://www.benzinga.com/news/22/06/27622768/18-stocks-moving-in-thursdays-pre-market-session", "time_published": "20220609T101302", "authors": ["Lisa Levin"], "summary": "View, Inc. VIEW rose 18.5% to $2.05 in pre-market trading after declining 5% on Wednesday. Kiora Pharmaceuticals, Inc. KPRX shares rose 16.7% to $0.56 in pre-market trading after jumping around 32% on Wednesday. Smart for Life, Inc. SMFL rose 14.8% to $0.51 in pre-market trading.", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/06/09/premkt_movers.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.82617"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Real Estate & Construction", "relevance_score": "0.2"}], "overall_sentiment_score": -0.035084, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALNA", "relevance_score": "0.170095", "ticker_sentiment_score": "0.003314", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXM", "relevance_score": "0.170095", "ticker_sentiment_score": "0.020037", "ticker_sentiment_label": "Neutral"}, {"ticker": "HMTV", "relevance_score": "0.252725", "ticker_sentiment_score": "0.000558", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMPP", "relevance_score": "0.170095", "ticker_sentiment_score": "0.004637", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMFL", "relevance_score": "0.252725", "ticker_sentiment_score": "0.077922", "ticker_sentiment_label": "Neutral"}, {"ticker": "KPRX", "relevance_score": "0.170095", "ticker_sentiment_score": "0.002211", "ticker_sentiment_label": "Neutral"}, {"ticker": "SZCRF", "relevance_score": "0.085537", "ticker_sentiment_score": "0.000419", "ticker_sentiment_label": "Neutral"}, {"ticker": "CALA", "relevance_score": "0.170095", "ticker_sentiment_score": "0.001303", "ticker_sentiment_label": "Neutral"}, {"ticker": "VIEW", "relevance_score": "0.170095", "ticker_sentiment_score": "0.00191", "ticker_sentiment_label": "Neutral"}, {"ticker": "QTT", "relevance_score": "0.170095", "ticker_sentiment_score": "-0.000592", "ticker_sentiment_label": "Neutral"}, {"ticker": "FIVE", "relevance_score": "0.252725", "ticker_sentiment_score": "-0.290589", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SCOR", "relevance_score": "0.170095", "ticker_sentiment_score": "0.000419", "ticker_sentiment_label": "Neutral"}, {"ticker": "AKBA", "relevance_score": "0.170095", "ticker_sentiment_score": "0.000607", "ticker_sentiment_label": "Neutral"}, {"ticker": "SVFA", "relevance_score": "0.085537", "ticker_sentiment_score": "0.021282", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.252725", "ticker_sentiment_score": "-0.071651", "ticker_sentiment_label": "Neutral"}, {"ticker": "EFOI", "relevance_score": "0.170095", "ticker_sentiment_score": "0.001862", "ticker_sentiment_label": "Neutral"}]}, {"title": "83 Biggest Movers From Yesterday", "url": "https://www.benzinga.com/news/22/06/27622472/83-biggest-movers-from-yesterday", "time_published": "20220609T094429", "authors": ["Lisa Levin"], "summary": "Symbotic Inc. SYM shares surged 120.6% to settle at $20.07 on Wednesday. Symbotic reported the completion of its business combination with SVF Investment Corp. to become a publicly traded company. HeartCore Enterprises, Inc.", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/06/08/yesterdays_movers_0.png?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.858979"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.99737"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.017657, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "IMPP", "relevance_score": "0.050572", "ticker_sentiment_score": "0.027299", "ticker_sentiment_label": "Neutral"}, {"ticker": "OCFT", "relevance_score": "0.050572", "ticker_sentiment_score": "0.005639", "ticker_sentiment_label": "Neutral"}, {"ticker": "VGFC", "relevance_score": "0.050572", "ticker_sentiment_score": "0.405938", "ticker_sentiment_label": "Bullish"}, {"ticker": "KPLT", "relevance_score": "0.050572", "ticker_sentiment_score": "0.001116", "ticker_sentiment_label": "Neutral"}, {"ticker": "QTNT", "relevance_score": "0.075794", "ticker_sentiment_score": "0.003115", "ticker_sentiment_label": "Neutral"}, {"ticker": "QTT", "relevance_score": "0.050572", "ticker_sentiment_score": "0.053323", "ticker_sentiment_label": "Neutral"}, {"ticker": "TGTX", "relevance_score": "0.050572", "ticker_sentiment_score": "0.004252", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXDX", "relevance_score": "0.050572", "ticker_sentiment_score": "0.032096", "ticker_sentiment_label": "Neutral"}, {"ticker": "KSFTF", "relevance_score": "0.050572", "ticker_sentiment_score": "0.015874", "ticker_sentiment_label": "Neutral"}, {"ticker": "YQ", "relevance_score": "0.050572", "ticker_sentiment_score": "0.007304", "ticker_sentiment_label": "Neutral"}, {"ticker": "MNSO", "relevance_score": "0.050572", "ticker_sentiment_score": "0.004561", "ticker_sentiment_label": "Neutral"}, {"ticker": "EFOI", "relevance_score": "0.050572", "ticker_sentiment_score": "0.014578", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATHX", "relevance_score": "0.050572", "ticker_sentiment_score": "0.00337", "ticker_sentiment_label": "Neutral"}, {"ticker": "PSTI", "relevance_score": "0.050572", "ticker_sentiment_score": "0.003473", "ticker_sentiment_label": "Neutral"}, {"ticker": "BABA", "relevance_score": "0.050572", "ticker_sentiment_score": "0.018655", "ticker_sentiment_label": "Neutral"}, {"ticker": "DBVT", "relevance_score": "0.050572", "ticker_sentiment_score": "0.033239", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMLX", "relevance_score": "0.075794", "ticker_sentiment_score": "0.009903", "ticker_sentiment_label": "Neutral"}, {"ticker": "LMNR", "relevance_score": "0.050572", "ticker_sentiment_score": "0.059412", "ticker_sentiment_label": "Neutral"}, {"ticker": "MICS", "relevance_score": "0.050572", "ticker_sentiment_score": "0.01417", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZD", "relevance_score": "0.025299", "ticker_sentiment_score": "-0.069298", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLCM", "relevance_score": "0.050572", "ticker_sentiment_score": "0.004559", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMG", "relevance_score": "0.050572", "ticker_sentiment_score": "-0.013928", "ticker_sentiment_label": "Neutral"}, {"ticker": "CYRN", "relevance_score": "0.050572", "ticker_sentiment_score": "0.018746", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMAR", "relevance_score": "0.050572", "ticker_sentiment_score": "-0.00257", "ticker_sentiment_label": "Neutral"}, {"ticker": "RDBX", "relevance_score": "0.050572", "ticker_sentiment_score": "0.003141", "ticker_sentiment_label": "Neutral"}, {"ticker": "CCSIV", "relevance_score": "0.025299", "ticker_sentiment_score": "-0.069298", "ticker_sentiment_label": "Neutral"}, {"ticker": "NUTX", "relevance_score": "0.050572", "ticker_sentiment_score": "0.004111", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACLX", "relevance_score": "0.050572", "ticker_sentiment_score": "0.005329", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCM", "relevance_score": "0.050572", "ticker_sentiment_score": "0.001067", "ticker_sentiment_label": "Neutral"}, {"ticker": "LCI", "relevance_score": "0.050572", "ticker_sentiment_score": "0.002725", "ticker_sentiment_label": "Neutral"}, {"ticker": "MITO", "relevance_score": "0.050572", "ticker_sentiment_score": "0.079989", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANVS", "relevance_score": "0.050572", "ticker_sentiment_score": "0.005222", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCP", "relevance_score": "0.050572", "ticker_sentiment_score": "3.7e-05", "ticker_sentiment_label": "Neutral"}, {"ticker": "OMEX", "relevance_score": "0.050572", "ticker_sentiment_score": "-0.00359", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMTE", "relevance_score": "0.050572", "ticker_sentiment_score": "0.007351", "ticker_sentiment_label": "Neutral"}, {"ticker": "CDTX", "relevance_score": "0.050572", "ticker_sentiment_score": "0.00195", "ticker_sentiment_label": "Neutral"}, {"ticker": "NH", "relevance_score": "0.075794", "ticker_sentiment_score": "-0.073886", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXAI", "relevance_score": "0.050572", "ticker_sentiment_score": "0.011918", "ticker_sentiment_label": "Neutral"}, {"ticker": "MATX", "relevance_score": "0.050572", "ticker_sentiment_score": "0.003463", "ticker_sentiment_label": "Neutral"}, {"ticker": "BJDX", "relevance_score": "0.050572", "ticker_sentiment_score": "0.023488", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOTU", "relevance_score": "0.075794", "ticker_sentiment_score": "0.007549", "ticker_sentiment_label": "Neutral"}, {"ticker": "KPRX", "relevance_score": "0.050572", "ticker_sentiment_score": "0.003853", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADTH", "relevance_score": "0.050572", "ticker_sentiment_score": "-0.008512", "ticker_sentiment_label": "Neutral"}, {"ticker": "AERC", "relevance_score": "0.050572", "ticker_sentiment_score": "0.012753", "ticker_sentiment_label": "Neutral"}, {"ticker": "CDRE", "relevance_score": "0.075794", "ticker_sentiment_score": "0.008428", "ticker_sentiment_label": "Neutral"}, {"ticker": "CALA", "relevance_score": "0.050572", "ticker_sentiment_score": "0.000746", "ticker_sentiment_label": "Neutral"}, {"ticker": "DDL", "relevance_score": "0.050572", "ticker_sentiment_score": "0.00106", "ticker_sentiment_label": "Neutral"}, {"ticker": "LOVE", "relevance_score": "0.050572", "ticker_sentiment_score": "0.10348", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKYX", "relevance_score": "0.050572", "ticker_sentiment_score": "0.008633", "ticker_sentiment_label": "Neutral"}, {"ticker": "TBLT", "relevance_score": "0.050572", "ticker_sentiment_score": "0.003535", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTIC", "relevance_score": "0.050572", "ticker_sentiment_score": "0.013897", "ticker_sentiment_label": "Neutral"}, {"ticker": "SJ", "relevance_score": "0.050572", "ticker_sentiment_score": "0.0047", "ticker_sentiment_label": "Neutral"}, {"ticker": "KC", "relevance_score": "0.075794", "ticker_sentiment_score": "0.015874", "ticker_sentiment_label": "Neutral"}, {"ticker": "COSM", "relevance_score": "0.050572", "ticker_sentiment_score": "4.9e-05", "ticker_sentiment_label": "Neutral"}, {"ticker": "HTCR", "relevance_score": "0.050572", "ticker_sentiment_score": "0.014091", "ticker_sentiment_label": "Neutral"}, {"ticker": "EOSE", "relevance_score": "0.050572", "ticker_sentiment_score": "0.003697", "ticker_sentiment_label": "Neutral"}, {"ticker": "DUO", "relevance_score": "0.050572", "ticker_sentiment_score": "0.009997", "ticker_sentiment_label": "Neutral"}, {"ticker": "PSTV", "relevance_score": "0.050572", "ticker_sentiment_score": "0.003825", "ticker_sentiment_label": "Neutral"}, {"ticker": "TLSA", "relevance_score": "0.075794", "ticker_sentiment_score": "0.049964", "ticker_sentiment_label": "Neutral"}, {"ticker": "XCUR", "relevance_score": "0.050572", "ticker_sentiment_score": "0.002609", "ticker_sentiment_label": "Neutral"}, {"ticker": "BOXD", "relevance_score": "0.075794", "ticker_sentiment_score": "0.013603", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMAB", "relevance_score": "0.075794", "ticker_sentiment_score": "0.039001", "ticker_sentiment_label": "Neutral"}, {"ticker": "VVPR", "relevance_score": "0.050572", "ticker_sentiment_score": "0.008504", "ticker_sentiment_label": "Neutral"}, {"ticker": "MNOV", "relevance_score": "0.075794", "ticker_sentiment_score": "0.290767", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MVST", "relevance_score": "0.050572", "ticker_sentiment_score": "0.002749", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRAX", "relevance_score": "0.075794", "ticker_sentiment_score": "0.002855", "ticker_sentiment_label": "Neutral"}, {"ticker": "BYSI", "relevance_score": "0.050572", "ticker_sentiment_score": "0.003164", "ticker_sentiment_label": "Neutral"}, {"ticker": "DAO", "relevance_score": "0.050572", "ticker_sentiment_score": "0.00272", "ticker_sentiment_label": "Neutral"}, {"ticker": "CFRX", "relevance_score": "0.075794", "ticker_sentiment_score": "0.009491", "ticker_sentiment_label": "Neutral"}, {"ticker": "LYLT", "relevance_score": "0.050572", "ticker_sentiment_score": "-0.055931", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZIMCF", "relevance_score": "0.050572", "ticker_sentiment_score": "-0.008758", "ticker_sentiment_label": "Neutral"}, {"ticker": "AUVI", "relevance_score": "0.050572", "ticker_sentiment_score": "0.006702", "ticker_sentiment_label": "Neutral"}, {"ticker": "SVFA", "relevance_score": "0.025299", "ticker_sentiment_score": "0.019203", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.050572", "ticker_sentiment_score": "-0.055017", "ticker_sentiment_label": "Neutral"}, {"ticker": "REKR", "relevance_score": "0.050572", "ticker_sentiment_score": "0.001144", "ticker_sentiment_label": "Neutral"}, {"ticker": "RUBY", "relevance_score": "0.050572", "ticker_sentiment_score": "0.012929", "ticker_sentiment_label": "Neutral"}, {"ticker": "CYCN", "relevance_score": "0.050572", "ticker_sentiment_score": "0.002766", "ticker_sentiment_label": "Neutral"}, {"ticker": "TAL", "relevance_score": "0.050572", "ticker_sentiment_score": "0.003772", "ticker_sentiment_label": "Neutral"}, {"ticker": "EFTR", "relevance_score": "0.050572", "ticker_sentiment_score": "0.013372", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZIM", "relevance_score": "0.050572", "ticker_sentiment_score": "-0.008758", "ticker_sentiment_label": "Neutral"}]}, {"title": "Mid-Afternoon Market Update: Dow Tumbles 300 Points; HeartCore Enterprises Shares Spike Higher", "url": "https://www.benzinga.com/news/earnings/22/06/27615806/mid-afternoon-market-update-dow-tumbles-300-points-heartcore-enterprises-shares-spike-higher", "time_published": "20220608T184614", "authors": ["Lisa Levin"], "summary": "U.S. stocks traded lower toward the end of trading, with the Dow Jones dipping over 300 points on Wednesday. The Dow traded down 0.93% to 32,871.16 while the NASDAQ fell 0.64% to 12,097.13. The S&P also fell, dropping, 1.03% to 4,117.63. Also check this: Lions Gate Entertainment And 2 Other ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/06/08/mid-afternoon-market-update.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}], "overall_sentiment_score": -0.034395, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ROKU", "relevance_score": "0.13299", "ticker_sentiment_score": "0.012078", "ticker_sentiment_label": "Neutral"}, {"ticker": "CPB", "relevance_score": "0.262311", "ticker_sentiment_score": "0.075896", "ticker_sentiment_label": "Neutral"}, {"ticker": "LYLT", "relevance_score": "0.13299", "ticker_sentiment_score": "-0.04121", "ticker_sentiment_label": "Neutral"}, {"ticker": "OCFT", "relevance_score": "0.13299", "ticker_sentiment_score": "0.001854", "ticker_sentiment_label": "Neutral"}, {"ticker": "WIMI", "relevance_score": "0.13299", "ticker_sentiment_score": "0.012078", "ticker_sentiment_label": "Neutral"}, {"ticker": "SVFA", "relevance_score": "0.066728", "ticker_sentiment_score": "0.010515", "ticker_sentiment_label": "Neutral"}, {"ticker": "HTCR", "relevance_score": "0.13299", "ticker_sentiment_score": "0.01972", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.13299", "ticker_sentiment_score": "-0.334324", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AWON", "relevance_score": "0.13299", "ticker_sentiment_score": "-0.057909", "ticker_sentiment_label": "Neutral"}, {"ticker": "LGF-A", "relevance_score": "0.066728", "ticker_sentiment_score": "0.001602", "ticker_sentiment_label": "Neutral"}]}, {"title": "12 Health Care Stocks Moving In Wednesday's Intraday Session", "url": "https://www.benzinga.com/trading-ideas/movers/22/06/27614232/12-health-care-stocks-moving-in-wednesdays-intraday-session", "time_published": "20220608T175343", "authors": ["Benzinga Insights"], "summary": "Kiora Pharmaceuticals KPRX shares increased by 37.9% to $0.5 during Wednesday's regular session. Kiora Pharmaceuticals's stock is trading at a volume of 7.0 million shares as of 13:30 EST. This is 2811.8% of its average full-day volume over the last 100 days. The company's market cap stands at ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/movers_image_10066.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.910869"}, {"topic": "Real Estate & Construction", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": -0.012194, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BJDX", "relevance_score": "0.145013", "ticker_sentiment_score": "0.00301", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCM", "relevance_score": "0.216023", "ticker_sentiment_score": "0.001698", "ticker_sentiment_label": "Neutral"}, {"ticker": "MITO", "relevance_score": "0.145013", "ticker_sentiment_score": "0.001679", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXDX", "relevance_score": "0.145013", "ticker_sentiment_score": "-0.001707", "ticker_sentiment_label": "Neutral"}, {"ticker": "KPRX", "relevance_score": "0.145013", "ticker_sentiment_score": "0.003871", "ticker_sentiment_label": "Neutral"}, {"ticker": "COSM", "relevance_score": "0.145013", "ticker_sentiment_score": "-0.000659", "ticker_sentiment_label": "Neutral"}, {"ticker": "CYCC", "relevance_score": "0.072809", "ticker_sentiment_score": "-0.000694", "ticker_sentiment_label": "Neutral"}, {"ticker": "CDTX", "relevance_score": "0.145013", "ticker_sentiment_score": "0.001894", "ticker_sentiment_label": "Neutral"}, {"ticker": "NH", "relevance_score": "0.145013", "ticker_sentiment_score": "-0.0236", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.145013", "ticker_sentiment_score": "-0.016193", "ticker_sentiment_label": "Neutral"}, {"ticker": "OTRK", "relevance_score": "0.072809", "ticker_sentiment_score": "-0.016782", "ticker_sentiment_label": "Neutral"}, {"ticker": "RUBY", "relevance_score": "0.145013", "ticker_sentiment_score": "0.010328", "ticker_sentiment_label": "Neutral"}]}, {"title": "Mid-Day Market Update: Crude Oil Rises 1%; Rigel Pharmaceuticals Shares Slide", "url": "https://www.benzinga.com/news/earnings/22/06/27613135/mid-day-market-update-crude-oil-rises-1-rigel-pharmaceuticals-shares-slide", "time_published": "20220608T164009", "authors": ["Lisa Levin"], "summary": "U.S. stocks traded mixed midway through trading, with the Nasdaq Composite adding around 50 points on Wednesday. The Dow traded down 0.21% to 33,110.37 while the NASDAQ rose 0.39% to 12,223.18. The S&P also fell, dropping, 0.12% to 4,155.85.", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/06/08/mid-day-market-update.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}], "overall_sentiment_score": -0.023775, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CPB", "relevance_score": "0.252921", "ticker_sentiment_score": "0.075896", "ticker_sentiment_label": "Neutral"}, {"ticker": "LYLT", "relevance_score": "0.128101", "ticker_sentiment_score": "-0.021366", "ticker_sentiment_label": "Neutral"}, {"ticker": "OCFT", "relevance_score": "0.128101", "ticker_sentiment_score": "0.002056", "ticker_sentiment_label": "Neutral"}, {"ticker": "DOYU", "relevance_score": "0.128101", "ticker_sentiment_score": "0.010487", "ticker_sentiment_label": "Neutral"}, {"ticker": "SVFA", "relevance_score": "0.064259", "ticker_sentiment_score": "0.015299", "ticker_sentiment_label": "Neutral"}, {"ticker": "HTCR", "relevance_score": "0.128101", "ticker_sentiment_score": "0.027667", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.128101", "ticker_sentiment_score": "-0.302811", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AWON", "relevance_score": "0.128101", "ticker_sentiment_score": "-0.057909", "ticker_sentiment_label": "Neutral"}, {"ticker": "RDBX", "relevance_score": "0.128101", "ticker_sentiment_score": "0.010487", "ticker_sentiment_label": "Neutral"}, {"ticker": "LGF-A", "relevance_score": "0.064259", "ticker_sentiment_score": "0.003009", "ticker_sentiment_label": "Neutral"}]}, {"title": "50 Stocks Moving In Wednesday's Mid-Day Session", "url": "https://www.benzinga.com/news/22/06/27612909/50-stocks-moving-in-wednesdays-mid-day-session", "time_published": "20220608T162921", "authors": ["Lisa Levin"], "summary": "HeartCore Enterprises, Inc. HTCR shares gained 81% to $1.8503 after the company authorized a $3.5 million buyback. Symbotic Inc. SYM shares climbed 76.3% to $16.04. Symbotic reported the completion of its business combination with SVF Investment Corp. to become a publicly traded company.", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/06/08/mid-day_movers_image.jpg?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.995015"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.007433, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "IMPP", "relevance_score": "0.083701", "ticker_sentiment_score": "0.012191", "ticker_sentiment_label": "Neutral"}, {"ticker": "OCFT", "relevance_score": "0.083701", "ticker_sentiment_score": "0.006589", "ticker_sentiment_label": "Neutral"}, {"ticker": "KPLT", "relevance_score": "0.083701", "ticker_sentiment_score": "1.4e-05", "ticker_sentiment_label": "Neutral"}, {"ticker": "QTT", "relevance_score": "0.083701", "ticker_sentiment_score": "0.000179", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXDX", "relevance_score": "0.083701", "ticker_sentiment_score": "0.002531", "ticker_sentiment_label": "Neutral"}, {"ticker": "KSFTF", "relevance_score": "0.083701", "ticker_sentiment_score": "0.006755", "ticker_sentiment_label": "Neutral"}, {"ticker": "YQ", "relevance_score": "0.083701", "ticker_sentiment_score": "0.00243", "ticker_sentiment_label": "Neutral"}, {"ticker": "MNSO", "relevance_score": "0.083701", "ticker_sentiment_score": "0.000588", "ticker_sentiment_label": "Neutral"}, {"ticker": "EFOI", "relevance_score": "0.083701", "ticker_sentiment_score": "0.01473", "ticker_sentiment_label": "Neutral"}, {"ticker": "MICS", "relevance_score": "0.083701", "ticker_sentiment_score": "0.004075", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZD", "relevance_score": "0.041908", "ticker_sentiment_score": "-0.0771", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMG", "relevance_score": "0.083701", "ticker_sentiment_score": "-0.013928", "ticker_sentiment_label": "Neutral"}, {"ticker": "CYRN", "relevance_score": "0.083701", "ticker_sentiment_score": "0.007985", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMAR", "relevance_score": "0.083701", "ticker_sentiment_score": "-0.001166", "ticker_sentiment_label": "Neutral"}, {"ticker": "CCSIV", "relevance_score": "0.041908", "ticker_sentiment_score": "-0.0771", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACLX", "relevance_score": "0.083701", "ticker_sentiment_score": "0.001985", "ticker_sentiment_label": "Neutral"}, {"ticker": "MITO", "relevance_score": "0.083701", "ticker_sentiment_score": "0.059392", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANVS", "relevance_score": "0.083701", "ticker_sentiment_score": "0.00149", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCP", "relevance_score": "0.083701", "ticker_sentiment_score": "0.000302", "ticker_sentiment_label": "Neutral"}, {"ticker": "OMEX", "relevance_score": "0.083701", "ticker_sentiment_score": "-0.001678", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMTE", "relevance_score": "0.083701", "ticker_sentiment_score": "1.6e-05", "ticker_sentiment_label": "Neutral"}, {"ticker": "YMM", "relevance_score": "0.083701", "ticker_sentiment_score": "0.001023", "ticker_sentiment_label": "Neutral"}, {"ticker": "CDTX", "relevance_score": "0.083701", "ticker_sentiment_score": "0.000991", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOTU", "relevance_score": "0.125264", "ticker_sentiment_score": "0.007224", "ticker_sentiment_label": "Neutral"}, {"ticker": "KPRX", "relevance_score": "0.083701", "ticker_sentiment_score": "0.000506", "ticker_sentiment_label": "Neutral"}, {"ticker": "AERC", "relevance_score": "0.083701", "ticker_sentiment_score": "0.009256", "ticker_sentiment_label": "Neutral"}, {"ticker": "CDRE", "relevance_score": "0.125264", "ticker_sentiment_score": "0.008829", "ticker_sentiment_label": "Neutral"}, {"ticker": "LOVE", "relevance_score": "0.083701", "ticker_sentiment_score": "0.149388", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKYX", "relevance_score": "0.083701", "ticker_sentiment_score": "0.000546", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTIC", "relevance_score": "0.083701", "ticker_sentiment_score": "0.002753", "ticker_sentiment_label": "Neutral"}, {"ticker": "KC", "relevance_score": "0.125264", "ticker_sentiment_score": "0.006755", "ticker_sentiment_label": "Neutral"}, {"ticker": "COSM", "relevance_score": "0.083701", "ticker_sentiment_score": "0.000105", "ticker_sentiment_label": "Neutral"}, {"ticker": "HTCR", "relevance_score": "0.083701", "ticker_sentiment_score": "0.001519", "ticker_sentiment_label": "Neutral"}, {"ticker": "TLSA", "relevance_score": "0.125264", "ticker_sentiment_score": "0.051692", "ticker_sentiment_label": "Neutral"}, {"ticker": "XCUR", "relevance_score": "0.083701", "ticker_sentiment_score": "0.001478", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMAB", "relevance_score": "0.125264", "ticker_sentiment_score": "0.007232", "ticker_sentiment_label": "Neutral"}, {"ticker": "MNOV", "relevance_score": "0.125264", "ticker_sentiment_score": "0.27256", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MVST", "relevance_score": "0.083701", "ticker_sentiment_score": "0.000997", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRAX", "relevance_score": "0.125264", "ticker_sentiment_score": "-0.001174", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACRX", "relevance_score": "0.083701", "ticker_sentiment_score": "0.000585", "ticker_sentiment_label": "Neutral"}, {"ticker": "LYLT", "relevance_score": "0.083701", "ticker_sentiment_score": "-0.07359", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZIMCF", "relevance_score": "0.083701", "ticker_sentiment_score": "-0.007938", "ticker_sentiment_label": "Neutral"}, {"ticker": "AUVI", "relevance_score": "0.083701", "ticker_sentiment_score": "0.002904", "ticker_sentiment_label": "Neutral"}, {"ticker": "SVFA", "relevance_score": "0.041908", "ticker_sentiment_score": "0.006429", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.083701", "ticker_sentiment_score": "-0.114445", "ticker_sentiment_label": "Neutral"}, {"ticker": "RUBY", "relevance_score": "0.083701", "ticker_sentiment_score": "0.001219", "ticker_sentiment_label": "Neutral"}, {"ticker": "TAL", "relevance_score": "0.083701", "ticker_sentiment_score": "0.007243", "ticker_sentiment_label": "Neutral"}, {"ticker": "EFTR", "relevance_score": "0.083701", "ticker_sentiment_score": "0.002596", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZIM", "relevance_score": "0.083701", "ticker_sentiment_score": "-0.007938", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Rigel Pharmaceuticals Shares Are Falling Today", "url": "https://www.benzinga.com/general/biotech/22/06/27609153/why-rigel-pharmaceuticals-shares-are-falling-today", "time_published": "20220608T141305", "authors": ["Randy Elias"], "summary": "Rigel Pharmaceuticals, Inc. RIGL shares are trading lower after the company announced data from the FORWARD Phase 3 clinical trial of Fostamatinib did not demonstrate statistical significance in the primary efficacy endpoint.", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/06/08/stock_chart_falling.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": -0.215996, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "RIGL", "relevance_score": "0.756001", "ticker_sentiment_score": "-0.245711", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Rigel Pharmaceuticals' Fostamatinib Flunks In Late-Stage Rare Blood Disorder Trial", "url": "https://www.benzinga.com/general/biotech/22/06/27607198/rigel-pharmaceuticals-fostamatinib-flunks-in-late-stage-rare-blood-disorder-trial", "time_published": "20220608T133147", "authors": ["Vandana Singh"], "summary": "Rigel Pharmaceuticals Inc RIGL shares are falling on disappointing data from the FORWARD Phase 3 trial of fostamatinib in patients with warm autoimmune hemolytic anemia ( wAIHA ) . wAIHA is an autoimmune disorder characterized by the premature destruction of healthy red blood cells ( ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/06/08/aapharma_3.png?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": -0.202738, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "KHTRF", "relevance_score": "0.176116", "ticker_sentiment_score": "0.008559", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.495647", "ticker_sentiment_score": "-0.297587", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Stocks That Hit 52-Week Lows On Tuesday", "url": "https://www.benzinga.com/markets/options/22/06/27591585/52-weeks-high-and-low-article", "time_published": "20220607T161020", "authors": ["Benzinga Insights"], "summary": "On Tuesday, 111 companies reached new 52-week lows. Things to Consider About Today's 52-Week Lows: Amazon.com ( NASDAQ:AMZN ) was the biggest company by market cap to set a new 52-week low. Yunhong CTI ( NASDAQ:CTIB ) is the smallest company on a market cap basis to set a new 52-week low. A-Mark", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/movers_image_9971.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Blockchain", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": -0.013953, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TELA", "relevance_score": "0.044543", "ticker_sentiment_score": "0.002129", "ticker_sentiment_label": "Neutral"}, {"ticker": "FLGC", "relevance_score": "0.044543", "ticker_sentiment_score": "0.008251", "ticker_sentiment_label": "Neutral"}, {"ticker": "REVG", "relevance_score": "0.044543", "ticker_sentiment_score": "0.009867", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZEN", "relevance_score": "0.044543", "ticker_sentiment_score": "0.013425", "ticker_sentiment_label": "Neutral"}, {"ticker": "CDXS", "relevance_score": "0.044543", "ticker_sentiment_score": "-0.007081", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTV", "relevance_score": "0.044543", "ticker_sentiment_score": "-0.035767", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXAS", "relevance_score": "0.044543", "ticker_sentiment_score": "0.025581", "ticker_sentiment_label": "Neutral"}, {"ticker": "QNRX", "relevance_score": "0.044543", "ticker_sentiment_score": "-0.003391", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMRA", "relevance_score": "0.044543", "ticker_sentiment_score": "0.011669", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNR", "relevance_score": "0.044543", "ticker_sentiment_score": "0.005939", "ticker_sentiment_label": "Neutral"}, {"ticker": "DFH", "relevance_score": "0.044543", "ticker_sentiment_score": "0.007407", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRAA", "relevance_score": "0.044543", "ticker_sentiment_score": "-0.000388", "ticker_sentiment_label": "Neutral"}, {"ticker": "SISI", "relevance_score": "0.044543", "ticker_sentiment_score": "0.004312", "ticker_sentiment_label": "Neutral"}, {"ticker": "XELA", "relevance_score": "0.044543", "ticker_sentiment_score": "0.002365", "ticker_sentiment_label": "Neutral"}, {"ticker": "PHAS", "relevance_score": "0.044543", "ticker_sentiment_score": "0.005095", "ticker_sentiment_label": "Neutral"}, {"ticker": "SLG", "relevance_score": "0.044543", "ticker_sentiment_score": "-0.23414", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "TBBK", "relevance_score": "0.02228", "ticker_sentiment_score": "-0.000893", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRON", "relevance_score": "0.044543", "ticker_sentiment_score": "-0.050716", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVTA", "relevance_score": "0.044543", "ticker_sentiment_score": "0.003841", "ticker_sentiment_label": "Neutral"}, {"ticker": "VCSA", "relevance_score": "0.044543", "ticker_sentiment_score": "0.004107", "ticker_sentiment_label": "Neutral"}, {"ticker": "MPW", "relevance_score": "0.044543", "ticker_sentiment_score": "-0.000644", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.044543", "ticker_sentiment_score": "-0.001316", "ticker_sentiment_label": "Neutral"}, {"ticker": "VINO", "relevance_score": "0.044543", "ticker_sentiment_score": "-0.019117", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENIA", "relevance_score": "0.044543", "ticker_sentiment_score": "-0.016609", "ticker_sentiment_label": "Neutral"}, {"ticker": "OSUR", "relevance_score": "0.044543", "ticker_sentiment_score": "-0.016283", "ticker_sentiment_label": "Neutral"}, {"ticker": "PSNL", "relevance_score": "0.044543", "ticker_sentiment_score": "0.027458", "ticker_sentiment_label": "Neutral"}, {"ticker": "PGNY", "relevance_score": "0.044543", "ticker_sentiment_score": "-0.006078", "ticker_sentiment_label": "Neutral"}, {"ticker": "CORZ", "relevance_score": "0.044543", "ticker_sentiment_score": "0.00068", "ticker_sentiment_label": "Neutral"}, {"ticker": "TDUP", "relevance_score": "0.044543", "ticker_sentiment_score": "-0.361333", "ticker_sentiment_label": "Bearish"}, {"ticker": "HRTX", "relevance_score": "0.044543", "ticker_sentiment_score": "0.00139", "ticker_sentiment_label": "Neutral"}, {"ticker": "EQOS", "relevance_score": "0.044543", "ticker_sentiment_score": "-0.00333", "ticker_sentiment_label": "Neutral"}, {"ticker": "SANW", "relevance_score": "0.044543", "ticker_sentiment_score": "-0.001657", "ticker_sentiment_label": "Neutral"}, {"ticker": "MMS", "relevance_score": "0.088947", "ticker_sentiment_score": "0.217922", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CONN", "relevance_score": "0.044543", "ticker_sentiment_score": "-0.182855", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "KIRK", "relevance_score": "0.044543", "ticker_sentiment_score": "2.2e-05", "ticker_sentiment_label": "Neutral"}, {"ticker": "APRN", "relevance_score": "0.044543", "ticker_sentiment_score": "-0.446784", "ticker_sentiment_label": "Bearish"}, {"ticker": "BTOG", "relevance_score": "0.044543", "ticker_sentiment_score": "-0.001088", "ticker_sentiment_label": "Neutral"}, {"ticker": "GMVD", "relevance_score": "0.044543", "ticker_sentiment_score": "0.002786", "ticker_sentiment_label": "Neutral"}, {"ticker": "MYGN", "relevance_score": "0.044543", "ticker_sentiment_score": "-0.38011", "ticker_sentiment_label": "Bearish"}, {"ticker": "CPTN", "relevance_score": "0.044543", "ticker_sentiment_score": "-0.00495", "ticker_sentiment_label": "Neutral"}, {"ticker": "SONN", "relevance_score": "0.044543", "ticker_sentiment_score": "0.016238", "ticker_sentiment_label": "Neutral"}, {"ticker": "RGS", "relevance_score": "0.044543", "ticker_sentiment_score": "-0.003028", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLK", "relevance_score": "0.02228", "ticker_sentiment_score": "0.056477", "ticker_sentiment_label": "Neutral"}, {"ticker": "MGNX", "relevance_score": "0.044543", "ticker_sentiment_score": "-0.010577", "ticker_sentiment_label": "Neutral"}, {"ticker": "NN", "relevance_score": "0.044543", "ticker_sentiment_score": "-0.009475", "ticker_sentiment_label": "Neutral"}, {"ticker": "GDRX", "relevance_score": "0.044543", "ticker_sentiment_score": "0.005894", "ticker_sentiment_label": "Neutral"}, {"ticker": "VAXX", "relevance_score": "0.044543", "ticker_sentiment_score": "-0.007008", "ticker_sentiment_label": "Neutral"}, {"ticker": "TTOO", "relevance_score": "0.044543", "ticker_sentiment_score": "-0.004317", "ticker_sentiment_label": "Neutral"}, {"ticker": "MESO", "relevance_score": "0.044543", "ticker_sentiment_score": "0.011967", "ticker_sentiment_label": "Neutral"}, {"ticker": "EMBK", "relevance_score": "0.044543", "ticker_sentiment_score": "0.026014", "ticker_sentiment_label": "Neutral"}, {"ticker": "AGIO", "relevance_score": "0.044543", "ticker_sentiment_score": "-0.028866", "ticker_sentiment_label": "Neutral"}, {"ticker": "CDAK", "relevance_score": "0.044543", "ticker_sentiment_score": "0.035579", "ticker_sentiment_label": "Neutral"}, {"ticker": "SG", "relevance_score": "0.044543", "ticker_sentiment_score": "0.010342", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTIB", "relevance_score": "0.088947", "ticker_sentiment_score": "0.057684", "ticker_sentiment_label": "Neutral"}, {"ticker": "MARA", "relevance_score": "0.044543", "ticker_sentiment_score": "-0.006233", "ticker_sentiment_label": "Neutral"}, {"ticker": "SFT", "relevance_score": "0.044543", "ticker_sentiment_score": "-0.005192", "ticker_sentiment_label": "Neutral"}, {"ticker": "OUST", "relevance_score": "0.044543", "ticker_sentiment_score": "0.003524", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESS", "relevance_score": "0.044543", "ticker_sentiment_score": "-0.000215", "ticker_sentiment_label": "Neutral"}, {"ticker": "HUT", "relevance_score": "0.044543", "ticker_sentiment_score": "0.006164", "ticker_sentiment_label": "Neutral"}, {"ticker": "SY", "relevance_score": "0.044543", "ticker_sentiment_score": "0.002841", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMAB", "relevance_score": "0.044543", "ticker_sentiment_score": "0.022449", "ticker_sentiment_label": "Neutral"}, {"ticker": "APLT", "relevance_score": "0.044543", "ticker_sentiment_score": "-0.028361", "ticker_sentiment_label": "Neutral"}, {"ticker": "QNGY", "relevance_score": "0.044543", "ticker_sentiment_score": "-0.020435", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBX", "relevance_score": "0.044543", "ticker_sentiment_score": "0.00136", "ticker_sentiment_label": "Neutral"}, {"ticker": "CNVY", "relevance_score": "0.044543", "ticker_sentiment_score": "-0.030627", "ticker_sentiment_label": "Neutral"}, {"ticker": "SOPH", "relevance_score": "0.044543", "ticker_sentiment_score": "0.011333", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPNE", "relevance_score": "0.044543", "ticker_sentiment_score": "-0.007461", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVNA", "relevance_score": "0.044543", "ticker_sentiment_score": "-0.022013", "ticker_sentiment_label": "Neutral"}, {"ticker": "PEAK", "relevance_score": "0.044543", "ticker_sentiment_score": "0.005677", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.044543", "ticker_sentiment_score": "-0.000477", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIOT", "relevance_score": "0.044543", "ticker_sentiment_score": "-0.025942", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMRK", "relevance_score": "0.02228", "ticker_sentiment_score": "0.052294", "ticker_sentiment_label": "Neutral"}, {"ticker": "MKFG", "relevance_score": "0.044543", "ticker_sentiment_score": "-0.014991", "ticker_sentiment_label": "Neutral"}, {"ticker": "WTRH", "relevance_score": "0.044543", "ticker_sentiment_score": "-0.000465", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALXO", "relevance_score": "0.044543", "ticker_sentiment_score": "0.013133", "ticker_sentiment_label": "Neutral"}, {"ticker": "FTDR", "relevance_score": "0.044543", "ticker_sentiment_score": "-0.008602", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.044543", "ticker_sentiment_score": "0.198883", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CRYPTO:BTX", "relevance_score": "0.02228", "ticker_sentiment_score": "0.007218", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks That Hit 52-Week Lows On Wednesday", "url": "https://www.benzinga.com/markets/options/22/06/27503658/52-weeks-high-and-low-article", "time_published": "20220601T161607", "authors": ["Benzinga Insights"], "summary": "On Wednesday, 73 stocks hit new 52-week lows. Noteworthy Highlights From Today's 52-Week Lows: Medtronic ( NYSE:MDT ) was the biggest company on a market cap basis to set a new 52-week low. Revelation Biosciences ( NASDAQ:REVB ) was the smallest firm on a market cap basis to set a new 52-week lo", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/movers_image_9599.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "0.999966"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": -0.022921, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TRIP", "relevance_score": "0.031237", "ticker_sentiment_score": "-0.003157", "ticker_sentiment_label": "Neutral"}, {"ticker": "SOFO", "relevance_score": "0.062426", "ticker_sentiment_score": "0.000402", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNCE", "relevance_score": "0.062426", "ticker_sentiment_score": "-0.296292", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "INZY", "relevance_score": "0.062426", "ticker_sentiment_score": "-0.016102", "ticker_sentiment_label": "Neutral"}, {"ticker": "SOBR", "relevance_score": "0.062426", "ticker_sentiment_score": "0.020527", "ticker_sentiment_label": "Neutral"}, {"ticker": "LX", "relevance_score": "0.062426", "ticker_sentiment_score": "-0.005377", "ticker_sentiment_label": "Neutral"}, {"ticker": "MODV", "relevance_score": "0.062426", "ticker_sentiment_score": "-0.017416", "ticker_sentiment_label": "Neutral"}, {"ticker": "TGTX", "relevance_score": "0.062426", "ticker_sentiment_score": "0.010131", "ticker_sentiment_label": "Neutral"}, {"ticker": "CYH", "relevance_score": "0.062426", "ticker_sentiment_score": "0.001171", "ticker_sentiment_label": "Neutral"}, {"ticker": "FANH", "relevance_score": "0.062426", "ticker_sentiment_score": "-0.255014", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MF", "relevance_score": "0.093519", "ticker_sentiment_score": "-0.022629", "ticker_sentiment_label": "Neutral"}, {"ticker": "BGXX", "relevance_score": "0.062426", "ticker_sentiment_score": "-0.009315", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.124469", "ticker_sentiment_score": "0.05545", "ticker_sentiment_label": "Neutral"}, {"ticker": "PSTI", "relevance_score": "0.062426", "ticker_sentiment_score": "0.000353", "ticker_sentiment_label": "Neutral"}, {"ticker": "THRX", "relevance_score": "0.062426", "ticker_sentiment_score": "-0.016127", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVRO", "relevance_score": "0.062426", "ticker_sentiment_score": "0.000543", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLDX", "relevance_score": "0.062426", "ticker_sentiment_score": "0.008098", "ticker_sentiment_label": "Neutral"}, {"ticker": "OSUR", "relevance_score": "0.062426", "ticker_sentiment_score": "-0.01018", "ticker_sentiment_label": "Neutral"}, {"ticker": "PSNL", "relevance_score": "0.062426", "ticker_sentiment_score": "0.007927", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALBO", "relevance_score": "0.062426", "ticker_sentiment_score": "-0.013771", "ticker_sentiment_label": "Neutral"}, {"ticker": "FULC", "relevance_score": "0.062426", "ticker_sentiment_score": "-0.006302", "ticker_sentiment_label": "Neutral"}, {"ticker": "PGNY", "relevance_score": "0.062426", "ticker_sentiment_score": "-0.044938", "ticker_sentiment_label": "Neutral"}, {"ticker": "MTEM", "relevance_score": "0.062426", "ticker_sentiment_score": "0.00726", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRTX", "relevance_score": "0.062426", "ticker_sentiment_score": "-0.005295", "ticker_sentiment_label": "Neutral"}, {"ticker": "OMER", "relevance_score": "0.062426", "ticker_sentiment_score": "-0.023907", "ticker_sentiment_label": "Neutral"}, {"ticker": "KIRK", "relevance_score": "0.062426", "ticker_sentiment_score": "-0.009574", "ticker_sentiment_label": "Neutral"}, {"ticker": "MYGN", "relevance_score": "0.062426", "ticker_sentiment_score": "-0.038035", "ticker_sentiment_label": "Neutral"}, {"ticker": "CPTN", "relevance_score": "0.093519", "ticker_sentiment_score": "-0.032891", "ticker_sentiment_label": "Neutral"}, {"ticker": "REVB", "relevance_score": "0.062426", "ticker_sentiment_score": "0.029709", "ticker_sentiment_label": "Neutral"}, {"ticker": "EPIX", "relevance_score": "0.062426", "ticker_sentiment_score": "0.00294", "ticker_sentiment_label": "Neutral"}, {"ticker": "EVER", "relevance_score": "0.062426", "ticker_sentiment_score": "0.060915", "ticker_sentiment_label": "Neutral"}, {"ticker": "ERAS", "relevance_score": "0.062426", "ticker_sentiment_score": "0.089993", "ticker_sentiment_label": "Neutral"}, {"ticker": "BHG", "relevance_score": "0.062426", "ticker_sentiment_score": "-0.003461", "ticker_sentiment_label": "Neutral"}, {"ticker": "GDRX", "relevance_score": "0.062426", "ticker_sentiment_score": "0.004133", "ticker_sentiment_label": "Neutral"}, {"ticker": "AERI", "relevance_score": "0.062426", "ticker_sentiment_score": "0.004163", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPWH", "relevance_score": "0.062426", "ticker_sentiment_score": "-0.017522", "ticker_sentiment_label": "Neutral"}, {"ticker": "CYCC", "relevance_score": "0.062426", "ticker_sentiment_score": "-0.007239", "ticker_sentiment_label": "Neutral"}, {"ticker": "EMBC", "relevance_score": "0.062426", "ticker_sentiment_score": "-0.002072", "ticker_sentiment_label": "Neutral"}, {"ticker": "HPP", "relevance_score": "0.062426", "ticker_sentiment_score": "0.000915", "ticker_sentiment_label": "Neutral"}, {"ticker": "LANC", "relevance_score": "0.062426", "ticker_sentiment_score": "0.001997", "ticker_sentiment_label": "Neutral"}, {"ticker": "XNCR", "relevance_score": "0.062426", "ticker_sentiment_score": "0.008059", "ticker_sentiment_label": "Neutral"}, {"ticker": "GRNQ", "relevance_score": "0.062426", "ticker_sentiment_score": "-0.006849", "ticker_sentiment_label": "Neutral"}, {"ticker": "PTCT", "relevance_score": "0.062426", "ticker_sentiment_score": "0.007631", "ticker_sentiment_label": "Neutral"}, {"ticker": "KNSA", "relevance_score": "0.062426", "ticker_sentiment_score": "-0.001538", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPGI", "relevance_score": "0.062426", "ticker_sentiment_score": "-0.009869", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLSI", "relevance_score": "0.062426", "ticker_sentiment_score": "0.001756", "ticker_sentiment_label": "Neutral"}, {"ticker": "JHX", "relevance_score": "0.062426", "ticker_sentiment_score": "-0.203906", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ACB", "relevance_score": "0.062426", "ticker_sentiment_score": "-0.002002", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIG", "relevance_score": "0.062426", "ticker_sentiment_score": "0.030163", "ticker_sentiment_label": "Neutral"}, {"ticker": "OUST", "relevance_score": "0.062426", "ticker_sentiment_score": "-0.008288", "ticker_sentiment_label": "Neutral"}, {"ticker": "APPS", "relevance_score": "0.062426", "ticker_sentiment_score": "-0.635593", "ticker_sentiment_label": "Bearish"}, {"ticker": "SOPH", "relevance_score": "0.062426", "ticker_sentiment_score": "0.054517", "ticker_sentiment_label": "Neutral"}, {"ticker": "IOVA", "relevance_score": "0.062426", "ticker_sentiment_score": "-0.002229", "ticker_sentiment_label": "Neutral"}, {"ticker": "BTMD", "relevance_score": "0.062426", "ticker_sentiment_score": "-0.016439", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCO", "relevance_score": "0.062426", "ticker_sentiment_score": "0.002566", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHRS", "relevance_score": "0.062426", "ticker_sentiment_score": "0.007777", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.062426", "ticker_sentiment_score": "-0.012854", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPRO", "relevance_score": "0.062426", "ticker_sentiment_score": "0.009263", "ticker_sentiment_label": "Neutral"}, {"ticker": "FTDR", "relevance_score": "0.062426", "ticker_sentiment_score": "-0.024419", "ticker_sentiment_label": "Neutral"}]}, {"title": "Knight Therapeutics Secures Rights To Rigel's Fostamatinib In Latin America", "url": "https://www.benzinga.com/news/22/05/27381629/knight-therapeutics-rigel-pharmaceuticals-ink-exclusive-license-and-supply-agreements-for-fostamatin", "time_published": "20220524T201312", "authors": ["Akanksha Bakshi"], "summary": "Knight Therapeutics Inc. ( TSX: GUD ) ( OTC: KHTRF ) entered into exclusive license and supply agreements with Rigel Pharmaceuticals ( NASDAQ: RIGL ) , securing the rights to commercialize fostamatinib, an oral spleen tyrosine kinase ( SYK ) inhibitor, in Latin America. Fostamatinib is commer", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/05/24/20170126-knightl-jpg.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.073244, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "KHTRF", "relevance_score": "0.365255", "ticker_sentiment_score": "0.002317", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.365255", "ticker_sentiment_score": "0.002317", "ticker_sentiment_label": "Neutral"}]}, {"title": "Applied UV Reports 1st Quarter 2022 Results", "url": "https://investingnews.com/applied-uv-reports-1st-quarter-2022-results/", "time_published": "20220524T193631", "authors": [], "summary": "Knight Therapeutics Inc. ( TSX: GUD ) , a pan-American ( ex-USA ) specialty pharmaceutical company, today announced that it has entered into exclusive license and supply agreements with Rigel Pharmaceuticals granting Knight the rights to commercialize fostamatinib, an oral spleen tyrosine kinase ...", "banner_image": "https://investingnews.com/media-library/applied-uv.png?id=29204888&width=1200&coordinates=0%2C74%2C0%2C75&height=600", "source": "Investing News Network", "category_within_source": "n/a", "source_domain": "investingnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.002138, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "KHTRF", "relevance_score": "0.288893", "ticker_sentiment_score": "0.002138", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.288893", "ticker_sentiment_score": "0.002138", "ticker_sentiment_label": "Neutral"}]}, {"title": "Knight Therapeutics Enters into Exclusive License and Supply Agreements with Rigel Pharmaceuticals to Commercialize Fostamatinib in Latin America", "url": "https://investingnews.com/knight-therapeutics-enters-into-exclusive-license-and-supply-agreements-with-rigel-pharmaceuticals-to-commercialize-fostamatinib-in-latin-america/", "time_published": "20220524T115646", "authors": [], "summary": "Knight Therapeutics Inc. ( TSX: GUD ) , a pan-American ( ex-USA ) specialty pharmaceutical company, today announced that it has entered into exclusive license and supply agreements with Rigel Pharmaceuticals granting Knight the rights to commercialize fostamatinib, an oral spleen tyrosine kinase ...", "banner_image": "https://investingnews.com/media-library/eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJpbWFnZSI6Imh0dHBzOi8vYXNzZXRzLnJibC5tcy8yNTg1ODg1NS9vcmlnaW4ucG5nIiwiZXhwaXJlc19hdCI6MTcwODY4MTIxOX0.Phin9ClvosnPNpkGRdBWHz_VFepTco5fqEYZcXCsZIQ/image.png?width=210", "source": "Investing News Network", "category_within_source": "n/a", "source_domain": "investingnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.012634, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "KHTRF", "relevance_score": "0.330286", "ticker_sentiment_score": "-0.013166", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.075516", "ticker_sentiment_score": "0.002193", "ticker_sentiment_label": "Neutral"}]}, {"title": "Knight Therapeutics Enters into Exclusive License and Supply Agreements with Rigel Pharmaceuticals to Commercialize Fostamatinib in Latin America", "url": "https://www.globenewswire.com/news-release/2022/05/24/2449210/0/en/Knight-Therapeutics-Enters-into-Exclusive-License-and-Supply-Agreements-with-Rigel-Pharmaceuticals-to-Commercialize-Fostamatinib-in-Latin-America.html", "time_published": "20220524T113000", "authors": ["Knight Therapeutics"], "summary": "MONTREAL, May 24, 2022 ( GLOBE NEWSWIRE ) -- Knight Therapeutics Inc. ( TSX: GUD ) , a pan-American ( ex-USA ) specialty pharmaceutical company, today announced that it has entered into exclusive license and supply agreements with Rigel Pharmaceuticals granting Knight the rights to commercial", "banner_image": "https://ml.globenewswire.com/Resource/Download/02c4072d-9fea-4ff1-bd39-1b5405586ad1?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.007452, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "KHTRF", "relevance_score": "0.259244", "ticker_sentiment_score": "-0.01236", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.06592", "ticker_sentiment_score": "0.003669", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rigel Pharmaceuticals  ( RIGL )  Reports Q1 Loss, Misses Revenue Estimates", "url": "https://www.zacks.com/stock/news/1914834/rigel-pharmaceuticals-rigl-reports-q1-loss-misses-revenue-estimates", "time_published": "20220503T213513", "authors": ["Zacks Investment Research"], "summary": "Rigel (RIGL) delivered earnings and revenue surprises of -33.33% and 9.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default112.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999892"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": -0.0372, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "RIGL", "relevance_score": "0.130394", "ticker_sentiment_score": "-0.028763", "ticker_sentiment_label": "Neutral"}, {"ticker": "OCUL", "relevance_score": "0.130394", "ticker_sentiment_score": "-0.206523", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Rigel: Q1 Earnings Snapshot", "url": "https://apnews.com/article/business-california-earnings-rigel-pharmaceuticals-inc-23f223af4166b0059bb2114d68f75f55", "time_published": "20220503T203233", "authors": [], "summary": "Rigel: Q1 Earnings Snapshot The Associated Press - en Espa\u00f1ol", "banner_image": "https://storage.googleapis.com/afs-prod/media/afs:Medium:751921853724/700.png", "source": "Associated Press", "category_within_source": "Business", "source_domain": "apnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": -0.333843, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "RIGL", "relevance_score": "0.89182", "ticker_sentiment_score": "-0.14435", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rigel Reports First Quarter 2022 Financial Results and Provides Business Update", "url": "https://www.prnewswire.com/news-releases/rigel-reports-first-quarter-2022-financial-results-and-provides-business-update-301538880.html", "time_published": "20220503T200100", "authors": ["Rigel Pharmaceuticals", "Inc."], "summary": "First quarter TAVALISSE\u00ae net product sales of $16.2 million and total revenues of $16.7 million", "banner_image": "https://mma.prnewswire.com/media/681135/rigel_logo_TM_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.769861"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.018354, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BRRGF", "relevance_score": "0.012421", "ticker_sentiment_score": "0.001782", "ticker_sentiment_label": "Neutral"}, {"ticker": "KSPHF", "relevance_score": "0.012421", "ticker_sentiment_score": "0.003842", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKXJF", "relevance_score": "0.012421", "ticker_sentiment_score": "0.001782", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.049655", "ticker_sentiment_score": "0.080599", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKYF", "relevance_score": "0.012421", "ticker_sentiment_score": "0.001782", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs", "url": "https://www.benzinga.com/general/biotech/22/05/26958446/the-daily-biotech-pulse-fdas-adcomm-for-acadias-pimavanserin-review-issues-for-speros-tebipenem-a", "time_published": "20220503T130106", "authors": ["Vandana Singh"], "summary": "Here's a roundup of top developments in the biotech space over the last 24 hours.\nStocks In Focus\nAcadia Announces FDA AdComm For Pimavanserin In Alzheimer's-Related Psychosis\nThe FDA's Psychopharmacologic Drugs Advisory Committee will review Acadia Pharmaceuticals Inc  ( NASDAQ: ACAD )  resubmitted", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/05/03/cells-gdd37bc5d2_1920.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.014358, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GRPH", "relevance_score": "0.093507", "ticker_sentiment_score": "0.084375", "ticker_sentiment_label": "Neutral"}, {"ticker": "TARS", "relevance_score": "0.093507", "ticker_sentiment_score": "0.006643", "ticker_sentiment_label": "Neutral"}, {"ticker": "INFI", "relevance_score": "0.093507", "ticker_sentiment_score": "-0.000393", "ticker_sentiment_label": "Neutral"}, {"ticker": "SAGE", "relevance_score": "0.093507", "ticker_sentiment_score": "0.001889", "ticker_sentiment_label": "Neutral"}, {"ticker": "SESN", "relevance_score": "0.093507", "ticker_sentiment_score": "0.010203", "ticker_sentiment_label": "Neutral"}, {"ticker": "PHAT", "relevance_score": "0.093507", "ticker_sentiment_score": "9e-05", "ticker_sentiment_label": "Neutral"}, {"ticker": "AQST", "relevance_score": "0.093507", "ticker_sentiment_score": "-0.000175", "ticker_sentiment_label": "Neutral"}, {"ticker": "OCUL", "relevance_score": "0.093507", "ticker_sentiment_score": "0.000117", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESPR", "relevance_score": "0.093507", "ticker_sentiment_score": "0.002993", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACAD", "relevance_score": "0.093507", "ticker_sentiment_score": "0.001586", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSHA", "relevance_score": "0.185734", "ticker_sentiment_score": "0.00393", "ticker_sentiment_label": "Neutral"}, {"ticker": "VCYT", "relevance_score": "0.093507", "ticker_sentiment_score": "-0.004863", "ticker_sentiment_label": "Neutral"}, {"ticker": "KOD", "relevance_score": "0.093507", "ticker_sentiment_score": "0.216957", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BLTE", "relevance_score": "0.093507", "ticker_sentiment_score": "0.059115", "ticker_sentiment_label": "Neutral"}, {"ticker": "BTAI", "relevance_score": "0.093507", "ticker_sentiment_score": "0.006528", "ticker_sentiment_label": "Neutral"}, {"ticker": "RYTM", "relevance_score": "0.093507", "ticker_sentiment_score": "0.000323", "ticker_sentiment_label": "Neutral"}, {"ticker": "LTRN", "relevance_score": "0.093507", "ticker_sentiment_score": "0.000551", "ticker_sentiment_label": "Neutral"}, {"ticker": "PLRX", "relevance_score": "0.093507", "ticker_sentiment_score": "0.034259", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRTX", "relevance_score": "0.093507", "ticker_sentiment_score": "0.125543", "ticker_sentiment_label": "Neutral"}, {"ticker": "INCY", "relevance_score": "0.093507", "ticker_sentiment_score": "4.5e-05", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXEL", "relevance_score": "0.093507", "ticker_sentiment_score": "0.001098", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.093507", "ticker_sentiment_score": "-0.003217", "ticker_sentiment_label": "Neutral"}, {"ticker": "BPMC", "relevance_score": "0.093507", "ticker_sentiment_score": "0.000267", "ticker_sentiment_label": "Neutral"}, {"ticker": "TEVA", "relevance_score": "0.093507", "ticker_sentiment_score": "0.000377", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPRO", "relevance_score": "0.093507", "ticker_sentiment_score": "0.00565", "ticker_sentiment_label": "Neutral"}]}, {"title": "Earnings Scheduled For May 3, 2022", "url": "https://www.benzinga.com/news/earnings/22/05/26953640/earnings-scheduled-for-may-3-2022", "time_published": "20220503T085235", "authors": ["Benzinga Insights"], "summary": "Companies Reporting Before The Bell\n\u2022 Kiniksa Pharmaceuticals  ( NASDAQ:KNSA )  is projected to report earnings for its first quarter.\n\u2022 Great Lakes Dredge & Dock  ( NASDAQ:GLDD )  is likely to report quarterly earnings at $0.16 per share on revenue of $170.53 million.\n\u2022 Enel Chile  ( NYSE:ENIC )  i", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/earnings_image_4854.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": -0.023122, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VIAV", "relevance_score": "0.01558", "ticker_sentiment_score": "0.001025", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATEN", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000601", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLDD", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000157", "ticker_sentiment_label": "Neutral"}, {"ticker": "LSCC", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.000735", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNFT", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.009373", "ticker_sentiment_label": "Neutral"}, {"ticker": "JBGS", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.050961", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKE", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.000113", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLT", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.101148", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVTA", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.024992", "ticker_sentiment_label": "Neutral"}, {"ticker": "FLGT", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000388", "ticker_sentiment_label": "Neutral"}, {"ticker": "RRR", "relevance_score": "0.01558", "ticker_sentiment_score": "0.001207", "ticker_sentiment_label": "Neutral"}, {"ticker": "HRMY", "relevance_score": "0.01558", "ticker_sentiment_score": "0.001063", "ticker_sentiment_label": "Neutral"}, {"ticker": "WLK", "relevance_score": "0.023368", "ticker_sentiment_score": "-0.00099", "ticker_sentiment_label": "Neutral"}, {"ticker": "DENN", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.006115", "ticker_sentiment_label": "Neutral"}, {"ticker": "IOSP", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.000279", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZBH", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.000359", "ticker_sentiment_label": "Neutral"}, {"ticker": "CNDT", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.00466", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRTS", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.015136", "ticker_sentiment_label": "Neutral"}, {"ticker": "OMI", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.003796", "ticker_sentiment_label": "Neutral"}, {"ticker": "HURN", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.000209", "ticker_sentiment_label": "Neutral"}, {"ticker": "IAG", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000258", "ticker_sentiment_label": "Neutral"}, {"ticker": "JKHY", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000381", "ticker_sentiment_label": "Neutral"}, {"ticker": "SEE", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.001404", "ticker_sentiment_label": "Neutral"}, {"ticker": "WTTR", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.038466", "ticker_sentiment_label": "Neutral"}, {"ticker": "EIX", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000453", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRSK", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.000965", "ticker_sentiment_label": "Neutral"}, {"ticker": "LSEA", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000194", "ticker_sentiment_label": "Neutral"}, {"ticker": "WEYS", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.011343", "ticker_sentiment_label": "Neutral"}, {"ticker": "KOPN", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.033852", "ticker_sentiment_label": "Neutral"}, {"ticker": "VREX", "relevance_score": "0.01558", "ticker_sentiment_score": "0.003116", "ticker_sentiment_label": "Neutral"}, {"ticker": "LXU", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000525", "ticker_sentiment_label": "Neutral"}, {"ticker": "IRT", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000961", "ticker_sentiment_label": "Neutral"}, {"ticker": "J", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.001111", "ticker_sentiment_label": "Neutral"}, {"ticker": "PUMP", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000576", "ticker_sentiment_label": "Neutral"}, {"ticker": "THG", "relevance_score": "0.01558", "ticker_sentiment_score": "1.6e-05", "ticker_sentiment_label": "Neutral"}, {"ticker": "CWH", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.001667", "ticker_sentiment_label": "Neutral"}, {"ticker": "GRBK", "relevance_score": "0.01558", "ticker_sentiment_score": "0.003186", "ticker_sentiment_label": "Neutral"}, {"ticker": "RDN", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000843", "ticker_sentiment_label": "Neutral"}, {"ticker": "INSP", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.034802", "ticker_sentiment_label": "Neutral"}, {"ticker": "STAG", "relevance_score": "0.01558", "ticker_sentiment_score": "0.00114", "ticker_sentiment_label": "Neutral"}, {"ticker": "WRAP", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.124907", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMCI", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.001518", "ticker_sentiment_label": "Neutral"}, {"ticker": "BEN", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.000522", "ticker_sentiment_label": "Neutral"}, {"ticker": "SLRC", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000347", "ticker_sentiment_label": "Neutral"}, {"ticker": "VMD", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.000549", "ticker_sentiment_label": "Neutral"}, {"ticker": "QSR", "relevance_score": "0.01558", "ticker_sentiment_score": "2.7e-05", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACT", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000286", "ticker_sentiment_label": "Neutral"}, {"ticker": "IPGP", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000597", "ticker_sentiment_label": "Neutral"}, {"ticker": "REG", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000409", "ticker_sentiment_label": "Neutral"}, {"ticker": "EHTH", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.094896", "ticker_sentiment_label": "Neutral"}, {"ticker": "APPH", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.128889", "ticker_sentiment_label": "Neutral"}, {"ticker": "INCY", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.002632", "ticker_sentiment_label": "Neutral"}, {"ticker": "BPMC", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.19712", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ADC", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.000682", "ticker_sentiment_label": "Neutral"}, {"ticker": "DD", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.003775", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSTR", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.001333", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACHC", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000125", "ticker_sentiment_label": "Neutral"}, {"ticker": "REZI", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.002671", "ticker_sentiment_label": "Neutral"}, {"ticker": "SQNS", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.014617", "ticker_sentiment_label": "Neutral"}, {"ticker": "DK", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.191192", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CZOO", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.02498", "ticker_sentiment_label": "Neutral"}, {"ticker": "INFI", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.088514", "ticker_sentiment_label": "Neutral"}, {"ticker": "TALK", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.114618", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRO", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.009574", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITW", "relevance_score": "0.01558", "ticker_sentiment_score": "0.001766", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHT", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.014078", "ticker_sentiment_label": "Neutral"}, {"ticker": "AQST", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.103317", "ticker_sentiment_label": "Neutral"}, {"ticker": "INFN", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.029263", "ticker_sentiment_label": "Neutral"}, {"ticker": "MLM", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000319", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTSO", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.059373", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRU", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.000754", "ticker_sentiment_label": "Neutral"}, {"ticker": "WTII", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000396", "ticker_sentiment_label": "Neutral"}, {"ticker": "NYMT", "relevance_score": "0.01558", "ticker_sentiment_score": "-2.8e-05", "ticker_sentiment_label": "Neutral"}, {"ticker": "HSC", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000371", "ticker_sentiment_label": "Neutral"}, {"ticker": "PAYC", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.000815", "ticker_sentiment_label": "Neutral"}, {"ticker": "PSA", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.000874", "ticker_sentiment_label": "Neutral"}, {"ticker": "VCYT", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.012943", "ticker_sentiment_label": "Neutral"}, {"ticker": "AQUA", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000373", "ticker_sentiment_label": "Neutral"}, {"ticker": "DKL", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000354", "ticker_sentiment_label": "Neutral"}, {"ticker": "RDWR", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.004981", "ticker_sentiment_label": "Neutral"}, {"ticker": "BXC", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.00589", "ticker_sentiment_label": "Neutral"}, {"ticker": "GPOR", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.002483", "ticker_sentiment_label": "Neutral"}, {"ticker": "LTHM", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.000396", "ticker_sentiment_label": "Neutral"}, {"ticker": "VVNT", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.00893", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRSP", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000585", "ticker_sentiment_label": "Neutral"}, {"ticker": "CNHI", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.001207", "ticker_sentiment_label": "Neutral"}, {"ticker": "CZR", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.31701", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SSRM", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000178", "ticker_sentiment_label": "Neutral"}, {"ticker": "FPI", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000213", "ticker_sentiment_label": "Neutral"}, {"ticker": "ONTO", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000509", "ticker_sentiment_label": "Neutral"}, {"ticker": "MGNX", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.090579", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATKR", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.0005", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPNS", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.004707", "ticker_sentiment_label": "Neutral"}, {"ticker": "OSPN", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.056163", "ticker_sentiment_label": "Neutral"}, {"ticker": "MASI", "relevance_score": "0.01558", "ticker_sentiment_score": "3.6e-05", "ticker_sentiment_label": "Neutral"}, {"ticker": "WAT", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.000734", "ticker_sentiment_label": "Neutral"}, {"ticker": "KNSA", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.001337", "ticker_sentiment_label": "Neutral"}, {"ticker": "WK", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.036825", "ticker_sentiment_label": "Neutral"}, {"ticker": "COKE", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.062861", "ticker_sentiment_label": "Neutral"}, {"ticker": "DMTK", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.084909", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDXG", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.076647", "ticker_sentiment_label": "Neutral"}, {"ticker": "OUST", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.09153", "ticker_sentiment_label": "Neutral"}, {"ticker": "OSH", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.154323", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "RYN", "relevance_score": "0.00779", "ticker_sentiment_score": "-0.121813", "ticker_sentiment_label": "Neutral"}, {"ticker": "RVLV", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000422", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMDX", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.039502", "ticker_sentiment_label": "Neutral"}, {"ticker": "SWKS", "relevance_score": "0.01558", "ticker_sentiment_score": "0.001492", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPNE", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.067239", "ticker_sentiment_label": "Neutral"}, {"ticker": "PEG", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.000315", "ticker_sentiment_label": "Neutral"}, {"ticker": "WSR", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000548", "ticker_sentiment_label": "Neutral"}, {"ticker": "PEN", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.002569", "ticker_sentiment_label": "Neutral"}, {"ticker": "PEAK", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000576", "ticker_sentiment_label": "Neutral"}, {"ticker": "NRC", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.051439", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRCY", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000419", "ticker_sentiment_label": "Neutral"}, {"ticker": "VAL", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.032537", "ticker_sentiment_label": "Neutral"}, {"ticker": "AHH", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000479", "ticker_sentiment_label": "Neutral"}, {"ticker": "MPC", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000109", "ticker_sentiment_label": "Neutral"}, {"ticker": "DLKGF", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.094131", "ticker_sentiment_label": "Neutral"}, {"ticker": "WCN", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.119931", "ticker_sentiment_label": "Neutral"}, {"ticker": "APEN", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.056021", "ticker_sentiment_label": "Neutral"}, {"ticker": "AHT", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.066193", "ticker_sentiment_label": "Neutral"}, {"ticker": "CEIX", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000165", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.004798", "ticker_sentiment_label": "Neutral"}, {"ticker": "VERI", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.046095", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESPR", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.233922", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SBUX", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000918", "ticker_sentiment_label": "Neutral"}, {"ticker": "WTS", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000419", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMI", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.002267", "ticker_sentiment_label": "Neutral"}, {"ticker": "AIG", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000837", "ticker_sentiment_label": "Neutral"}, {"ticker": "HWM", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.011161", "ticker_sentiment_label": "Neutral"}, {"ticker": "AYX", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.062652", "ticker_sentiment_label": "Neutral"}, {"ticker": "LUNG", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.08927", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVLT", "relevance_score": "0.01558", "ticker_sentiment_score": "0.00165", "ticker_sentiment_label": "Neutral"}, {"ticker": "RYTM", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.06484", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMS", "relevance_score": "0.01558", "ticker_sentiment_score": "0.010791", "ticker_sentiment_label": "Neutral"}, {"ticker": "VSH", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000123", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMG", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000667", "ticker_sentiment_label": "Neutral"}, {"ticker": "GEO", "relevance_score": "0.01558", "ticker_sentiment_score": "-2e-06", "ticker_sentiment_label": "Neutral"}, {"ticker": "POWL", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.110751", "ticker_sentiment_label": "Neutral"}, {"ticker": "AIZ", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.002233", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENVA", "relevance_score": "0.01558", "ticker_sentiment_score": "0.003033", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMP", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.00018", "ticker_sentiment_label": "Neutral"}, {"ticker": "SABR", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.062796", "ticker_sentiment_label": "Neutral"}, {"ticker": "MATX", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.002418", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLKB", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.00031", "ticker_sentiment_label": "Neutral"}, {"ticker": "CNP", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.000992", "ticker_sentiment_label": "Neutral"}, {"ticker": "HSIC", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.001964", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRNA", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.006678", "ticker_sentiment_label": "Neutral"}, {"ticker": "WWDH", "relevance_score": "0.00779", "ticker_sentiment_score": "-0.000122", "ticker_sentiment_label": "Neutral"}, {"ticker": "PTCT", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.079606", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRUS", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.013187", "ticker_sentiment_label": "Neutral"}, {"ticker": "LPX", "relevance_score": "0.01558", "ticker_sentiment_score": "0.003468", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKYT", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.121793", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRTN", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000186", "ticker_sentiment_label": "Neutral"}, {"ticker": "QUAD", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.0432", "ticker_sentiment_label": "Neutral"}, {"ticker": "XHR", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.031426", "ticker_sentiment_label": "Neutral"}, {"ticker": "KO", "relevance_score": "0.00779", "ticker_sentiment_score": "-0.062861", "ticker_sentiment_label": "Neutral"}, {"ticker": "USAC", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.176415", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "RTLR", "relevance_score": "0.01558", "ticker_sentiment_score": "6.9e-05", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANDE", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000733", "ticker_sentiment_label": "Neutral"}, {"ticker": "NRDS", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.029172", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMLP", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.144807", "ticker_sentiment_label": "Neutral"}, {"ticker": "RCKY", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000749", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.014644", "ticker_sentiment_label": "Neutral"}, {"ticker": "ETN", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.001451", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZBRA", "relevance_score": "0.01558", "ticker_sentiment_score": "0.001718", "ticker_sentiment_label": "Neutral"}, {"ticker": "CPK", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000145", "ticker_sentiment_label": "Neutral"}, {"ticker": "LDOS", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.006754", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNL", "relevance_score": "0.01558", "ticker_sentiment_score": "-7.8e-05", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCY", "relevance_score": "0.01558", "ticker_sentiment_score": "0.001097", "ticker_sentiment_label": "Neutral"}, {"ticker": "TAP", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.002996", "ticker_sentiment_label": "Neutral"}, {"ticker": "HLMN", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000231", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMCR", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.013422", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALR", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.019707", "ticker_sentiment_label": "Neutral"}, {"ticker": "SAGE", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.250651", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "TRI", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.000151", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABNB", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.139426", "ticker_sentiment_label": "Neutral"}, {"ticker": "UTL", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.000889", "ticker_sentiment_label": "Neutral"}, {"ticker": "DOOR", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.000144", "ticker_sentiment_label": "Neutral"}, {"ticker": "LFVN", "relevance_score": "0.01558", "ticker_sentiment_score": "0.003821", "ticker_sentiment_label": "Neutral"}, {"ticker": "MTW", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000105", "ticker_sentiment_label": "Neutral"}, {"ticker": "RNR", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000171", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMD", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.002332", "ticker_sentiment_label": "Neutral"}, {"ticker": "AME", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.006865", "ticker_sentiment_label": "Neutral"}, {"ticker": "MG", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.071403", "ticker_sentiment_label": "Neutral"}, {"ticker": "YUMC", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.065932", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSP", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.103163", "ticker_sentiment_label": "Neutral"}, {"ticker": "GIC", "relevance_score": "0.01558", "ticker_sentiment_score": "0.001545", "ticker_sentiment_label": "Neutral"}, {"ticker": "WERN", "relevance_score": "0.01558", "ticker_sentiment_score": "0.006764", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENIC", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000823", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRTX", "relevance_score": "0.01558", "ticker_sentiment_score": "0.001065", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTLT", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.000463", "ticker_sentiment_label": "Neutral"}, {"ticker": "VOYA", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.00092", "ticker_sentiment_label": "Neutral"}, {"ticker": "MEC", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000743", "ticker_sentiment_label": "Neutral"}, {"ticker": "MX", "relevance_score": "0.01558", "ticker_sentiment_score": "0.004872", "ticker_sentiment_label": "Neutral"}, {"ticker": "PKI", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.001457", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROK", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.003439", "ticker_sentiment_label": "Neutral"}, {"ticker": "KYMR", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.101597", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSP", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.160834", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "DCO", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.000677", "ticker_sentiment_label": "Neutral"}, {"ticker": "KAI", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.000483", "ticker_sentiment_label": "Neutral"}, {"ticker": "NAUT", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.04397", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFIE", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.026018", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARNC", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.000207", "ticker_sentiment_label": "Neutral"}, {"ticker": "CGBD", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.000262", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATRC", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.036742", "ticker_sentiment_label": "Neutral"}, {"ticker": "LFUS", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.001962", "ticker_sentiment_label": "Neutral"}, {"ticker": "KAR", "relevance_score": "0.01558", "ticker_sentiment_score": "0.004879", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGRY", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.012236", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000324", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENLC", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000222", "ticker_sentiment_label": "Neutral"}, {"ticker": "HLF", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.004896", "ticker_sentiment_label": "Neutral"}, {"ticker": "NR", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.078428", "ticker_sentiment_label": "Neutral"}, {"ticker": "PARA", "relevance_score": "0.023368", "ticker_sentiment_score": "0.00458", "ticker_sentiment_label": "Neutral"}, {"ticker": "AKAM", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.000971", "ticker_sentiment_label": "Neutral"}, {"ticker": "INN", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.073825", "ticker_sentiment_label": "Neutral"}, {"ticker": "BGFV", "relevance_score": "0.01558", "ticker_sentiment_score": "0.002012", "ticker_sentiment_label": "Neutral"}, {"ticker": "LIND", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.01804", "ticker_sentiment_label": "Neutral"}, {"ticker": "HLT", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.000122", "ticker_sentiment_label": "Neutral"}, {"ticker": "MUSA", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.002893", "ticker_sentiment_label": "Neutral"}, {"ticker": "CIGI", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.001829", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPGI", "relevance_score": "0.01558", "ticker_sentiment_score": "2.8e-05", "ticker_sentiment_label": "Neutral"}, {"ticker": "KBAL", "relevance_score": "0.01558", "ticker_sentiment_score": "0.00058", "ticker_sentiment_label": "Neutral"}, {"ticker": "LTRN", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.007513", "ticker_sentiment_label": "Neutral"}, {"ticker": "OKE", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.000225", "ticker_sentiment_label": "Neutral"}, {"ticker": "DEI", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000124", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLAD", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000189", "ticker_sentiment_label": "Neutral"}, {"ticker": "LEA", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.001505", "ticker_sentiment_label": "Neutral"}, {"ticker": "MTOR", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000313", "ticker_sentiment_label": "Neutral"}, {"ticker": "EGY", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.043468", "ticker_sentiment_label": "Neutral"}, {"ticker": "SCI", "relevance_score": "0.023368", "ticker_sentiment_score": "-0.001283", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLRE", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.001462", "ticker_sentiment_label": "Neutral"}, {"ticker": "LGIH", "relevance_score": "0.01558", "ticker_sentiment_score": "0.003032", "ticker_sentiment_label": "Neutral"}, {"ticker": "LEV", "relevance_score": "0.01558", "ticker_sentiment_score": "-0.079106", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXR", "relevance_score": "0.01558", "ticker_sentiment_score": "0.000626", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:BGN", "relevance_score": "0.00779", "ticker_sentiment_score": "-0.079106", "ticker_sentiment_label": "Neutral"}]}, {"title": "Emergent BioSolutions Provides Corporate Governance Update", "url": "https://www.globenewswire.com/news-release/2022/03/23/2408968/33240/en/Emergent-BioSolutions-Provides-Corporate-Governance-Update.html", "time_published": "20220323T200500", "authors": ["Emergent Biosolutions", "Inc."], "summary": "GAITHERSBURG, Md., March  23, 2022   ( GLOBE NEWSWIRE )  -- Emergent BioSolutions Inc.  ( NYSE: EBS )  today announced that its board of directors  ( the \"board\" )  has undertaken a series of changes consistent with its commitment to continuous improvement of best practices for corporate governance.", "banner_image": "https://ml.globenewswire.com/Resource/Download/56a9097d-af91-4bcf-8c42-5905e1614ef1?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.009894, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ELDN", "relevance_score": "0.035773", "ticker_sentiment_score": "0.008707", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNDX", "relevance_score": "0.035773", "ticker_sentiment_score": "0.008707", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.035773", "ticker_sentiment_score": "0.008707", "ticker_sentiment_label": "Neutral"}, {"ticker": "APVO", "relevance_score": "0.035773", "ticker_sentiment_score": "0.004219", "ticker_sentiment_label": "Neutral"}, {"ticker": "EBS", "relevance_score": "0.107032", "ticker_sentiment_score": "0.010347", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.035773", "ticker_sentiment_score": "0.008707", "ticker_sentiment_label": "Neutral"}]}]}